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 ABSTRACT
 
 Specific delivery of chemotherapeutic agents to cancerous tissues can 
potentially result in increased safety and decreased toxicity.  For example, 
nanomedicines, including polymer-drug conjugates, can potentially accumulate in solid 
tumors via the “enhanced permeability and retention” (EPR) effect.  Further increases in 
delivery can be achieved via active targeting strategies, wherein cancer-specific 
targeting moieties enhance cellular binding and internalization.  This dissertation 
describes a strategy which attempts to increase the tumor accumulation and efficiency 
of active targeting using a combination of tumor hyperthermia and heat shock protein 
(HSP) targeted N-(2-hydroxypropyl)methacrylamide (HPMA) copolymer-drug 
conjugates.  Following exposure to hyperthermia, increases in cellular stress results in 
initiation of the heat shock response, which includes the synthesis and migration of 
certain heat shock proteins to the cell surface.  It is hypothesized that the induced 
expression of these HSPs can serve as specific molecular targets for the delivery of 
anticancer macromolecular chemotherapeutics.  HPMA copolymer-drug conjugates 
bearing peptides targeting cell surface expressed glucose regulated protein 78 kDa 
(GRP78), a member of the HSP70 family of proteins, were synthesized, characterized, 
and evaluated for activity in prostate cancer models.  Following exposure to 
hyperthermia, the cell surface expression of GRP78 was also evaluated and correlated 
to increases in cellular delivery and cytotoxicity of GRP78 targeted HPMA copolymer-
iv 
  
drug conjugates.  Combination index analyses indicated that a combination of 
hyperthermia and HSP targeted drug therapy resulted in combined synergistic effects.  
In vivo, gold nanorod-mediated plasmonic photothermal therapy was utilized to induce 
tumor hyperthermia in a human prostate cancer animal model to enhance the delivery 
and efficacy of GRP78 targeted HPMA copolymer-drug conjugates.  Results 
demonstrate that a combination of tumor hyperthermia and HSP targeting can increase 
tumor accumulation and cellular delivery of macromolecular chemotherapeutics, 
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1.1.1  Drug delivery 
Drug delivery is the method or process by which a pharmaceutically active 
agent, or drug, is administered.  The intended goal is to “deliver” the drug in a manner 
that allow for its therapeutic effect to be realized by a patient.  The field of drug 
delivery has undergone tremendous evolution over the past few decades.
1
  Early drug 
delivery scientists were primarily focused on technologies to modify drug release 
kinetics and expand the common routes of drug administration (i.e. transdermal, nasal, 
pulmonary, etc.).  Recent advances, particularly in the field of nanotechnology have 
provided an array of tools to aid in the successful delivery of drugs.
2
  Association of 
therapeutic compounds with nano-scaled carriers allows new mechanisms by which 
drug release kinetics can be altered.  In addition, modifications in the size and 
physicochemical properties of these “nanomedicines” offer opportunities to modify 
their pharmacokinetics and distribution in the body following administration.
3
  It is 
anticipated that these new technologies will allow scientists and clinicians the ability to 




1.1.2  Polymer therapeutics 
The use of water-soluble polymeric materials for drug delivery provides several 
advantages.  First, many drugs are natively hydrophobic, and association of such drugs 
with water soluble polymers via complexation or conjugation can dramatically improve 
their aqueous solubility.
4
  Second, if these carriers are made sufficiently large in size 
(generally above 7-10 nm in diameter), they can evade renal filtration via the glomeruli, 
resulting in prolonged systemic circulation.
5
  In anticancer applications, such carriers 
can potentially accumulate in solid tumor tissue via the enhanced permeability and 
retention (EPR) effect
6
, where a combination of increased vascular permeability and 
reduced lymphatic drainage exist within the tumor microenvironment.
7
  Despite these 
advantages, clinical translation of polymer therapeutics has proven challenging.  
Anticancer clinical trials to date have demonstrated that while these systems are 
generally advantageous with respect to safety and tolerability, efficacy has remained 
marginal due to poor overall tumor delivery.
8
  Therefore, strategies to increase specific 
tumor delivery while minimizing distribution in other organs and tissues are needed. 
 
1.1.3  Active targeting 
One way in which a polymer therapeutic may be made more selective towards 
tumor tissue is via the inclusion of targeting moieties.  These targeting moieties are 
designed to be recognized by and bind to receptors expressed on the surface of cells in 
target tissues.  Antibodies, antibody fragments, peptides, carbohydrates, and other small 
molecules have been attached to a variety of nanomedicines for this purpose.
9
  
However, it should be acknowledged that such strategies rely on short-ranged 
3 
 
electrostatic interactions to facilitate binding.
10
  Therefore, these strategies are most 
effective when coupled with other passive targeting strategies (i.e., EPR).  Selection of 
a specific molecular target is critically important.  The ideal target is one that is highly 
expressed on the surface of cells in the tissue of interest with no expression elsewhere.  
However, this is rarely the case, and the criterion for selection is usually 
“overexpression” of the target in the region of interest.11  The difference in the native 
expression levels between target and nontarget tissues is therefore a fundamental 
limitation in achieving successful active targeting.  The focus of this dissertation is to 
investigate a strategy to increase total tumor accumulation that does not have this 
inherent limitation.  This approach utilizes tumor hyperthermia and the induced 
expression of heat shock proteins. 
 
1.1.4  Hyperthermia and the heat shock response 
Tumor hyperthermia has been widely investigated as an anti-cancer strategy, 
wherein the temperature of tumors is elevated to levels high enough to induce 
cytotoxicity.
12
  The alternative approach under evaluation in this dissertation uses 
moderate hyperthermia to increase the subsequent delivery of polymer therapeutics 
(Figure 1.1).  This occurs through two primary mechanisms:  First, moderate tumor 
hyperthermia can increase the blood flow and vascular permeability of tumor tissue, 
thereby enhancing passive delivery via the EPR effect.
13
  Second, when exposed to 
moderate hyperthermia, tumor cells respond by inducing the expression of heat shock 
proteins.
14
  While much of this response occurs inside cells, recent observations have 
indicated that some of these heat shock proteins (i.e. glucose regulated protein 78 kDa, 
4 
 
Figure 1.1.  Rationale to increase the delivery of macromolecular 
chemotherapeutics using tumor hyperthermia.  The primary focus of this thesis is 
on the induction of cell surface heat shock proteins (HSPs), and their subsequent 
targeting using polymer-drug conjugates. 
5 
 
GRP78) also play active roles in signal transduction on the cell surface.
15, 16
  Our 
strategy therefore utilizes these induced cell surface heat shock proteins as specific 
molecular targets.  Through the use of polymer therapeutics targeting this response, we 
can therefore achieve increased binding and internalization into cancer cells.  Increased 
delivery of polymer therapeutics via these phenomena can translate into better efficacy 
and safety of cancer chemotherapeutics. 
 
1.2  Specific aims 
While the aforementioned phenomena provide rationale for a combination 
therapy of polymer therapeutics and tumor hyperthermia, the primary focus of this 
thesis is investigation of the latter, wherein polymer therapeutics are targeted towards 
the induced expression of the cell surface heat shock protein GRP78.  This investigation 
was carried out by evaluation of the following specific aims: 
1.  To synthesize and characterize heat shock protein targeted N-(2-
hydroxypropyl)methacrylamide (HPMA) copolymer-drug conjugates in vitro for their 
ability to bind cell surface expressed GRP78 and induce cytotoxicity in prostate cancer 
cells. 
2.  To evaluate the potential for increased delivery of GRP78 targeted HPMA 
copolymers in combination with hyperthermia.   
3.  To evaluate the in vitro synergism and in vivo efficacy of GRP78 targeted 





1.3  Scope and organization 
Chapter 2 provides the necessary background on polymer therapeutics and 
polymer-drug conjugates, along with a discussion of the challenges facing their 
utilization in anticancer applications.
17
  Background is also provided on the role of 
tumor hyperthermia in anticancer therapy and the utilization of heat shock proteins as 
anticancer targets.  Specifically, the role of GRP78 and its implications in targeted 
tumor therapy will be reviewed.  As localized tumor hyperthermia in this study was 
delivered via gold nanorod-mediated plasmonic photothermal therapy, a brief 
discussion of this technique is also included.  In Chapter 3, HPMA copolymers bearing 
the model anticancer drug aminohexylgeldanamycin (AHGDM) and the GRP78 
targeting peptide WIFPWIQL were synthesized.
18
  Their ability to bind to cell surface 
expressed GRP78 and induce cytotoxicity in human prostate cancer cells was then 
evaluated.  In Chapter 4, the expression profile of cell surface expressed GRP78 
following hyperthermia was evaluated and its impact on the cellular uptake and 
cytotoxicity of targeted HPMA copolymers assessed.
19
  The in vivo tumor accumulation 
and biodistribution of GRP78 targeted HPMA copolymers were also investigated in 
prostate tumor bearing mice following localized tumor hyperthermia.  In Chapter 5, 
GRP78 targeted conjugates bearing three different drugs (AHGDM, docetaxel (DOC), 
and cisplatin (Pt)) were evaluated for their ability to demonstrate synergistic cytotoxic 
effects in combination with moderate hyperthermia.
20
  Based on these results, 
conjugates bearing DOC were selected and evaluated for in vivo efficacy in 
combination with localized tumor hyperthermia in prostate tumor bearing mice.  
7 
 
Finally, Chapter 6 briefly summarizes the major finding and implications of the 
dissertation and suggests potential future directions. 
In Appendix A, the synthesis and evaluation of HPMA copolymers bearing the 
chemotherapeutic DOC and the angiogenesis targeting peptide RGDfK is described, 
wherein the utility of a well characterized active targeting strategy was demonstrated.
21
  
This study provided a basis for the proposed work.   
During the course of the described studies, it was observed that the chemical 
modification necessary for conjugation of the drug geldanamycin to the HPMA 
copolymer backbone resulted in a significant decrease in its activity.  This prompted 
work with a non-conjugated micellar system, which is described in Appendix B.
22
 
During initial in vivo biodistribution studies of HPMA copolymers bearing the 
WIFPWIQL GRP78 targeting peptide, significant nonspecific uptake in healthy tissues 
was observed.  This prompted an investigation into the use of an alternative, more 
hydrophilic, GRP78 targeting peptide, namely WDLAWMFRLPVG.  A brief 
comparison of the biodistribution of the two systems is included in Appendix C. 
Additional size exclusion data for selected HPMA copolymer-drug conjugates is 
also included in Appendix D. 
 
1.4  References 
1. A.S. Hoffman. The origins and evolution of "controlled" drug delivery systems. 
J Control Release. 132:153-163 (2008). 
 
2. M. Chakraborty, S. Jain, and V. Rani. Nanotechnology: emerging tool for 




3. S. Venkataraman, J.L. Hedrick, Z.Y. Ong, C. Yang, P.L. Ee, P.T. Hammond, 
and Y.Y. Yang. The effects of polymeric nanostructure shape on drug delivery. 
Adv Drug Deliv Rev. 63:1228-1246 (2011). 
 
4. L.E. van Vlerken, T.K. Vyas, and M.M. Amiji. Poly(ethylene glycol)-modified 
nanocarriers for tumor-targeted and intracellular delivery. Pharm Res. 24:1405-
1414 (2007). 
 
5. V. Torchilin. Tumor delivery of macromolecular drugs based on the EPR effect. 
Adv Drug Deliv Rev. 63:131-135 (2011). 
 
6. Y. Matsumura and H. Maeda. A new concept for macromolecular therapeutics 
in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins 
and the antitumor agent smancs. Cancer Res. 46:6387-6392 (1986). 
 
7. H. Maeda. Tumor-selective delivery of macromolecular drugs via the EPR 
effect: background and future prospects. Bioconjug Chem. 21:797-802 (2010). 
 
8. R. Duncan and M.J. Vicent. Do HPMA copolymer conjugates have a future as 
clinically useful nanomedicines? A critical overview of current status and future 
opportunities. Adv Drug Deliv Rev. 62:272-282 (2010). 
 
9. V.P. Torchilin. Passive and active drug targeting: drug delivery to tumors as an 
example. Handb Exp Pharmacol:3-53 (2010). 
 
10. Y.H. Bae and K. Park. Targeted drug delivery to tumors: myths, reality and 
possibility. J Control Release. 153:198-205 (2011). 
 
11. T.A. Denison and Y.H. Bae. Tumor heterogeneity and its implication for drug 
delivery. J Control Release (2012). 
 
12. R.L. Manthe, S.P. Foy, N. Krishnamurthy, B. Sharma, and V. Labhasetwar. 
Tumor ablation and nanotechnology. Mol Pharm. 7:1880-1898 (2010). 
 
13. S.L. Hokland, T. Nielsen, M. Busk, and M.R. Horsman. Imaging tumour 
physiology and vasculature to predict and assess response to heat. Int J 
Hyperthermia. 26:264-272 (2010). 
 
14. K. Richter, M. Haslbeck, and J. Buchner. The heat shock response: life on the 
verge of death. Mol Cell. 40:253-266 (2010). 
 
15. M. Sato, V.J. Yao, W. Arap, and R. Pasqualini. GRP78 signaling hub a receptor 




16. M. Ni, Y. Zhang, and A.S. Lee. Beyond the endoplasmic reticulum: atypical 
GRP78 in cell viability, signalling and therapeutic targeting. Biochem J. 
434:181-188 (2011). 
 
17. N. Larson and H. Ghandehari. Polymeric conjugates for drug delivery. Chem 
Mater. 24:840-853 (2012). 
 
18. N. Larson, A. Ray, A. Malugin, D.B. Pike, and H. Ghandehari. HPMA 
copolymer-aminohexylgeldanamycin conjugates targeting cell surface expressed 






, S. Sadekar, R. Robinson, A. Ray, and H. 
Ghandehari. (
*
first co-authors). Guided Delivery of Polymer Therapeutics Using 
Plasmonic Photothermal Therapy. Nano Today. 7:158-167 (2012). 
 
20. N. Larson, A.J. Gormley, N. Frazier, and H. Ghandehari. In vitro synergism and 
in vivo efficacy of combination tumor hyperthermia and heat shock protein 






, D.B. Pike, M. Gruner, S. Naik, H. Bauer, A. Malugin, K. 
Greish, and H. Ghandehari. (
*
first co-authors). Comparison of active and passive 
targeting of docetaxel for prostate cancer therapy by HPMA copolymer-RGDfK 
conjugates. Mol Pharm. 8:1090-1099 (2011). 
 
22. N. Larson, K. Greish, H. Bauer, H. Maeda, and H. Ghandehari. Synthesis and 
evaluation of poly(styrene-co-maleic acid) micellar nanocarriers for the delivery 














Throughout history, the practice of medicine has utilized therapeutic compounds 
to treat disease.  Beginning is 1894, Felix Hoffman, working for the German medical 
company Bayer began searching for compounds to alleviate the pain of his father, who 
suffered from arthritis.
1
  His work led him to discover the compound salicylic acid, 
found in willow bark.  A slight chemical modification to reduce the inherent gastric 
stress of the compound was made followed by development of a commercial method to 
produce it.  The result, aspirin, is still widely used today.  From that time until the past 
few decades, pharmaceutical companies have focused their development efforts on low 
molecular weight, organically synthesized compounds.
2
  With the modern advent of 
combinatorial chemistry,
3
 vast numbers of compounds are now routinely synthesized 
and screened against a variety of potential therapeutic targets.  More recently, however, 
much attention has been directed towards the development of new classes of 
therapeutics.  The utilization of therapeutic proteins and monoclonal antibodies and 
their commercial success, particularly in anticancer therapies, has reshaped 
development efforts of the pharmaceutical industry, primarily as a result of an increased 
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ability to control and manipulate biological processes.
4
  In a similar manner, recent 
advances in multiple scientific fields have increased our ability to control and 
manipulate chemical structures and materials at the nanometer scale.
5
  The emerging 
fields of nanotechnology and nanomedicine, as it applies to the medical sciences, are 
providing new opportunities for improvement in the diagnosis and treatment of 
diseases.  From an industrial standpoint, it is anticipated that the impact of these 
technologies, which are used in advanced drug delivery systems will continue to grow 
(see Figure 2.1).
6
  For the drug delivery scientist, these new materials and structures can 
be utilized as tools to more effectively administer and deliver therapeutic agents.  The 
use of synthetic polymers, in particular, has been increasingly used to provide 
advantageous properties to such materials and structures. 
The objective of controlled drug delivery is to provide control over both the 
drug location and concentration as a function of time in order to maximize therapeutic 
effect and minimize toxicity.  This is of particular importance in anticancer applications 
where the drug to be delivered is usually potently cytotoxic, resulting in a narrow 
therapeutic index.  In this chapter, the overall rationale for using polymeric materials as 
carriers to enhance the therapeutic index of chemotherapeutics will be introduced, with 
a particular emphasis on polymeric drug conjugates.  Current strategies to “target” these 
types of carriers to tumor tissues will also be reviewed, along with a discussion of 
factors currently limiting these targeting strategies.  As the strategy under investigation 
in this thesis involves a combination therapy utilizing tumor hyperthermia to facilitate 
the delivery of polymer-drug conjugates, the natural response of tumor tissue and tumor 




Figure 2.1.  Anticipated growth in the global market for advanced drug delivery 





shock protein response.  In particular, the function of glucose regulated protein 78 kDa 
(GRP78) within and on the surface of tumor cells will be discussed.  Studies described 
in this thesis utilize gold nanorod mediated plasmonic photothermal therapy
7
 as a tool to 
induce localized hyperthermia in vivo, so a brief introduction to this method is also 
included.  Finally, challenges in the delivery of chemotherapy for prostate cancer and 
how this combination strategy can be utilized to improve current treatment options will 
be presented, along with an introduction to the various anticancer agents utilized herein 
to test our hypotheses. 
 
2.2  Polymer therapeutics and polymer-drug conjugates 
Concepts utilizing polymers in the design of therapeutic agents have been 
widely investigated for a number of decades.  Initial work of the 1960s focused on 
utilizing polymers as blood plasma expanders, wound dressings, and injectable or 
implantable depots.
8, 9
  In 1975, a rational model for pharmacologically active polymers 
was first proposed by Helmut Ringsdorf.
10
  His concept of covalently bound polymer-
drug conjugates still forms the basis for much of the work in this area performed today.  
The Ringsdorf model (Figure 2.2) primarily consists of a biocompatible polymer 
backbone bound to three components: 1) a solubilizer, which serves the purpose of 
imparting hydrophilicity and ensuring water solubility, 2) a drug, usually bound to the 
polymeric backbone via a linker, and 3) a targeting moiety whose function is to provide 
transport to a desired physiological destination or bind to a particular biological 
target.
11
The Ringsdorf model is particularly attractive to drug delivery scientists, whose 
primary objective is the specific delivery of therapeutic agents to their intended site of 
14 
 
Figure 2.2.  Modified Ringsdorf model providing a rationale for drug delivery via 




action in an attempt to improve efficacy and reduce toxicity.  These polymer-drug 
conjugates offer several significant advantages over traditional small molecule 
therapeutics.  First, the aqueous solubility of a drug can be dramatically improved 
following conjugation to a water soluble polymer.
12, 13
  This is of significant relevance 
as it has been estimated that 40-60% of drugs in development exhibit poor 
bioavailability due to low aqueous solubility.
14
  Next, polymer-drug conjugates offer the 
potential for a drug to be delivered in a controlled manner, with drug release from the 
conjugate occurring over a defined time interval.  In this way, the rate and duration of 
delivery can be custom designed to achieve the desired therapeutically effective 
concentration.  Thus it is possible to avoid large fluctuations associated with periodic 
administration, which can lead to high systemic drug concentrations resulting in 
undesired side effects, organ damage, or toxicity.  Polymer conjugation also provides an 
opportunity to alter drug pharmacokinetics and biodistribution.  This is particularly 
useful for drugs which exhibit a short blood plasma half-life due to rapid metabolism or 
clearance or for drugs which exhibit off target toxicities (i.e., anticancer agents).  As 
previously mentioned, another major advantage that can be realized through drug-
polymer conjugation is the inclusion of targeting moieties, which function to carry the 
drug to the site of pharmacological action. 
A substantial amount of effort is currently directed toward developing anticancer 
polymer-drug conjugates.  Anticancer agents are often limited by poor water solubility 
and metabolic instability, and their clinical use is often limited by dose dependent 
toxicity.  The therapeutic index of a given drug is defined as the ratio between its toxic 
and therapeutic dose.  For the clinician, the goal is to deliver an anticancer agent at a 
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dose high enough to achieve cytotoxicity within tumor tissues.  However, the actual 
dose administered is very often limited by toxicity to other vital organs.  Thus, any 
improvement in the therapeutic index for such drugs which allows the clinician the 
ability to deliver higher drug concentrations to tumor tissue while maintaining 
manageable side effects can yield benefits for cancer patients.  One of the primary ways 
in which polymer-drug conjugates can increase the therapeutic index of anticancer 
agents is via the “enhanced permeability and retention (EPR) effect” first described by 
Matsumura and Maeda in 1986.
15
  They proposed that increased uptake of 
macromolecules by solid tumors can occur due to a combination of poor lymphatic 
drainage and increased vascular permeability present within the tumor 
microenvironment (Figure 2.3).  Detailed information about the EPR effect and its 
implications in cancer chemotherapy has been the subject of several review articles.
16-19
 
Despite the vast amount of effort directed toward the development of therapeutic 
polymer-drug conjugates, success in terms of translation to clinical practice has been 
slow due to a variety of unique challenges.  Many conjugates are, for example, complex 
multi-component drug delivery systems that must ultimately satisfy the identity and 
purity regulatory requirements necessary for any new chemical entity (NCE).  Validated 
methods for reproducible synthesis and characterization such as reversible-addition 
fragmentation chain-transfer (RAFT) polymerization
20-22
 or atom transfer radical 
polymerization (ATRP)
23
 need to be further utilized to satisfy drug product quality 
requirements.  In addition to this, regulatory requirements require studies examining the 
metabolic fate of such conjugates, which can become increasingly difficult to 
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Figure 2.3.  The enhanced permeability and retention or “EPR” effect.  Increased 
tumor accumulation of macromolecules occurs via a combination of increased 





characterize for multicomponent systems as compared to traditional small molecule 
therapeutics.   
Safety and efficacy of polymer-drug conjugates, as with other more traditional 
therapeutics, is obviously of the utmost concern during the drug development process.  
Those conjugates that have progressed to clinical trials have primarily utilized 
previously approved drugs.
24-30
  Although a polymer-drug conjugate is defined as a 
NCE for regulatory purposes,
31
 information pertaining to the safety of the free drug can 
be utilized as a guide in designing toxicity studies.  However, careful consideration 
must be taken as polymer-drug conjugates frequently show altered biodistribution and 
pharmacokinetic patterns.  A critical parameter directly associated with both safety and 
efficacy is release of the drug from the polymeric carrier.  Generally, drug release from 
a polymeric carrier is necessary for the drug to elicit its pharmacological effect.
32, 33
  
This is advantageous as a conjugate will be mostly inactive during systemic transport.  
If release of the drug from the conjugate occurs prematurely during systemic transport, 
undesired toxicities may result, and the overall safety profile of the conjugate will be 
poor.
26, 34
  Therefore, the stability of the conjugate is one critical parameter.  However, 
upon reaching the desired target destination, release of the drug is then required to 
achieve efficacy.  There is therefore a critical balance between conjugate stability and 
drug release that directly impacts safety and efficacy.  
The focus of this section is to provide background on the rational design of 
polymer-drug conjugates and their biological evaluation.  Polymer-drug conjugates of 
various chemistries and architectures will be reviewed with emphasis given on the 
design of each system and potential applications.  Stimuli-sensitive systems and the 
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emerging field of theranostics based on polymeric systems will also be briefly 
discussed.   
 
2.2.1  Linear polymers 
 Many different drug conjugates have been synthesized utilizing water soluble 










 two of the most widely investigated chemistries are those based 
on poly(ethylene glycol) (PEG)
29
 and N-(2-hydroxypropyl)methacrylamide (HPMA) 
copolymers,
40
 which will be reviewed in detail. 
2.2.1.1  Poly(ethylene) glycol.  Although numerous different polymer 
compositions have been synthesized and studied, some of the simplest polymers, such 
as poly(ethylene glycol) (PEG), maintain widespread use and versatility.  PEG-protein 
conjugates have gained particular importance due to the ability of PEG to protect 
against protein enzymatic degradation and reduce uptake by the reticulo-endothelial 
system (RES),
41, 42
 both properties imparted via simple steric hindrance.  Protein 
PEGylation has led to the development of numerous therapeutics, including the FDA 









 PEG-interferon -2a (Pegasys),45 PEG-interferon -2b (PEG-Intron),46 









  Most commonly, conjugation to PEG is performed 
via coupling to the end chains.
49
  Functionalities such as N-hydroxysuccinimide (NHS) 
esters or aldehydes allow conjugation to the amine of lysine residues whereas 
20 
 
maleimides react readily with the thiol of cysteine residues.  Numerous functionalized 
PEGs are available to aid in conjugation.  Whereas some functionalities allow 
conjugation to biomolecules such as proteins and antibodies, others can be more 
generally applied in the synthesis of novel biomaterials.   
 PEG-drug conjugates have several advantages.  First and foremost, the use of 
PEG as a biocompatible polymer has been established clinically.
50
  Due to the 
widespread use of PEGs in drug conjugation, an array of functional PEGs are now 
commercially available.
51
  In addition, large scale synthesis of PEGs are generally 
routine, and they can be readily synthesized with narrow molecular weight and 
molecular weight distribution specifications.
52
  These properties make PEG-drug 
conjugates attractive for pharmaceutical applications. 
The use of PEG in conjugation is, however, not without limitations.  A 
fundamental disadvantage of PEG is its nonbiodegradability.  As previously mentioned, 
conjugates with a hydrodynamic radius of approximately 3.5 nm are preferred in many 
applications due to their ability to avoid renal filtration.
53
  However, conjugates of this 
size have the potential for long term accumulation, resulting in toxic side effects.  
Another significant disadvantage of traditional PEG-drug conjugates is the low drug 
loading that is achieved due to conjugation at only the end chains of PEG.
54
  In an effort 




 PEGs have been 
investigated which can be excreted more easily following biodegradation.   
2.2.1.2  HPMA copolymers.  Copolymers of HPMA, first developed by 
Kopecek and coworkers, have also been widely investigated as hydrophilic, 
biocompatible, polymeric drug carriers.
31, 40, 60, 61
  Substitution of the -carbon and the 
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presence of an amide linkage in the side chain helps ensure hydrolytic stability.  In 
addition, HPMA was selected over other derivatives as the presence of divinyl 
compounds can be eliminated due to the crystalline nature of the monomer, as 
compared to 2-hydroxyethyl methacrylate type esters.  Various functionalities may be 
incorporated into HPMA copolymers via functionalized comonomers, allowing control 
over the composition of these systems.  In particular, side chains that include drugs, 
targeting moieties, imaging agents, or reactive groups can be combined with relative 
synthetic ease.  A major driving force behind the continued development of HPMA 
copolymers as drug carriers was the development of oligopeptide sequences as drug 
linkers.
62, 63
  These sequences were specifically designed to ensure hydrolytic stability 
during systemic transport and the ability to be enzymatically cleaved by lysosomal 
enzymes following cellular internalization.
64
  In developing such a system, early studies 
with model enzymes demonstrated that factors such as peptide sequence structure and 
length, drug loading, drug structure, and steric hindrance play important roles in 
stability and drug release kinetics.
65, 66
  Studies evaluating release in the presence of the 
lysosomal enzyme cathepsin B resulted in the isolation of the tetrapeptide sequence 
glycylphenylalanylleucylglycine (GFLG).  Numerous HPMA copolymer-drug 
conjugates utilizing this lysosomally cleavable linker have been reported to date,
67-70
 
including several HPMA copolymers used in clinical trials.
25, 71
   
 PK1 was the first clinically investigated water soluble polymer-drug conjugate 
for cancer therapy.
72
  This agent consists of the anticancer anthracycline antibiotic 
doxorubicin attached to a HPMA copolymer backbone via the lysosomally degradable 
sequence GFLG (Figure 2.4).  PK1 has a molecular weight of approximately 30 kDa 
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Figure 2.4.  Representative structure of PK1 (FCE28068), a HPMA copolymer 
conjugate bearing the anticancer agent doxorubicin bound via the lysosomally 
degradable Gly-Phe-Leu-Gly (GFLG) linker (≠).  PK1 was the first anticancer 




and contains 8.5% doxorubicin by weight.
73
  The stability of the GFLG linkage to 
doxorubicin was demonstrated following intravenous administration, with no release of 
free doxorubicin and biological inactivity of covalently bound doxorubicin.
73
  PK1 in 
comparison with free doxorubicin also demonstrated decreased cardio- and bone 
marrow toxicity in animals.  In addition, tumor accumulation of doxorubicin was 
increased 17- to 70-fold as compared to free doxorubicin in melanoma tumor bearing 
mice.
74
  These promising results led to the further clinical development of PK1.
25, 75
  
PK1 was generally well tolerated with no alopecia until doses greater than 180 mg/m
2
, 
and no anthracycline related cardiotoxicity until doses greater than 1680 mg/m
2
.  
Efficacy was marginal with 2 partial and 2 minor responses out of 36 patients observed 
during phase I studies, and 6 partial responses out of 56 evaluable patients during phase 
II studies.  Building on the experience gained during the evaluation of PK1, a number of 




In the recent decade, strategies to improve on the first generation of HPMA 
based polymer conjugates have been investigated.  For example, HPMA copolymers 
exhibiting pH dependent drug release have been described (see Section 2.3.6 on pH 
sensitive systems). The versatility of HPMA copolymer design has also allowed a wide 














  Conjugates bearing a combination of drugs have also been 
investigated.
82, 86, 87
  A “drug-free” strategy has also been reported, wherein apoptosis of 





  More recent attention has also focused on developing backbone 




2.2.2  Dendrimers 
 Dendrimers are branched polymeric macromolecules forming a star-like 
structure.  Such unique structures allow conjugation of drugs to the surface, thus 
maximizing the potential for biological interactions.  A wide array of chemistries can be 
employed in the synthesis of dendrimers, where the core, monomer units, and surface 
functionality determine physiochemical characteristics.  However, for use in drug 
delivery applications, it is necessary to maintain biocompatibility.  Physiochemical 
properties such as solubility, surface group functionality, surface charge density, and 
stability must therefore be considered.  Tomalia et al. first described the synthesis of 
poly(amido amine) (PAMAM) dendrimers in 1985.
90, 91
  Synthesis, which occurs for 
each “generation” in a stepwise fashion, can result in dendrimers with precisely defined 
structures. With each synthetic step, the generation increases resulting in a linear 
increase in radius and an exponential increase in surface groups.
92
  For example, 
PAMAM dendrimers are synthesized from an ethylenediamine core followed by 
subsequent half-generation addition by reaction with methyl acrylate and complete 
generation synthesis by reaction with ethylenediamine.  A major advantage of 
dendrimers, as compared to most linear polymers, is their synthetic precision, often 
yielding structures with polydispersity indices (Mw/Mn) less than 1.05.
93
  In addition, 
the large number and density of functional groups at the dendrimer surface provides 






 etc.  
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 In the field of drug delivery, much of the work with dendrimers has focused on 
their use in the encapsulation and formulation of drugs.
98
  Due to their hyper branched 
structure, dendrimers often possess open cavities between adjacent branches, thus 
allowing encapsulation of drugs.
99
  This can aid in the solubilization of poorly water 
soluble drugs.  In addition, dendrimers formulated (physically mixed) with drugs have 




 delivery systems.  Dendrimers with 
positively charged surface functionalities, such as poly(ethyleneimine) and PAMAM 
dendrimers, have also been investigated as gene carriers,
102
 due to their ability to 
complex with negatively charged DNA. 
 Despite much progress, clinical translation of dendrimer based drug delivery 
systems has been limited due to concerns over their biocompatibility and toxicity.  
Dendrimers have been shown to exhibit high affinity for metal ions, lipids, bile salts, 
proteins, and nucleic acids, resulting in the disrupting of biological processes and 
leading to toxicity.
103
  The molecular toxicity of dendrimers depends primarily upon 
their surface functionalization.  In particular, dendrimers with a highly positive surface 
charge have been shown to elicit toxicities in vitro
104, 105
 and in vivo.
106, 107
  Therefore, 
much effort is currently focused towards surface modification of dendrimers to increase 
biocompatibility.  In addition, the difficulty and expense associated with dendrimer 
synthesis needs to be addressed before clinical translation can be achieved. 
 
2.2.3  Polymeric micelles  
Micelles are colloidal particles with a size of about 5-150 nm that consist of self-
assembled aggregates of amphiphilic molecules or surfactants.  Amphiphiles, at low 
26 
 
concentrations in aqueous media exist as unimers in solution.  However, as their 
concentration is increased, thermodynamic processes drive the formation of aggregates 
which sequester hydrophobic regions into core like structures surrounded by a 
hydrophilic corona or shell.  The concentration at which aggregation occurs is 
commonly referred to as the critical micelle concentration (CMC).  Traditionally, low 
molecular weight surfactants (i.e., polysorbates, sodium dodecyl sulfate, etc.) with 




 M have been used extensively in 
pharmaceutical formulations, primarily as excipients to increase the aqueous solubility 
of poorly water soluble drugs.
108
  Hydrophobic drugs are contained within and associate 
with the hydrophobic regions of the micelle.  However, following administration, 
dilution of a given pharmaceutical formulation occurs rapidly, and as the micelle 
concentration drops below its CMC, its stability is compromised. 




 and coworkers described the potential 
use of amphiphilic polymers as drug carriers. These polymeric micelles are primarily 
composed of block-copolymers with hydrophilic and hydrophobic units that also self-
assemble into a hydrophobic core surrounded by a hydrophilic shell (Figure 2.5).  Each 
micellar unimer unit can be assembled in various fashions such as A-B diblock 
copolymers, A-B-A triblock copolymers, and grafted copolymers.  A major advantage 
of polymeric micelles as compared to traditional low molecular weight surfactant 
derived systems is their increased stability.  Polymeric micelles commonly exhibit 






  The ideal polymeric micelle should demonstrate 
high drug loading, controlled drug release, and suitable biological compatibility and 
stability.  Physiochemical properties of polymeric micelles are primarily based on the 
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Figure 2.5.  An example of a polymeric micelle.  A typical example of a polymeric 
micelle unimer structure composed of both hydrophilic (mPEG) and hydrophobic 
(PCL) blocks.  Hydrophobic drugs associate with hydrophobic domains of the micelle 





characteristics and lengths of the hydrophilic and hydrophobic blocks.  PEG is the most 
commonly employed hydrophilic polymer, due to highly hydrated nature and ability to 
resist uptake by the reticuloendothelial system (RES).  However, a number of other 
hydrophilic polymer chemistries have been applied including poly(N-vinyl-2-
pyrrolidone) (PVP),
112
 poly(vinyl alcohol) (PVA),
113
 and poly(ethyleneimine) (PEI).
114
  
PEG remains the polymer of choice due to its widespread acceptance and availability.  
A large variety of unimers to form hydrophoblic blocks have been utilized in forming 
the hydrophobic core of polymeric micelles.  Examples include propylene oxide, L-
lysine, caprolactone, D,L-lactic acid, styrene, aspartic acid, β-benzoyl-L-aspartate, and 
spermine among others.
115
  More hydrophobic unimers (i.e., styrene) form micelle cores 
spontaneously, while other less hydrophobic unimers (i.e., lysine) first interact via 
electrostatic interactions with hydrophobic drug molecules, followed by micelle 
formation.
116
  CMC tends to depend more on the type and length of the hydrophobic 




Continued advances are being made in the development of polymeric micelles.  
Increasingly, there is a trend towards “smart” polymeric micelles in terms of their 
response to various biological stimuli and their ability to target specific tissues.  
Another interesting application involves the use of polyion complex (PIC) micelles, 
wherein the micelle core is composed of a polycation block, for the delivery of 
negatively charged DNA or small interfering RNA (siRNA).
119, 120
 Polymeric micelles 
based on HPMA copolymers have also been described.
121
  PolyHPMA has been used 





 or following chemical modification, as the hydrophobic 
core.
126, 127
  A variety of hydrophobic drugs have also been encapsulated in these 
micelles; however, the majority of the data on the activity of these systems to date have 
been obtained in vitro,
121, 127, 128
 and more in vivo data are needed to ascertain their 
potential as carriers. 
An advantage of polymeric micelles as compared to other polymeric drug 
carriers is their relative ease of fabrication, due to their inherent self-assembly 





2.2.4  Biodegradable polymers 
  A major advantage of polymer-drug conjugates is their ability to escape 
filtration via the kidneys, resulting in an increased blood circulation time.  For anti-
cancer conjugates, an added advantage is increased tumor accumulation via the 
previously described EPR effect for conjugates at least greater than 3.5 nm.
53
  However, 
eventual elimination from the body is also required to reduce potential long term 
adverse effects of these carriers.  The use of biodegradable systems allows conjugates of 
a sufficient size to both evade renal filtration and allow subsequent degradation and 
elimination.  Such conjugates should have degradation rates slow enough to allow 
adequate biodistribution, and such degradation should result in the production of non-
toxic degradation products.  A number of biologically degradable bonds have been 
described.  Biodegradation generally occurs via hydrolysis, enzymatic cleavage, or 





include poly(-amino acids) such as poly(L-lysine),132 poly(L-glutamic acid),133 and 
poly ((N-hydroxyalkyl)glutamine)
134













 An example of a biodegradable polymer-drug conjugate currently under phase 
III clinical development in the United States is OPAXIO

 (formerly branded as 
XYOTAX), which is a conjugate of poly(L-glutamic acid) and the anticancer agent 
paclitaxel.
38
  Poly(L-glutamic acid) was chosen as its breakdown product L-glutamic 
acid can enter normal cellular metabolism and is not cleared via the kidneys.  Paclitaxel 
is conjugated via an ester bond to the -carboxylic acid side chains.  In addition, 
because conjugation is via the 2’ hydroxyl of paclitaxel, the conjugate is unable to bind 
tubulin and elicit its pharmacological action, thus rendering it inactive.  In one example, 
the poly(L-glutamic acid) conjugate had a molecular weight of 48 kDa, and contained 
approximately 37% by weight paclitaxel, while maintaining water solubility.  During 
preclinical investigation, this conjugate demonstrated a higher maximum tolerated dose 
(MTD) and was more efficacious than paclitaxel formulated in Cremophor EL/ethanol.  




 in prostate, breast, 
ovarian, colorectal, and lung cancers. 
 Strategies to produce biodegradable derivatives of more traditional polymers 
such as PEG and HPMA copolymers have also been investigated.  As mentioned 
previously, biodegradable multiarm PEGs
143
 (i.e., ENZ-2208) containing ester bonds 
between PEG chains have entered clinical trials.  Another strategy in which a 
biodegradable polymer consisting of small molecular weight PEG blocks is linked 
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together via enzymatically cleavable oligopeptide groups, and bearing the anti-cancer 
agent doxorubicin, has been described.
144
  Work by Ulbrich and coworkers has utilized 
a variety of approaches to generate biodegradable HPMA copolymer-drug conjugates 
including graft systems containing oliogopeptide sequences and/or reductive disulfide 
bonds,
145
 as well as the generation of biodegradable star HPMA copolymer-drug 
conjugates.
146
  In the latter, PAMAM dendrimers were modified with polyHPMA grafts 
via enzymatically cleavable or reducible linkers, thus enabling degradation of the high 
molecular weight polymer.  These star polymer conjugates bearing doxorubicin 
exhibited prolonged blood circulation, increased tumor accumulation, and anti-tumor 
efficacy in lymphoma tumor bearing mice.
147
  Other recent work by Kopecek and 
coworkers on the synthesis of biodegradable multiblock poly(HPMA) conjugates 
generated via a combination of RAFT polymerization and click chemistry has been 
described.
83, 89, 148
  This demonstrates how advances in chemistry (i.e., RAFT 
polymerization and click chemistry) can be utilized to generate new biodegradable 
polymer-drug conjugates with well-defined physicochemical properties. 
 
2.2.5  Stimuli-sensitive polymers 
 So called “smart polymers” have been engineered to contain a vast array of 
properties, including the ability to respond to changes in environmental stimuli such as 
pH, ionic strength, temperature or externally applied heat, magnetic or electric fields, or 
ultrasound.
149
  Such polymers commonly respond via conformational and/or 
electrostatic changes, which can be exploited to help facilitate a particular function (i.e., 
drug release, endosomal escape, etc.).  Carriers which respond to variations in pH and 
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temperature have found the greatest versatility in drug delivery and will be reviewed in 
brief below. 
 
2.2.6  pH sensitive systems 
 Exploiting physiological variations in pH has been widely investigated as a 
means to obtain site specific delivery.  The pH of diseased areas such as tumors, 
infarcts, and sites of inflammation may drop to around 6.5, almost one full pH unit 
below that of normal blood (pH 7.4) due to hypoxic conditions and extensive cell 
death.
150, 151
  In addition, following cellular uptake via endocytosis, the pH of late 
endosomes may reach values as low as 5.0, further providing a gradient over which 
release may be triggered.
152
  The polymer backbone can be made pH sensitive, typically 
through the inclusion of acidic (i.e., carboxylic and sulfonic acids) or basic (i.e., 
ammonium salts) groups that undergo protonation or deprotonation in response to 
changes in pH.  Commonly studied chemistries of this nature include poly(acrylamide) 
(PAAm), poly(methacrylic acid) (PMAA), poly(acrylic acid) (PAA), and poly(2-
(dimethylamino)ethyl methacrylate (PDMAEMA).
153
  Utility is primarily found in non-
conjugated systems such as micelles, liposomes, and other nanocarriers, where 
conformational changes disrupt the stability of the carrier resulting in drug release.
154
 
As for polymer-drug conjugation, pH sensitivity is introduced primarily via pH 
sensitive chemical bonds, which can result in site specific drug delivery.  For example, 
hydrazone bonds formed via the action of hydrazine on ketones or aldehydes exhibit 
hydrolysis under mildly acidic conditions (pH 5-6) such as that present in lysosomes 





A number of pH responsive polymeric micelles have also been described 
including systems in which doxorubicin was conjugated to the side chains of the micelle 
core-forming blocks via hydrazone bonds.
157
  The micelles demonstrated both time and 
pH dependent release, with increased release under endosomal low pH conditions (5.0-
5.5).
157
  Biodistribution studies showed minimal signs of premature drug release, and 
selective accumulation in tumors and the anti-tumor efficacy of these pH sensitive 





2.2.7  Temperature-sensitive systems 
 The concept of using temperature to control drug delivery is in part due to the 
observation that elevated temperature can be associated with diseased tissues.  In 
addition, the external application of hyperthermia can be utilized as a trigger to induce 
changes in polymer structure resulting in drug release.  Water soluble temperature 
sensitive polymers such as those based on poly(N-isopropylacrylamide) 
(poly(NIPAAM)) undergo a lower critical solution temperature (LCST) phase 
transition, wherein polymer chains collapse and aggregate at temperatures above their 
LCST due to the reversible dehydration of hydrocarbon side chains.
159
  The LCST for 
poly(NIPAAM) is approximately 32C.  However, the LCST of such polymers can be 
adjusted by changing the N-substituted carbon chain or via copolymerization.
160
 
 Over the past decade, elastin-like polypeptides (ELPs) have been investigated in 
drug delivery applications.  ELPs are recombinant polymers produced using genetic 
engineering techniques,
161, 162
 resulting in monodisperse polymers with precisely 
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defined molecular weights and compositions.
163
  They consist of a repeated peptide 
sequence based on a motif found in mammalian tropoelastin (VPGXG)n, where X is 
defined as any residue except proline.
164
  ELPs exhibit an LCST above which they 
become insoluble.  This LCST can be varied by modifications in molecular weight and 
composition.  A number of strategies utilizing the thermo sensitive nature of ELPs have 
been investigated.  For example, ELPs with LCST above normal body temperature but 
below 43C have been utilized as anticancer drug carriers, in which systemic delivery is 
combined with localized hyperthermia to tumor tissue, resulting in an increased 
accumulation of ELP aggregates within the tumor.
165
  Other strategies including the use 





2.2.8  Theranostics 
 In addition to their application as therapeutics agents, polymer-drug conjugates 
and other nanomedicines are increasingly being studied for diagnostic purposes.  The 
combination of use of therapeutics and diagnostics has resulted in the term 
“theranostics” which defines delivery systems bearing both therapeutic and imaging or 
contrast agents.
168
  Such systems allow for a more personalized medicine approach, 
wherein therapy can be directly monitored and custom tailored.  Multiple benefits may 
be realized from these multifunctional systems.  For example, biodistribution and 
accumulation at the target site of therapy can be monitored in a non-invasive manner.  
In addition, localization at the target site can be used as an accurate predictor of 
efficacy, thus relieving a patient from subsequent therapy that might not prove 
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efficacious.  This can be achieved by first administering a tracer version of an imaging 
agent labeled conjugate.  Those patients who demonstrate abnormal or unfavorable 
biodistribution, pharmacokinetics, or localization at the target site are then disqualified 
from treatment with a therapeutic version of the conjugate.  Imaging modalities such as 
optical imaging, x-ray computed tomography (CT), dynamic contrast enhanced 
magnetic resonance imaging (DCE-MRI), single photon emission computerized 
tomography (SPECT) and positron emission tomography (PET) are well established and 
provide the necessary tools to allow spatial visualization and quantification of delivery.  
For example, during the initial clinical evaluation of HPMA copolymer-doxorubicin 
conjugates (PK1, PK2), localization was visualized in patients following treatment with 
131
I radiolabeled conjugates, allowing information related to potential toxicities and 
tumor accumulation to be obtained early in the development process.  Details regarding 
the use of macromolecules in theranostic applications are outside the current scope, but 
have been the subject of several reviews
168, 169
 and it is anticipated that going forward, 
multifunctional polymer-drug conjugates bearing imaging agents will play a role in the 
future of image guided drug delivery and personalized medicine. 
 
2.3  Targeted anticancer therapies 
The inherent cytotoxicity and resulting dose limiting toxicity of cancer 
chemotherapeutics has driven the development of targeted anticancer therapies.  The 
first goal of any targeted therapy is to concentrate the effect, or pharmacological action, 
of a therapeutic agent at the intended site of disease.  The second goal is to minimize 
undesired side effects.  For polymer-drug conjugates, this can be achieved passively via 
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the EPR effect (see Section 2.3).  Specificity is also gained through a combination of 
pharmacologic and/or active targeting strategies.  The basis and rationale of these 
strategies, along with their current limitations, will be discussed in this section. 
 
2.3.1.  Pharmacological targeting 
 In anticancer therapy, the common goal of most chemotherapeutics is to disrupt 
cellular division, thereby inhibiting proliferation of the cancerous tissue.  Therefore, the 
pharmacologic targets of these chemotherapeutics are often proteins or enzymes 
associated with cell division.  For example, the chemotherapeutic camptothecin, which 
demonstrates strong anti-tumor activity, strongly inhibits DNA and RNA synthesis via 
inhibition of topoisomerase I, an enzyme required for nucleic acid coiling and 
uncoiling.
170
  DNA itself is also a potential target as DNA duplication is also required 
for cell division.  For example, the anthracycline antibiotic doxorubicin inhibits cell 
division by intercalating DNA, thereby inhibiting the progression of topoisomerase II, 
effectively halting DNA replication.
171
  This form of pharmacological targeting, has 
proven itself very successful, given the current array of chemotherapeutics on the 
market today.  However, since the process being targeted is not fundamentally cancer 
specific, but is cell division specific, other cells in the body are affected.  Primary 
examples included white blood cells, gastrointestinal epithelial cells, and hair cells.  
These off-target interactions give rise to adverse effects, many of which are dose 
limiting and can be life threatening.  Therefore, additional strategies have been sought 




2.3.2  Active targeting 
 Active targeting strategies seek to exploit inherent differences between cancer 
cells and cells of healthy, normal, tissues.  In particular, differences in the expression of 
cell surface receptors are an attractive target.  For a number of targeted therapeutic 
agents, such as monoclonal antibodies, receptor binding is intended to result in a 
pharmacological response, commonly via signal transduction (i.e., receptor tyrosine 
kinases), or receptor inhibition via competition with native ligands (i.e., vascular 
endothelial growth factors).  For drug delivery systems already carrying therapeutic 
agents (i.e., antibody-drug conjugates, polymer-drug conjugates, or other 
nanomedicines), pharmacological action upon binding is not a prerequisite.  Instead, 
interaction and binding with the receptor is intended to facilitate retention and 
internalization. 
A tremendous amount of effort developing therapeutic polymer-drug conjugates 
and other nanomedicines has focused on the inclusion of targeting moieties.  In the 
majority of cases, physicochemical properties of polymer-drug conjugates such a size, 
surface charge, conformation, and biocompatibility dictate how absorption, distribution, 
metabolism, and excretion take place.
172
  As previously described, polymer-drug 
conjugates with a size above renal threshold exhibit longer blood circulation times, 
thereby increasing the probability for a conjugate to interact with its target.  The 
benefits of so called “active targeting” are realized by increasing binding to and 
internalization into the cells of target tissues, phenomena which occur over short 
distances.  Targeting can therefore be utilized as a way to maximize the effect of 
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“passive targeting” mechanisms, by ensuring that physically delivered polymer-drug 
conjugates remain at their intended site of action. 
 A number of features characterize an ideal target.  The target should be 
universally and uniquely expressed by the diseased tissue.  The vast majority of 
targeting strategies rely on the over expression of particular cell surface markers in 
diseased cells as compared to normal cells.  Therefore, the probability of binding and 
cellular uptake of a conjugate with its intended target is increased as compared to 
normal cells.  While it is well understood that expression of a particular target is 
generally not entirely specific, it is nevertheless anticipated that the large relative 
differences in expression between diseased and normal cells can still be utilized as an 
effective targeting strategy.  Ideally, the target should also facilitate endocytosis 
following binding of the conjugate, thereby allowing the agent to exert its 
pharmacological action within the cell. 
 Sugars, hormones, growth factors, antibodies, antibody fragments, peptides, or 
other small molecules can be utilized as targeting moieties.
173-176
  The targeting moiety 
must include the necessary functionality to facilitate conjugation, and should be 
conjugated in a manner that will ensure its stability during systemic circulation.  
Different targeting moieties have distinct advantages and disadvantages.  Antibodies, 
for example, provide excellent binding affinity and target selectivity.  However, their 
large size can drastically influence the properties of the carrier.  Also, the relative cost 
associated with antibody production, conjugation, and concerns over their stability and 
immunogenicity remain important issues.  The use of antibody fragments (Fab, single-
chain variable fragments (scFvs)) can partially address these concerns.
177
  These 
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proteins retain the specificity of the original antibody, but are reduced in size, and can 
often be synthesized in bacterial cultures and thus reduce synthetic cost.  Other targeting 
moieties such as peptides, sugars, and hormones can generally be readily synthesized at 
low cost, but they typically have reduced binding affinity and specificity as compared to 
antibodies and antibody fragments.  These advantages and disadvantages and the choice 
of carrier dictate targeting moiety selection.  How the binding affinity of the targeting 
moiety is affected following conjugation must also be evaluated. 
 Recent work has focused on developing HPMA copolymers containing cyclic 
Arg-Gly-Asp (RGD) peptides that target vβ3 integrins expressed on angiogenic tumor 
blood vessels and tumor cells.
70, 84, 178-180
  Copolymers containing a derivative of the 
anticancer and antiangiogenic agent geldanamycin (aminohexylgeldanamycin 
(AHGDM)) bound to the polymer backbone via the lysosomally degradable GFLG 
linker were synthesized and characterized.  Molecular weight was maintained below 40 
kDa to allow eventual renal clearance following administration.  The conjugates 
demonstrated the ability for drug release, binding to vβ3 integrins, and introduced 
cytotoxicity in endothelial and prostate cancer cells at concentrations similar to the free 
drug controls.  To assess the efficiency of targeting, the biodistribution of 
125
I-labeled 
copolymers was evaluated in prostate cancer bearing mice.  Significantly higher 
localization was observed in the tumor following administration of the HPMA 
copolymer containing cyclic RGD peptides as compared to an untargeted control 
(Figure 2.6).  In addition, the tumor accumulation of released drug was quantified by 
tumor extraction followed by HPLC analysis.  Significantly higher concentrations of 
AHGDM were observed following administration of the targeted conjugate.  In vivo 
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efficacy studies were performed in prostate cancer tumor bearing mice.  Percent tumor 
growth as a function of time was evaluated following a single dose of HPMA 
copolymer-AHGDM-cyclic RGD, HPMA copolymer-AHGDM (untargeted control), 
AHGDM (free drug control), or saline (negative control).  The study also included a 
large molecular weight HPMA copolymer-AHGDM conjugate so as to see how efficacy 
via RGD targeting would compare to conjugates relying solely on “passive” targeting 
via the EPR effect.  Tumor growth was suppressed more for HPMA copolymers bearing 
cyclic RGD peptides as compared to both untargeted controls (small and large 
molecular weight) and free drugs (Figure 2.6).  The results demonstrate that an 
appropriately selected targeting strategy can yield increased tumor delivery resulting in 
the increased efficacy of cancer chemotherapy. 
2.3.2.1  Challenges and limitations of active targeting.  While substantial 
progress has been made in utilizing active targeting strategies to deliver nanomedicines 
and polymer-drug conjugates, challenges and fundamental limitations remain. 
First, inclusion of targeting moieties is often associated with increased material 
cost and synthetic complexity.  This is of significant concern when dealing with 
advanced drug delivery systems, where cost is already elevated as compared to 
traditional therapeutics.  Clinical translation of such a system will require significant 
benefits in measureable patient outcomes, the most significant of which are safety and 
efficacy.  Simply put, the benefit must outweigh the cost.  In an attempt to find an 
alternative, low cost, effective targeting strategy, Torchilin and coworkers have 
described paclitaxel loaded polymeric micelles modified with a tumor-specific phage 
protein.
181
  The amphiphilic nature of the phage fusion coat protein enabled stable 
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Figure 2.6.  Active targeting.  (A) Tumor regression as a function of time in 
DU145 human prostate cancer tumor bearing nu/nu mice. RGD targeted HPMA 
copolymers demonstrated significant efficacy as compared to untargeted HPMA 
copolymers and free drug controls. (B) Biodistribution in DU145 bearing mice of 
125
I-radiolabeled HPMA copolymers bearing AH-GDM and cyclic RGD peptides. 
Increased accumulation was observed in tumor tissues, as compared to the 




incorporation into the polymeric micelles without the requirement for specific 
conjugation chemistry and this approach relied completely on the inherent self-
assembly of the phage protein into the micelles, resulting in synthetic ease.  In vitro 
evaluation of cellular uptake and cytotoxicity demonstrated enhanced activity as 
compared to free paclitaxel and nontargeted micelles.
181
  However, the clinical utility of 
such systems remain to be proven. 
A more fundamental limitation of active targeting strategies is the inherent 
difference in cell surface expression of the target receptor in cancer cells as compared to 
normal cells.  Most often, the criteria for target selection is “overexpression” of the 
receptor on the surface of cells in cancerous tissues.  For example, breast cancer tumors 
are often diagnosed via immunohistochemistry or fluorescence in situ hybridization as 
either positive or negative for human epidermal growth factor receptor 2 (HER2/neu).
182
  
If diagnosis is positive, treatment with trastuzumab
183
 (trade name Herceptin
®
), a 
monoclonal antibody that interferes with the action of HER2/neu is often indicated.  If 
the diagnosis is negative, trastuzumab treatment is not considered.  While this approach 
has proven successful, it does not fully consider the heterogeneous nature of tumors.  In 
reality, tumors are comprised of phenotypically distinct cell types, due to high genetic 
instability.
184, 185
  Treatment, which focuses on a particular cell surface target, will 
therefore elicit its response to a higher degree in cells expressing this target.  This 
process of selection can result in tumor adaptation.  The effectiveness of subsequent 
treatments can then be diminished, due to lack of expression of the required target, 
eventually resulting in tumor resistance.  Therefore, additional strategies, without such 
fundamental limitations are required. 
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This thesis proposes and evaluates an additional targeting strategy that can 
supplement the aforementioned pharmacological, passive, and active targeting 
strategies.  This is achieved through the use of tumor hyperthermia to first induce the 
expression of cell surface heat shock proteins, followed by subsequent treatment with 
heat shock protein targeted polymer-drug conjugates. 
 
2.4  Hyperthermia and the heat shock response 
Hyperthermia, defined herein as the elevation of tissue temperature, has been 
investigated for some time due to its inherent ability to induce cell death.
186
  In this 
Section, the potential role of hyperthermia in anticancer therapy will be reviewed, 
including a discussion regarding currently utilized methods such as radiofrequency (RF) 
and microwave (MW) radiation and a relatively new option for inducing hyperthermia, 
high intensity focused ultrasound (HIFU).  An introduction to photothermal therapy, 
generated via laser radiation of plasmonic gold nanorods, will be presented, as this was 
the method utilized to induce tumor hyperthermia during the in vivo studies of this 
thesis.  The biological response to hyperthermia at both the tissue and cellular level will 
be reviewed, and the rationale and potential for using these responses as a means to 
increase the delivery of nanomedicines, and polymer-drug conjugates in particular, will 
then be explained.  Specifically, the biological role of glucose regulated protein 78 kDa 






2.4.1  Anticancer applications of tumor hyperthermia 
Application of hyperthermia to tumor tissue has been investigated in anticancer 
applications for many decades.
186
  The term hyperthermia generally refers to the 
temperatures between 40°C and 45°C, with those exceeding 45°C referred to a 
thermoablative.
187, 188
  A fundamental difference in the response of tumors to heat as 
compared to normal tissues provides a basis for achieving an anticancer clinical 
approach.  The vasculature of normal tissues responds to heat by dilation, which aids in 
heat dissipation.
189
  This dilation is made possible via autoregulation of the smooth 
muscle layer.  In contrast, the vasculature of tumor tissue, due to its lack of smooth 
muscle development and proper innervation as a result of rapid growth, is unable to 
respond in a similar manner to the same extent.
190
  These observations have driven the 
investigation of thermoablative strategies, where the goal is to deliver a thermal dose 
that is large enough so that the tumor cannot dissipate the heat, resulting in localized 
cell death.  However, these strategies are subject to the following theoretical limitations.  
First, this phenomena has been primarily investigated in laboratory animal models of 
cancer, where tumors are growing at a rapid rate.
191
  The resulting vasculature of such 
tumors is therefore less likely to be as maturely developed as that occurring in humans.  
The observations made in such models may therefore be overestimating this 
phenomenon.  Also, in human tumors, tumor growth often invades normal tissues, 
where the vasculature will be more developed and able to respond to external stimuli.
189
  
Therefore, these differences in the ability to dissipate heat may be minimized in these 
regions.  Despite these limitations, tumor hyperthermia has proven effective and is 
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2.4.2  Effects of moderate hyperthermia on the tumor microenvironment 
In early clinical studies evaluating the efficacy of hyperthermia against various 
tumors, difficulty in achieving the temperatures necessary to produce cytotoxic effect 
(greater than 42-43°C) was encountered.
189
  However, such therapies nonetheless 
affected the response of tumors to chemotherapy and radiotherapy wherein increased 
sensitization was observed in combination with these hyperthermic treatments.
193-195
  
Over time, it became clear that this added effect was not primarily due to an increase in 
cellular death elicited by hyperthermia, but due to changes in tumor blood flow.
189
 
During conditions of moderate hyperthermia (less than 43°C), increases in 
tumor blood flow have been observed in numerous studies.
196
  For example, one 
study
197
 reported a 2-fold increase in rat carcinoma tumors when heated to 43°C for 20 
min.  Interestingly, this increase was then followed by a decrease when the heating was 
further prolonged.  Similar observations have been made by others, suggesting the use 
of shorter periods of hyperthermic treatment where increased tumor blood flow is 
desired.
198
  As previously described, the developing structure of the tumor vasculature is 
poorly organized, with small gaps present between endothelial cells.  The extravasation 
of polymer-drug conjugates through these gaps is a major factor in driving increased 
tumor accumulation.  During condition of moderate hyperthermia, these gaps 
potentially can be further opened, resulting in augmentation of the EPR effect.  It has 
also been suggested that during hyperthermic treatment, as the tumor works to dissipate 
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heat via increases in blood flow, an increase in the average temperature of circulating 
blood can occur.
199
  This can then result in an elevation of cardiac output during the 
hyperthermic treatment, thereby further increasing blood flow.  The resulting increases 
in tumor blood flow provide an increased opportunity for circulating polymer-drug 
conjugates to accumulate in tumor tissue via the EPR effect.  These phenomena 
therefore provide additional rationale for a combination therapy of hyperthermia and 
polymer-drug conjugates.  
 
2.4.3  Methods for inducing tumor hyperthermia 
Initially, primitive methods for inducing tumor hyperthermia were limited in 
their ability to achieve clinically necessary temperature increases in a specific 
manner.
189
  Often these methods resulted in application of significant heat to 
surrounding tissues.  Some of these early methods include heated needles and water 
baths coupled with peristaltic pumps.  For example, one clinical study
200
 evaluated a 
system wherein a heat exchanger and a peristaltic pump were used to circulate a 42-
43°C electrolyte solution containing the anticancer agent cisplatin throughout the 
peritoneal cavity of cancer patients.  This method was reported to be successful, in that 
patients achieved a median survival time of 20 months as compared to the anticipated 
period of 6 months (control).  Similar techniques have also been utilized by other 
groups to achieve positive results. 
2.4.3.1  Radiofrequency and microwave devices.  To date, the most commonly 
used methods of inducing hyperthermia are via RF and MW radiation.  These devices 
generally consist of an applicator (i.e., catheter) which is directed under imaging into 
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the region of interest, such as a tumor.  Localized generation of an electromagnetic 
(EM) field induces ionic movement resulting in local heat generation from resistive 
losses.
201
  For both RF and MW radiation, the amount of energy absorbed/transduced 
into heat decreases exponentially in tissues surrounding the applicator.
201
  Selection of 
the appropriate EM wavelength is based upon considerations of tumor size and depth.  
Lower frequencies (i.e., RF radiation) provide advantages with respect to tissue 
penetration, but suffer from low resolution due to the large wavelengths involved.
202
  
Conversely, higher frequencies (i.e., MW radiation) allow focused heat generation, but 
suffer from higher attenuation which restricts penetration.  While these methods are 
performed in a minimally invasive manner, they can cause significant heating in 
surrounding fat tissues, and are generally not capable of delivering hyperthermia 
selectively without damaging adjacent tissues.
188
  In addition, the performance of these 
devices is marginalized when placed next to large vessels that can carry away generated 
heat.
202
  Although these methods and others previously described have demonstrated the 
clinical utility of hyperthermia, it is acknowledged that such techniques are crude at best 
in their ability to treat tumors in a specific manner.  Therefore, other methods are being 
developed that allow hyperthermia to be induced with a greater degree over both 
temperature and temporal distribution. 
2.4.3.2  High intensity focused ultrasound (HIFU).  HIFU utilizes ultrasound 
waves generated using a spherical transducer.  As these waves travel through tissue, 
they deposit some of their energy in a kinetic manner.  During imaging applications, 
this amount of energy is generally insignificant.  However, by focusing the waves to 
coincide with constructive interference at a fixed point, a large amount of energy can be 
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transduced, resulting in localized hyperthermia.
203
  HIFU has generally been 
investigated in anticancer applications as an ablative therapy, where high temperatures 
are delivered to elicit cellular and vascular damage.  Two primary mechanisms are 
responsible for such damage.
204
  First, the thermal effect, due to absorption of the 
ultrasound energy and its subsequent conversion into heat, elicits damages as previously 
described.  Second, a process termed cavitation occurs at higher energies as a result of 
the interaction of ultrasound waves and micro-bubbles of water.  These microbubbles 
can grow and oscillate in the ultrasound field, and ultimately collapse, resulting in 
mechanical damage to tissue.  This damage is marginally visible and can generally by 
visualized by magnetic resonance imaging (MRI), using gadolinium-enhanced T1 
mapping.
205
  MRI is also being investigated as a means to monitor temperature changes 
during HIFU, but this technique is not, as of now, widely used in clinical settings.
206
  It 
is probable that the clinical use of HIFU in anticancer therapies will continue to grow, 
due to its ability to generate high temperatures in a highly specific and minimally 
invasive manner. 
2.4.3.3  Gold nanoparticle-induced hyperthermia.  Gold nanoparticles have been 
utilized in a number of biomedical applications.
207
  Traditionally, colloidal gold and 
gold salts have been found useful as a pharmacologic agent by the medical and holistic 
health communities for the treatment of conditions ranging from depression, headache, 
fever, and most predominantly, rheumatoid arthritis.
208
  In addition, over time, its 
widespread use with little observed adverse effects have minimized safety concerns.  In 
one particular study, treatment with gold nanoparticles at doses less than 2 g/year for 10 
years has been well tolerated, without any signs of general toxicity.
209
  This can be 
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attributed to the chemically inert nature of gold itself, showing little physical reactivity 
with biological chemicals and structures.
210
  While there have been some concerns 
raised regarding biocompatibility due to reported activation of the immune complement 
system,
211, 212
 methods intended to enhance their biocompatibility by surface 
modifications with PEG or dextrans have imparted advantages by way of reducing bio 
recognition,
213
 similar to that observed for PEG-protein conjugates as previously 
described.  Gold nanoparticles can also be synthesized in a controlled manner with 
relative ease using inexpensive starting materials.  The combination of these 
characteristics has made gold nanoparticles attractive candidates for biomedical 
applications. 
 An important characteristic of gold nanoparticles, which is utilized in this thesis, 
is their ability to absorb light and convert this energy of absorption into localized heat.  
This light absorption occurs due to the characteristic surface plasmon resonance (SPR) 
of these particles when they are in the colloidal form.
214
  This resonance often occurs in 
the near infrared region of the electromagnetic spectrum, which is advantageous 
because light of these wavelengths can penetrate deep (up to 2-3 cm) into tissues.
215
  
Gold nanorods, utilized in our studies, are advantageous as their characteristics, 
including size and aspect ratio, can be synthetically controlled, allowing for fine-tuning 
of the SPR peak.  Utilization of these nanoparticles for induction of local hyperthermia 
can thus be performed via the following.  First, the particles must be delivered to the 
tumor mass.  While this can be performed via interstitial injection directly into tumors, a 
more universal approach is to deliver them in a systemic manner, and allow them to 
accumulate in the tumor mass passively (i.e., via EPR) or actively using targeting 
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strategies as previously described.  Previous studies in our lab have demonstrated that 
gold nanorods, surface modified with PEG, can accumulate via the EPR effect in 
tumors at concentrations exceeding those required for photothermal therapy following 
systemic administration.
216
  This approach is utilized in this thesis to deliver PEGylated 
gold nanorods to the tumor mass.  Second, the tumor is radiated using a laser with a 
wavelength that matches the corresponding SPR peak of the nanoparticles, resulting in 
heat generation.  This method allows for hyperthermia to be administered in a highly 
selective manner, without significant disruption of surrounding tissue. 
One of the first reports by West et al. to demonstrate the systemic administration 
of gold nanoparticles and subsequent hyperthermia for thermal ablation utilized gold 
nanoshells, wherein a solid, silica core is surrounded by a thin gold shell.
217
  Following 
systemic administration of the nanoparticles in tumor bearing mice, tumor accumulation 
was observed 6 hrs after injection.  Near infrared laser treatment at 4 W/cm
3
 for a mere 
3 min resulted in 90% survival, as compared to 0% for saline administered and non-
radiated controls, clearly demonstrating the potential of this type of therapy.
218
  Much 
effort is currently being directed toward utilization of gold nanoparticles in ablative 
therapies, particularly in anticancer applications.   
In this thesis, PEGylated gold nanorods were utilized to deliver moderate 
hyperthermia.  Temperatures for this application were between 42°C and 43°C.  This 
elevation in temperature was used to trigger the heat shock protein response within the 





2.4.4  The heat shock protein response 
Organisms have adapted the ability to cope with a variety of stressful conditions 
in their quest for survival, including exposures to sudden increases in temperature.  At 
the cellular level, response to heat involves the expression of heat shock proteins 
(HSPs), whose primary roles are protective in nature.  As molecular chaperones, they 
serve to assist in folding of proteins into their native structure and under conditions of 
stress, they act to prevent protein aggregation.
219
  More recently, it has been shown that 
they play a role in signal transduction at the cell surface.  This section will summarize 
key elements of the heat shock protein response and their significance in anticancer 
therapy. 
Proteins are dynamic and flexible and relatively minor changes in conformation 
often drive various functions and catalysis.  Over time, they have adapted to perform 
these functions efficiently with minimal energy loss.  Therefore, they inherently exist in 
semi-stable states.  Thus, it is not surprising that increases in heat can quickly result in 
loss of protein function.  The adverse effects of heat on proteins include unfolding, 
misfolding, entanglement, and aggregation, with the latter being the most prominent.
220
  
Aggregation occurs as a result of increased exposure and intermolecular interactions 
between hydrophobic residues.  Molecular chaperones, including heat shock proteins 
recognize and interact with these exposed hydrophobic amino acids, thereby inhibiting 
intermolecular interactions and aggregation.
221
  This occurs through controlled binding 
and release of the substrate by the chaperone, and this difference in affinity is usually 
controlled via ATP binding and hydrolysis.
222
  Heat shock proteins can be generally 
classified as “holdases,” which act primarily under stress conditions to prevent 
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aggregation, or “foldases,” which act to stabilize proteins during folding, and can be 
either stress-induced or constitutively expressed.  Structurally similar HSPs can also 
coexist.  For example, the heat induced heat shock protein 70 kDa (HSP70) protein is 
highly homologous to constitutive heat shock protein 70kDa (HSC70).
219
  The prior is 
expressed in response to stress, while the latter’s primary role is in assisting folding of 
newly synthesized proteins. 
In anticancer applications, the goal is to provide therapy specifically in cancer 
cells, and so only those heat shock proteins which are stress induced are utilized as 
molecular or pharmacologic targets.  A large amount of this effort has been directed 
towards inhibition of heat shock protein 90 kDa (HSP90) and HSP70, due to their 
elevated expression in cancer cells where they play a role in stabilizing a number of 
cancer related proteins, including mutated p53, Bcr-Abl, Raf-1, Akt, ErbB2, and HIF-1 
alpha (Figure 2.7).
223, 224
  The ability to affect multiple cancer pathways via inhibition of 
a single HSP has made these proteins attractive anticancer targets, with a number of 
inhibitors currently under clinical investigation. 
 The most widely investigated HSP as an anticancer target is HSP90.  HSP90 is 
an ATP-dependent chaperone protein that is involved in the regulation, activation, and 
stability of a number of so called “client” proteins.  Its anticancer potential lies in the 
fact that many of these client proteins are involved in signal transduction and other 
major pathways important for cancer progression.
224
  Inhibition of HSP90 for cancer 
therapy was initially viewed with much skepticism, due to the fact that it is expressed 
constitutively in normal cells, where it plays a role in maintaining protein 
homeostasis.
223
  Initial work in the 1990s was led by the U.S. National Cancer Institute.  
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Figure 2.7.  Central role of heat shock protein (HSP) chaperones, including 




This work established HSP90 as a viable anticancer target, due to several reasons.  First, 
HSP90 functions by supporting various forms of oncoproteins, including receptor 
tyrosine kinases and transcription factors that are mutated, incorrectly located, or 
overexpressed in cancer cells.  Second, HSP90 helps to maintain cellular protein 
function under stress conditions, such as those observed in the tumor 
microenvironment.  Third, HSP90 itself is often overexpressed, and is linked to 
malignancy and cancer progression.  Combined, these results have driven the 




The use of HSP90 inhibitors in combination with hyperthermia has also been 
investigated.  As hyperthermia increases protein denaturation and aggregation, it makes 
logical sense that co-administration of a HSP90 inhibitor would impair the cellular 
response to this increased stress, resulting in eventual apoptosis.  A number of studies 
have established such synergistic effects using HSP90 inhibitors in combination with 
hyperthermia.
226-228
  For example, one study investigated the use of geldanamycin, a 
potent inhibitor of HSP90, in combination with hyperthermia in a melanoma model.
226
  
They demonstrated in vitro that treatment with geldanamycin increased susceptibility to 
hyperthermia and reduced the expression of the HSP90 client protein Akt.  They also 
demonstrated in vivo that a combination of geldanamcyin and hyperthermia resulted in a 
superior anti-tumor effect as compared to either treatment alone, as measured by tumor 
regression with time.  These results led to the decision to utilize geldanamycin as a 




2.4.5  Glucose regulated protein 78 kDa (GRP78) 
In this thesis, the primary goal is to use the cell surface expression of heat shock 
proteins as a molecular target to increase the delivery of chemotherapeutics.  The cell 
surface expression of heat shock proteins has only been recently established, and the 
implications and potential applications of such work are currently under investigation.  
One such protein that is utilized extensively in this thesis is glucose regulated protein 78 
kDa (GRP78), which will be reviewed in detail. 
Historically, GRP78, also known as BiP or HSPA5, is a chaperone protein of the 
HSP70 family found in abundance within the endoplasmic reticulum (ER), where it 
plays a role in protein folding.
229
  GRP78 also plays a master regulatory role in 
initiation of the unfolded protein response (UPR) (Figure 2.8).
230, 231
  During normal 
conditions, GRP78 is primarily bound to the UPR sensor proteins ATF6, PERK, and 
IRE1.  In cancer cells, inherent stress conditions of the tumor microenvironment 
including glucose deprivation, hypoxia, and acidosis can initiate the UPR.  Under these 
conditions of stress, where aggregated or misfolding proteins accumulate in the ER,  
GRP78 is released from ATF6, PERK, and IRE1 and binds to exposed hydrophobic 
residues of malformed proteins, resulting in activation of the UPR sensor proteins.  
ATF6 is then free to migrate to the nucleus, where is acts eventually as a transcriptional 
factor for additional ER chaperones.  PERK activation results in the eventual 
attenuation of translational initiation complexes involved in recognition of AUG 
initiation codons during protein synthesis.  This results in reducing the rate of overall 
protein synthesis, and thereby minimizing the number of potential unfolded proteins 
within the ER.  When IRE1 is activated, it exhibits RNAse activity on mRNA encoding 
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Figure 2.8.  Role of GRP78 (and its isoform GRP78va) in regulating the 
unfolded protein response (UPR) pathway and cell survival via interaction with 





for UPR related proteins, eventually leading to increased activation and transcription of 
UPR target genes.  Therefore, by regulating AFT6, PERK, and IRE1, GRP78 acts as a 
direct mechanism by which the stress conditions of the ER can be sensed and regulated. 
In 1997, the cell surface localization of GRP78 was first reported
232
, and its 
existence on the surface of various cancer cell types including melanoma, 
osteosarcoma, hepatoma, breast, gastric, and pancreatic cancer has since been 
described.
233-235
  Under conditions of elevated stress, localization of GRP78 to the cell 
surface occurs.  Here, it assumes a different function where it acts as a receptor/co-
receptor for signal transduction.  This occurs through the formation of various 
complexes with other proteins (Figure 2.9).
231
  For example, its interaction with 
activated α2-macroglobulin (α2M*) is probably the best understood.
235-237
  In 1-LN 
metastatic prostate cancer cells, GRP78 on the cell surface acts as a receptor for α2M*, 
leading to activation of PAK-2 (p21-activated kinase-2), which works with LIMK1 
(LIM domain kinase 1) and cofilin phosphorylation to increase cell motility and 
facilitate metastasis.  In addition, cell surface GRP78 also acts to increase cell  
proliferation via the activation of ERK1/2 (extracellular-signal-regulated kinase 1/2), 
p38 MAPK (mitogen-activated protein kinase) and PI3K (phosphoinositide 3-kinase) 
and acts to increase cell survival via the Akt and NF-κB (nuclear factor κB) signaling 
cascade. 
Recent studies have also described GRP78 expression of the cell surface of 
proliferating endothelial cells, where it plays a role in the endothelial cell survival and 
as a signaling receptor.
238
  The expression of GRP78 on the cell surface of VEGF 
(vascular endothelial growth factor)-activated HUVECs (human umbilical vein 
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Figure 2.9.  Extracellular GRP78.  Cell surface expressed glucose regulated 
protein 78 kDa (GRP78) forms complexes with various extracellular ligands, 
leading to both pro-survival and pro-apoptotic pathways, thereby serving as a 









These combined studies provide the basis for utilizing cell surface expressed 
GRP78 as a cancer specific target.  Beyond its inherent expression in cancer cells, the 
current study is primarily focused on the induction of cell surface GRP78 following the 
initiation of cellular stress via hyperthermia.  A correlation between cellular stress and 
GRP78 cell surface expression has been demonstrated via an in vitro study wherein 
thapsigargin, an agent which induces ER stress, was shown to promote cell surface 
expression.
234
  Interestingly, the increase in cell surface expression observed was higher 
than the intracellular response.  The ability of hyperthermia to induce ER stress and the 
subsequent expression of GRP78 has also been described.  In one study,
240
 melanoma 
cells were exposed to hyperthermia (45°C, 60 min) and the expression of GRP78 
followed as a function of time.  An elevated expression of approximately 7X was 
observed 3 hrs post hyperthermia, with elevated levels remaining out to 18 hrs.  The 
role of temperature and treatment duration may, however, play a major role in inducing 
expression.  For example, one study
241
 clearly demonstrated a decrease in expression of 
GRP78 following induction of higher temperature, possibly due to a global repression 
of transcription and translation.  However, mild hyperthermia resulted in increased 
expression of GRP78 along with other HSPs.  Therefore, there is most likely a small 
window of opportunity wherein cell surface expression of GRP78 can be induced, and it 
was therefore critical in this project that hyperthermia be applied precisely in a 
controlled manner to avoid such complications. 
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2.4.5.1  Peptides targeting cell surface expressed GRP78.  As previously 
described, a number of different targeting moieties can be utilized to direct the 
localization of polymer-drug conjugates.  Work by Pasqualini and coworkers
233, 242
 has 
developed a combinatorial strategy to find relevant, specific anticancer targets.  In this 
strategy, they isolated peptides recognized by antibodies from the serum of prostate 
cancer patients.  They were then able to identify a consensus motif that bound to these 
antibodies preferentially over control antibodies from other blood donors.  They then 
identified the corresponding protein, GRP78, and demonstrated a correlation between 
GRP78 expression and development of metastatic disease and short overall survival.  
By such a method of screening libraries of peptides and antibodies using phage display, 
GRP78 was identified with high specificity for cancerous tissue.  This type of approach 
is advantageous as the selection process occurs in vivo, resulting in more relevant 
targets as compared to traditional in vitro assays.  Via subsequent phage display, two 
peptide ligands for GRP78 with amino acid sequences of WIFPWIQL and 
WDLAWMFRLPVG were identified.  It was shown that these sequences were specific 
for binding to GRP78, and their ability to target prostate cancer tumor cells in vitro, in 
vivo, and in human cancer specimens ex vivo was verified.  Building upon this work, 
one study
239
 demonstrated that liposomes modified with the WIFPWIQL peptide were 
uptaken to a greater extent by VEGF-activated HUVECs as compared to the non-
targeted carriers.  The ability of the WIFPWIQL liposomes to accumulate in tumor 
endothelial cells in vivo and suppress tumor growth in a colon carcinoma mouse tumor 
model was also demonstrated.  These results demonstrate that these peptide ligands can 
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be successfully utilized as targeting moieties in a strategy to target cell surface 
expressed GRP78. 
 
2.5  Prostate cancer 
In the United States, prostate cancer
243
 is the second leading cause of cancer 
death in men, behind only lung cancer.  It is estimated that approximately 242,000 new 
cases will be diagnosed in 2012, and approximately 28,000 men will die of the disease.  
Approximately 1 out of every 6 men will be diagnosed with prostate cancer at some 
point during their lifetime.  Disease progression generally occurs slowly, resulting in a 
5-year survival rate of nearly 100% and even a 15-year survival rate of 91%.  There is, 
however, a clear distinction between localized and metastatic disease.  When prostate 
cancer is no longer localized (Stage IV), the 5-year survival rate drops precipitously to 
29%.  There is therefore a critical need for treatment while the disease is localized and 
manageable.  In this Section, the current treatment options for prostate cancer will be 
introduced, including the role of chemotherapy for late stage disease.  In addition, the 
chemotherapeutic agents utilized in this thesis for evaluation against prostate cancer 
will be briefly discussed. 
 
2.5.1  Current treatment options 
 In many cases, prostate cancer diagnosis may occur so early in the disease 
progression process that there is little immediate health threat posed by the cancer.  For 
many of these patients, a strategy of watchful waiting, also known as active 
surveillance, is used.
244
  These patients are monitored routinely for disease progression, 
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often via PSA tests and digital rectal exams.  Treatment may be required at a later stage. 
However, for some patients, especially those older patients where the risks of treatment 
outweigh the potential benefits, treatment may not be required. 
 When prostate cancer is still localized to the prostate gland, other approaches 
using radiation therapy are widely used.  External beam radiation is used to deliver X-
rays from outside the body to the diseased area.  This can be conducted in a non-
invasive manner with very little pain.  However, it is often associated with adverse 
effects which include sexual dysfunction, fatigue, and urinary or rectal bleeding.
245
  A 
somewhat similar strategy delivers radiation via small radioactive metal pellet or seeds.  
These are implanted in the prostate near the cancerous tissue where they release low 
doses of radiation over a period of several months.  This type of procedure, called 
brachytherapy
246
 is advantageous over external beam radiation in that it can minimize 
damage to surrounding tissues.  However, it has a higher risk of impaired urinary 
function, and still maintains a risk of sexual dysfunction.   
 Surgery is also used for the treatment of localized prostate cancer.  
Prostatectomy,
247
 or removal of the prostate gland itself, is the primary goal of a number 
of surgical procedures.  The choice of surgical procedure is generally dependent on the 
location of the disease, with more invasive procedures required if the cancer has spread 
to surrounding lymph nodes.  As with many surgeries, outlook is dependent on the skill 
and expertise of the surgeon.  While prostatectomy is the most effective way to remove 
prostate cancer when localized to the prostate gland, a high risk of loss of urinary 
control and sexual functions remains. 
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 For more advanced disease, hormone therapy is the first line of treatment.
248
  
The male sex hormones, including testosterone, are required for prostate cancer growth.  
The goal of hormone therapy is to deprive the cancer of these hormones.  Hormone 
therapy is often used to treat advanced disease, where the cancer has spread from the 
region surrounding the prostate, but it can also be used as a means to reduce primary 
tumor size to enhance the effectiveness of other treatments (i.e., after surgery).  
Hormone therapy is generally effective in reducing tumor burden and slowing tumor 
growth.  However, tumor cells over time often become “androgen independent” and no 
longer require hormones for survival and proliferation, and hormone therapy becomes 
ineffective.
249
  In addition, hormone therapy is associated with a number of adverse 
effects due to the loss of androgens which include sexual problems, loss of muscle 
mass, weight gain, and fatigue. 
 For patients with advanced or metastatic disease, chemotherapy is indicated.  As 
previously described, the goal of chemotherapy is to kill rapidly dividing cells.  
However, it often kills other rapidly dividing healthy cells, resulting in adverse effects 
which include neutropenia, nausea, vomiting, loss of appetite, mouth sores, and hair 
loss.  Because of these side effects, its use in the treatment of advanced, localized 
disease is generally not warranted.  In addition, chemotherapy for those with metastatic 
disease is primarily beneficial in extending life and decreasing pain.  It is not 
anticipated to provide a cure.  However, if chemotherapy could be delivered in a 
targeted, site-specific manner, the benefit-to-risk ratio could potentially be shifted 
enough to allow for more aggressive treatment in late-stage disease, and more routine 
use in localized disease. 
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Three different chemotherapeutic agents were conjugated to HPMA copolymers 
in the current thesis.  They are aminohexylgeldamycin, docetaxel, and cisplatin, and 
each will be briefly reviewed hereafter. 
 
2.5.2  Geldanamycin 
Geldanamycin (GDM), a benzoquinone ansamycin, is a naturally occurring 
inhibitor of heat shock protein 90 (Hsp90) and has been widely studied as an anticancer 
agent.
250
  Hsp90 is highly expressed in a variety of cancers including melanoma, 
leukemia, colon, lung, breast, and prostate cancers,
251
 and is thought to play an 
important role in regulating the folding and activity of its client proteins, which include 
growth-stimulating proteins involved in malignant transformation.
252
  As Hsp90 client 
proteins have also been implicated in prostate cancer progression,
253
 GDM naturally 
presents itself as an attractive therapeutic agent against this disease.  In addition, GDM 
derivatives have been shown to exert synergistic effects when combined with 
hyperthermia.  For example, one study showed that treatment with GDM resulted in 
increased susceptibility of melanoma cells to treatment with hyperthermia, which was 
delivered using thermosensitive ferromagnetic particles.
240
  However, the clinical use of 
GDM has been limited by several factors.  It exhibits high hepatotoxicity at therapeutic 
doses in animal models,
254
 is poorly soluble in water, and is metabolically unstable.
251
  
While GDM derivatives with improved tolerance, metabolic stability, and water 
solubility are currently under investigation (Table 2.1), clinical response is still 
limited,
255, 256
 and further increases in the therapeutic index for Hsp90 inhibitors is 




Table 2.1.  Selected clinical trials of geldanamycin analogues as mono- or 

























































































































2.5.3  Docetaxel 
Docetaxel (Taxotere
®
), is a semi-synthetic anti-mitotic chemotherapeutic of the 
taxane family that stabilizes microtubules necessary for cell division by binding β-
tubulin, resulting in cell-cycle arrest and induction of apoptosis.
257
  It is currently 
approved for marketing in the United States for the treatment of patients with cancers of 
the breast, lungs, prostate, gastro-intestinal tract, and head and neck.  Compared to its  
taxane predecessor paclitaxel (Taxol
®
), docetaxel provides superior in vitro 
cytotoxicity
258
 and has greater potency with regard to tubulin promotion and inhibition 
of depolymerization.
259
  Docetaxel has proven effective in combination with other 
traditional chemotherapeutics
260-262
 and does not demonstrate complete cross resistance 
with paclitaxel.
263-265
  Docetaxel is also currently under clinical investigation for the 
treatment of a number of cancers
260, 266-271
 and is currently approved as a first line 
treatment for advanced stage, metastatic prostate cancer.
272
 However, the clinically 
approved formulation for intravenous administration of docetaxel (Taxotere
®
) contains 
polysorbate 80 as a solubilizing agent, which has been associated with acute 





2.5.4  Cisplatin 
 Cisplatin (Platin
®
) is a platinum containing compound that binds to and 
crosslinks DNA, eliciting DNA repair mechanisms, followed by eventual apoptosis.  
Cisplatin, in combination with other chemotherapeutic agents, is a mainstay in the 
treatment of a variety of cancers, and its use has been approved by the FDA since the 
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late 1970s.  It is currently under clinical investigation as a second-line treatment for 
prostate cancer in patients whose cancer progressed following docetaxel therapy.
275
  In 
this thesis, cisplatin was chosen for evaluation due to its reported synergism with 
hyperthermia.  For example, in the treatment of ovarian cancer, hyperthermic 
intraperitoneal chemotherapy (HIPEC) is used to deliver cisplain.
276
  While the 
hyperthermia itself induces some efficacy in this therapy, it has also been shown to 
increase the sensitivity to chemotherapeutics, including cisplatin, in various in vitro and 
in vivo animal models.  Although the exact mechanisms are not known, studies have 
suggested that hyperthermia in combination with cisplatin therapy increases DNA 
crosslinking and adduct formation.
277
  It also can act to deepen penetration into tumor 
tissues.  For the majority of cancer patients, initial response to platinum therapy is high, 
but a large number eventually relapse with cisplatin resistance.  Cisplatin also exhibits 
marked dose-limiting nephrotoxicity, resulting in a cumulative loss of renal function 
over time.  This is primarily attributed to the accumulation of cisplatin within the 
proximal tubule as a result of its uptake by basolateral drug transporters.
278
  These 
limitations make cisplatin an excellent candidate for delivery via the proposed targeting 
system. 
 
2.6  Summary 
Drug delivery systems based on polymeric carriers can be utilized in anticancer 
applications to increase the therapeutic index of chemotherapeutic agents.  This can be 
achieved through either passive or active targeting strategies.  However, clinical 
translation has remained difficult, due to only modest improvements in safety and 
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efficacy.  Therefore, strategies to increase delivery of macromolecular 
chemotherapeutics are warranted. 
Tumor hyperthermia has also been investigated in anticancer applications due to 
inability of cancerous tissues to effectively dissipate heat, thereby causing significant 
cellular damage.  As a result, most of the work in this area has focused on ablative 
therapies, where the primary goal of the hyperthermic treatment is direct eradication of 
the tumor mass.  However, moderate hyperthermia has been shown to increase tumor 
blood flow and vascular permeability, and can therefore be utilized as a tool to increase 
the passive delivery of macromolecular chemotherapeutics.  In addition, part of the 
cellular response to hyperthermia includes the expression of heat shock proteins, 
including the expression of particular heat shock proteins (i.e., GRP78) on the cell 
surface.  This induced expression can therefore be utilized to improve the active 
delivery of targeted drug carriers by enhancing binding and internalization into cancer 
cells.  
It is therefore proposed that a combination of tumor hyperthermia and 
administration of heat shock targeted polymer-drug conjugates can effectively enhance 
both passive and active delivery mechanisms.  Increases in overall tumor delivery can 
therefore widen the therapeutic index for chemotherapeutics, resulting in more safe and 
efficacious therapy. 
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CONJUGATES TARGETING CELL SURFACE 
EXPRESSED GRP78 IN PROSTATE CANCER 
 
3.1 Introduction 
As previously described in Chapter 2, prostate cancer remains a significant 
health challenge and a significant cause of cancer related deaths.  Geldanamycin 
(GDM), a benzoquinone ansamycin, is a naturally occurring inhibitor of heat shock 
protein 90 (Hsp90) and has been widely studied as an anticancer agent.
1
  Hsp90 is 
highly expressed in a variety of cancers including melanoma, leukemia, colon, lung, 
breast, and prostate cancers,
2
 and is thought to play an important role in regulating the 
folding and activity of its client proteins, which include growth-stimulating proteins 
involved in malignant transformation.
3
  As Hsp90 client proteins have also been 
implicated in prostate cancer progression,
4
 GDM naturally presents itself as an 
attractive therapeutic agent against this disease.  However, the clinical use of GDM has 
been limited by several factors.  It exhibits high hepatotoxicity at therapeutic doses in 
animal models,
5
 is poorly soluble in water, and is metabolically unstable.
2
  While GDM 
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derivatives with improved tolerance, metabolic stability, and water solubility are 
currently under investigation, clinical response is still limited.
6, 7
   
As described in Chapter 2, the use of drug conjugates with water soluble 
polymers such as poly ethylene glycol (PEG) and N-(2-hydroxypropyl)methacrylamide 
(HPMA) copolymers are well suited to overcome these limitations.
8, 9
  First, polymeric 
carriers can increase the water solubility of poorly water soluble drugs.
10
  Second, the 
use of polymeric conjugates can significantly alter drug pharmacokinetics and 
biodistribution.
11, 12
  This can result in a significant increase in the blood plasma half-
life of the drug, which in turn results in an increased total drug exposure.  Third, these 
polymeric conjugates accumulate in solid tumors by the passive “enhanced permeability 
and retention” (EPR) effect due to the leaky tumor vasculature and reduced lymphatic 
drainage within the tumor microenvironment.
13
  This translates to a higher maximum 
tolerated dose (MTD) of a given chemotherapeutic agent.
14
  The advantage of HPMA 
copolymers over other water-soluble polymers is that simple chemical modifications 
can be used to alter drug loading, targeting moiety content, and molecular weight.
15, 16
  
Drug molecules can be attached to the polymer backbone via the lysosomally 
degradable peptide sequence Gly-Phe-Leu-Gly (GFLG) allowing intracellular release 
by lysosomal proteases
17
 while remaining stable during systemic circulation.
18
  Several 
HPMA copolymer-drug conjugates have progressed to clinical trials for the treatment of 
a variety of solid tumor cancers.
19, 20
  However, clinical success has remained 
marginal.
21
  The inclusion of targeting moieties bound to the polymer backbone can 
further enhance accumulation in the target site while minimizing systemic exposure.  
For example, previous work has described anti-angiogenic HPMA copolymer 
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conjugates bearing RGD (Arg-Gly-Lys) peptides as targeting moieties toward 
endothelial cells in the neovasculature of solid tumors (also see Appendix A).
22-24
 The 
success of anti-angiogenic therapy however is limited as angiogenesis inhibitors can 
inhibit tumor growth in areas of neovascularization but have no direct effect on the 
survival of tumor cells in the regions of mature, nonproliferating vessels and do not 
exert cytotoxicity directly to tumor cells.
25
  An alternative strategy is to use a 
combination treatment of targeted drug delivery to both the tumor vasculature and 
tumor cells. 
Glucose regulated protein 78 (GRP78), also known as immunoglobulin heavy-
chain binding protein (BiP) was first discovered following glucose starvation in chicken 
embryo fibroblasts.
26
  GRP78 is a member of the Hsp70 protein family and is primarily 
found in the endoplasmic reticulum (ER) where it acts by facilitating protein folding 
and functions as a regulator of ER stress signaling.
27
  In the tumor microenvironment 
characterized by glucose deprivation, acidosis, and hypoxia, the accumulation of 
misfolded and underglycosylated proteins trigger the unfolded protein response, 
inducing the expression of GRP78 and migration of GRP78 to the cell surface.  This 
presents an attractive molecular target with specific expression occurring presumably in 
cancer cells.  In mouse models, GRP78 expression is selectively induced in cancer cells 
and cancer associated macrophages but not in major adult organs.
28
  GRP78 is also 
detected on the surface of human prostate cancer cells and may play a role in promoting 
cell proliferation, survival, and metastasis.
29, 30
 
The octopeptide WIFPWIQL, selected by phage display, specifically binds to 





  Recent results demonstrate the ability of WIFPWIQL peptide bearing 
liposomes to target DU145 prostate cancer cells as well as vascular endothelial growth 
factor (VEGF)-activated human umbilical vein endothelial cells (HUVECs),
32
 an 
attractive target for anti-angiogenic therapy which may also be utilized by the 




In this Chapter, the synthesis and in vitro characterization of HPMA copolymer-
aminohexylgeldanamycin (AHGDM) conjugates is described.  AHGDM was attached 
to the HPMA copolymer backbone via the lysosomally degradable GFLG linker as well 
as a non-degradable Gly-Gly (GG) linker for comparison in growth inhibition studies.  
Conjugates were further modified to incorporate the WIFPWIQL peptide to facilitate 
binding to cell surface expressed GRP78 in human prostate cancer cells lines. 
 
3.2  Materials and methods 
3.2.1  Materials   
Geldanamycin (NSC 122750) was supplied by the National Cancer Institute 
Developmental Therapeutics Program (NCI DTP).  The GRP78 targeting peptide 









; N-methacryloyl-glycylphenylalanylleucylglycine-p-nitrophenyl ester (MA-
GFLG-ONp)
36
; and N-methacryloyl-tyrosinamide (MA-Tyr)
37
 were synthesized and 
characterized according to previously described methods.  Anti-GRP78 polyclonal 
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antibody was obtained from Assay Designs, Inc. (Ann Arbor, MI).  Na-
125
I was 
obtained from American Radiolabeled Chemicals, Inc. (St. Louis, MO).  Iodogen 
reagent, 1,3,4,6-tetrachloro-3,6-diphenylglycoluril, was obtained from Thermo 
Fisher Scientific (Rockford, IL). 
 
3.2.2  Synthesis and characterization of drug-containing monomers 
17-(6-aminohexylamino)-17-demethoxygeldanamycin (AHGDM) and N-
methacryloylglycylphenylalanylleucylglycl-17-(6-aminohexylamino)-17-demethoxy-
geldanamycin (MA-GFLG-AHGDM) were synthesized according to previously 
described procedures with minor modifications.
14, 38
  Briefly, GDM (200 mg, 0.357 
mmol) and 1,6-Diaminohexane (1.24 g, 10.7 mmol) were dissolved in anhydrous 
chloroform (30 mL) and stirred under N2 gas for 2 hrs at room temperature. Product 
formation was monitored by thin layer chromatography (TLC) on silica gel with 
chloroform: methanol [9:1] as the mobile phase.  Following product formation, the 
reaction mixture in chloroform was combined and washed 15X with 30 mL aqueous 
saturated sodium chloride to ensure removal of excess 1,6-diaminohexane.  Complete 
removal of 1,6-diaminohexane was confirmed by its absence on silica gel eluted with 
chloroform: methanol [75: 25].  Organic layer was then dried over sodium sulfate, and 
solvent removed by rotary evaporation.  Resulting dark purple solid AHGDM was 
verified by mass spectrometry (MS).  MA-GFLG-AHGDM comonomer was 
synthesized by adding AHGDM (223 mg, 0.346 mmol) to MA-GFLG-ONp (201 mg, 
0.415 mmol) in 3 mL anhydrous dimethylsulfoxide (DMSO).  N,N-
Diisopropylethylamine (181 L, 1.04 mmol) was added and the reaction mixture 
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protected from light and stirred overnight at room temperature.  Product formation was 
monitored by TLC on silica gel with chloroform: methanol [9: 1] and purified by silica 
gel column with ethyl acetate: methanol [9: 1] as the mobile phase.  Solvent was 
removed and resulting product MA-GFLG-AHGDM was identified by MS.  N-
methacryloylglycylglycl-17-(6-aminohexylamino)-17-demethoxygeldanamycin (MA-
GG-AHGDM) comonomer was synthesized in a manner similar to MA-GFLG-
AHGDM utilizing MA-GG-ONp comonomer as a starting material instead of MA-
GFLG-ONp.  MA-GG-AHGDM comonomer was similarly purified by silica gel 
column and the resulting product was identified by mass spectrometry. 
 
3.2.3  Synthesis and characterization of HPMA copolymer conjugates 
HPMA copolymers were synthesized via free radical precipitation 
copolymerization of comonomers in acetone: DMSO [9: 1] using N, N’-
azobisisobutyronitrile (AIBN) as initiator.  The concentrations of monomers and AIBN 
in solution were maintained at 12.5% and 0.6% (w/v) respectively.  The feed 
composition of comonomers for all copolymers is given in Table 3.1 and a resulting 
HPMA copolymer structure is graphically represented in Figure 3.1.  The comonomer 
mixtures were sealed in a glass ampoule under N2 gas and stirred at 50°C for 24 hrs.  
Following polymerization, product was obtained by precipitation into diethyl ether.  p-
Nitrophenol (ONp) content in the polymeric precursors was assessed by release of ONp 
from the copolymer in 1.0 N sodium hydroxide and quantification of released ONp by 
UV spectrophotometry at 400 nm.  To obtain the final untargeted conjugates, ONp was 












































































 Estimated by size exclusion chromatography. 
b
 Determined by UV spectroscopy. 
c
 Determined by amino acid analysis. 
d









 Lysosomally degradable GFLG linker represented as found in HPMA-(GFLG-




 WIFPWIQL peptide attached to HPMA copolymer backbone via non-degradable 
GG linker as shown.  Untargeted HPMA-(GFLG-AHGDM) copolymer does not 




hrs in a 3.5 KDa molecular weight cut-off (MWCO) regenerated cellulose dialysis 
membrane (Spectrum Laboratories, Inc., Rancho Dominguez, CA). Apparent weight 
average molecular weight (Mw) and polydispersity (Mw/ Mn) were estimated by size 
exclusion chromatography (SEC) on a Superose 12 column (10 mm x 30 cm) (GE 
Healthcare, Piscataway, NJ) using a Fast Protein Liquid Chromatography (FPLC) 
system (GE Healthcare).  The Superose 12 column was previously calibrated with 
fractions of known molecular weight HPMA homopolymers. 
HPMA copolymer-WIFPWIQL conjugate was synthesized via ONp ester 
aminolysis of polymeric precursors.  HPMA copolymer precursor was reacted with 
WIFPWIQL peptide in anhydrous DMSO in the presence of pyridine for 24 hrs.  The 
reaction was terminated and unreacted ONp was released by slow addition of 0.1 N 
NaOH.  Conjugates were dialyzed against distilled water in a 3.5 KDa MWCO 
regenerated cellulose dialysis membrane to remove low molecular weight compounds.  
Targeting peptide content of the conjugate was determined by amino acid analysis 
(University of Utah Core Research Facilities, Salt Lake City, UT).  AHGDM content of 
conjugates was determined spectrophotometrically at 340 nm. 
 
3.2.4  Synthesis of AHGDM hydrochloride salt (AHGDM·HCl) 
The water soluble hydrochloride salt of AHGDM was synthesized for use as a 
control in stability studies.  AHGDM was dissolved in freshly prepared methanol 
hydrochloric acid and stirred overnight.  The solvent was removed by rotary 
evaporation and the resulting material was dissolved in deionized water, filtered through 
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a 0.22 m filter to remove insoluble AHGDM, frozen and lyophilized.  The resulting 
product was freely soluble upon reconstitution with deionized water. 
 
3.2.5  Stability of HPMA copolymer conjugates 
The release of free AHGDM from the conjugates was assessed in 50 mM 
NaH2PO4 pH 7.4 buffer, 50 mM NaH2C3O2 pH 5.0 buffer, complete DU145 cell culture 
media containing 10% FBS, and 100% FBS.  AHGDM equivalent concentrations were 
maintained below the aqueous solubility of free AHGDM (< 300 ug /mL) in all test 
solutions to prevent saturation.  Quantitative amounts of conjugates or AHGDMHCl 
control were dissolved in 1.5 mL of each test solution.  One-hundred L was removed 
at 0.5, 1, 2, 4, 8, 24, 48 and 72 hrs time points, extracted 3X with 100 uL 
dichloromethane and transferred to an HPLC vial.  Solvent was removed by 
evaporation, and the resulting residue was reconstituted in HPLC mobile phase, and 20 
L injected for analysis by HPLC.  HPLC analyses were performed with an Agilent 
1100 HPLC system (Agilent Technologies, Santa Clara, CA, USA) equipped with a 
photo diode array detector set at 350 nm for quantification using a Waters XBridge 
column (C18, 4.6 x 250mm, 5m) and an isocratic mobile phase of 50 mM 
NH4C2H3O2: Acetonitrile [65: 35 v/v].  A calibration curve was generated by extracting 
and processing AHGDMHCl as noted above.  An extraction efficiency of 99.4 ± 0.6 % 
was obtained using this method.  The cumulative percent AHGDM released was 
calculated and plotted as a function of time.  Conjugates dissolved in mobile phase 




3.2.6  Cell culture 
DU145 and PC3 human prostate cancer cell lines were obtained from ATCC 
(Manassas, VA).  DU145 cell lines were cultured in Eagle’s Minimum Essential 
Medium with Earle’s Balanced Salt Solution (ATCC) supplemented with 10 % (v/v) 
fetal bovine serum (FBS) (Thermo Scientific HyClone, Logan, UT).  PC3 cell lines 
were cultured in F-12K Medium (ATCC) supplemented with 10% (v/v) FBS.  Cell lines 
were cultured at 37C in a humidified atmosphere of 5% CO2.  For all procedures, cells 
were harvested using TrypLE
TM
 Express (Invitrogen, Carlsbad, CA) and cell lines were 
maintained in a logarithmic growth phase during the studies. 
 
3.2.7  Radiolabeling of anti-GRP78 antibody 
Anti-GRP78 antibody was radiolabeled with 
125
Iodine using the Iodogen method 
with slight modification.
39
  Briefly, 20 L of a 1 mg / mL solution of iodogen reagent in 
dichloromethane was added to a 1 cm x 7.5 cm glass tube and evaporated to dryness 
under N2 gas.  Ten g of anti-GRP78 antibody and 1.0 mCi of Na-
125
Iodine were 
combined in the glass tube and allowed to react at room temperature for 10 min with 
gentle mixing.  The solution was transferred to another tube and diluted to 650 L with 
phosphate buffered saline (PBS) at pH 7.4.  Radiolabeled anti-GRP78 antibody was 
purified using a Zeba Spin Desalting Column (Thermo Fisher Scientific) with a MWCO 





3.2.8  Competitive cell receptor binding assay and comparative  
expression of cell surface expressed GRP78 
The comparative affinities of free WIFPWIQL peptide and HPMA copolymer 
conjugates were assessed using a competitive binding assay to cell surface expressed 
GRP78 on DU145 and PC3 cells.  DU145 and PC3 cells were harvested, washed with 
PBS, and re-suspended in binding buffer (20 mmol/L tromethamine, pH 7.4, 150 
mmol/L NaCl, 2 mmol/L CaCl2, 1 mmol/L MgCl2, 1 mmol/L MnCl2, 0.1% bovine 
serum albumin).  Cell suspension was added in 1.2 m pore size 96-well Multiscreen 
HV filter plates (Millipore, Billerica, MA) at 50,000 cells per well.  They were then co-
incubated at 4C with 2 ng 125I-anti-GRP78 antibody and increasing targeting peptide 
equivalent concentrations of copolymer conjugates or free WIFPWIQL peptide between 
0 and 500 M.  Following 1 hr incubation, media was removed from cells using a 
Multiscreen vacuum manifold (Millipore) and cells were washed 3X with binding 
buffer.  Filters were collected and radioactivity determined using a Cobra Auto-
Gamma-counter (Canberra Industries, Inc., Meriden, CT).  Binding percentage relative 
to control wells containing only 
125
I-anti-GRP78 antibody was calculated and nonlinear 
regression analysis and determination of IC50 values was carried out using GraphPad 
Prism (GraphPad Software, Inc., La Jolla, CA). 
The relative cell surface expression of GRP78 in DU145 and PC3 cell lines was 
estimated by calculating the absolute radioactivity recovered in wells incubated with 2 
nm 
125
I-anti-GRP78 antibody in binding buffer at 4C for 1 hr (control wells) from the 




3.2.9  Cell growth inhibition studies 
The ability of the conjugates to inhibit growth of DU145 and PC3 human 
prostate cancer cell lines was evaluated in vitro using a 2-(2-methoxy-4-nitrophenyl)-3-
(4-nitrophenyl)-5-(2,4-disulfophenyl)-2H-tetrazolium monosodium salt (WST-8) cell 
viability assay (Dojindo Molecular Technologies, Inc., Rockville, MD).  Due to the 
poor water solubility of the free drugs GDM and AHGDM, stock solutions of 
conjugates, free drugs, and controls were prepared in DMSO and subsequently diluted, 
resulting in a final concentration of 0.5 % (v/v) DMSO in complete growth medium.  
No significant toxicities were observed for DU145 or PC3 cells when exposed to 0.5% 
DMSO concentrations for 72 hrs. DU145 or PC3 cells (3,000 or 7,500 cells per well 
respectively) were plated in 96-well plates for 24 hrs.  Cell culture medium was then 
replaced with media containing conjugates, free drugs, or controls, and cells were 
treated for 72 hrs.  Following treatment, medium was removed and wells were washed 
with 200 L PBS.  WST-8 reagent in complete growth medium (100 µL as 10% v/v) 
was added to each well and cells were incubated at 37C / 5% CO2 for 120 min and  
absorbance at 450 nm minus 630 nm was determined by UV spectrophotometry using a 
SpectraMax M2 microplate reader (Molecular Devices, Sunnyvale, CA).  Relative 
viability was calculated by normalization of the absorbance of untreated cells.  
Nonlinear least-squares regression analysis was performed using GraphPad Prism. 
 
3.2.10  Statistical analysis 
Differences in relative cell binding affinity and in vitro growth inhibition IC50 
values were determined by one-way ANOVA.  Where differences were detected, a 
107 
 
Bonferroni test was used to test for significance between groups.  Differences in relative 
cell surface expression between DU145 and PC3 cells were evaluated using two-sided 
Student’s T-test.  The significance level was set at =0.05 for all statistical tests. 
 
3.3  Results 
3.3.1  Synthesis and characterization of the conjugates 
Characteristics of HPMA copolymers synthesized are summarized in Table 3.1.  
AHGDM containing copolymers with the degradable peptide linker GFLG, i.e., HPMA 
copolymer-(GFLG-AHGDM) and HPMA copolymer-(GFLG-AHGDM)-WIFPWIQL 
had an apparent weight average molecular weight of 23.7 KDa, a polydispersity index 
of 1.67, and an AHGDM drug content of 5.1 mol% (16.2%, wt/wt) based on evaluation 
of the polymeric precursor.  The ONp content of the polymeric precursor was 0.639 
mmol / g.  Following attachment of WIFPWIQL peptide to the polymeric precursor, 
HPMA copolymer-(GFLG-AHGDM)-WIFPWIQL had a peptide content of 6.2 mol% 
(0.147 mmol / g).  The AHGDM containing copolymer utilizing the nondegradable 
peptide linker GG had an apparent weight average molecular weight of 26.4 kDa, a 
polydispersity index of 1.50 and an AHGDM drug content of 6.3 mol% (24.6%, wt/wt).  
No targeting peptide was attached to the AHGDM containing copolymer utilizing the 
non-degradable linker. 
 
3.3.2  Stability of the conjugates 
The release of AHGDM as a function of time from copolymer conjugates was 
assessed in 50 mM NaH2PO4 pH 7.4 buffer, 50 mM NaH2C3O2 pH 5.0 buffer, complete 
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DU145 cell culture media containing 10% FBS, and in 100% FBS (Figure 3.2).  FBS 
was used to evaluate the potential for enzymatic release during in vivo systemic 
circulation.
40, 41
  Release was minimal at pH 7.4 and pH 5.0 and in complete DU145 cell 
culture medium containing 10% FBS with less than approximately 1% release over 72 
hrs and no difference was observed for conjugates with and without WIFPWIQL 
peptide.  In 100% FBS, release from conjugates was increased, with 6.6% and 11.3% 
released after 72 hrs from conjugates with and without WIFPWIQL peptide.  The 
release from the conjugate with WIFPWIQL was less than the untargeted conjugate at 
72 hrs (p < 0.05).  Overall, the conjugates were stable and exhibited less than 5% 
release over 24 hrs in test solutions. 
 
3.3.3  Comparative cell surface expression and competitive binding 
Competitive binding studies with DU145 and PC3 cells showed binding of 
copolymer-peptide conjugates to cell-surface expressed GRP78 with IC50 values of 1.2 
± 0.3 M and 4 ± 1 M respectively as shown in Figure 3.3.  Untargeted conjugates 
showed no competitive binding.  At equivalent peptide concentrations, free peptide 
showed greater binding affinity (p < 0.05) as compared to polymer conjugates with IC50 
values of 0.29 ± 0.07 M and 1.1 ± 0.1 M for both DU145 and PC3 cell lines.  
Comparative cell surface expressions of GRP78 as determined by 
125
I-anti-GRP78 
antibody binding and gamma counting were 2900 ± 300 and 1200 ± 200 cpm for 
DU145 and PC3 cell lines respectively, indicating statistically significantly higher cell 





Figure 3.2. Stability of HPMA copolymer–AHGDM-WIFPWIQL conjugates in 
aqueous media.  Release of free AHGDM from HPMA copolymer-(GFLG-
AHGDM) (green bars) and HPMA copolymer-(GFLG-AHGDM)-WIFPWIQL (blue 
bars) was assessed in: a) 50 mM NaH2PO4 pH 7.4 buffer, b) 50 mM NaH2C3O2 pH 
5.0 buffer, c) complete DU145 cell culture media containing 10% FBS, and d) 100% 
FBS.  AHGDMHCl salt (red bars) was included in each case as control.  Data 




Figure 3.3. Competitive binding of HPMA copolymer – AHGDM 
WIFPWIQL conjugates to DU145 and PC3 cells lines.  a) DU145 or b) PC3 
cells were seeded in filter plates and co-incubated at 4C with 125I-anti-GRP78 
antibody and increasing targeting peptide equivalent concentrations of HPMA 
copolymer-(GFLG-AHGDM) (green squares), HPMA copolymer-(GFLG-
AHGDM)-WIFPWIQL (blue triangles), or free WIFPWIQL peptide (red circles).  
Following 1 hr incubation, media was removed and cells washed.  Filters were 
collected and radioactivity determined by -counting.   
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Figure 3.4. Relative GRP78 cell surface expression in DU145 and PC3 cell 
lines. 
a) DU145 or b) PC3 cells were seeded in filter plates and incubated with 2 nM 
125
I-anti-GRP78 antibody in binding buffer at 4C for 1 hr.  Following 1 hr 
incubation, media was removed and cells were washed.  Filters were collected 
and radioactivity determined by -counting.  Data expressed as mean ± SD.  





3.3.4  Cell growth inhibition studies 
 
Cell growth inhibition activity of conjugates in DU145 and PC3 cell lines is 
shown in Figure 3.5.  Results demonstrate that modification of geldanamycin at position 
17 with 1,6-diaminohexane reduced its ability to inhibit cell growth.  All conjugates 
containing AHGDM were capable of inhibiting cell growth.  Conjugation of AHGDM 
to HPMA copolymers did not have any statistically significant effect on growth 
inhibition (p > 0.05), and attachment of WIFPWIQL peptide statistically significantly 
reduced growth inhibition in both cell lines with GI50 values of 1.7 ± 0.1 M and 1.8 ± 
0.1 μM as compared to 2.6 ± 0.2 μM and 2.8 ± 0.3 μM for untargeted conjugates in 
DU145 and PC3 cell lines respectively (p < 0.05) (Table 3.2, Figure 3.5).  Attachment 
of AHGDM to the HPMA backbone via the nondegradable GG linker resulted in a 
statistically significant loss of growth inhibition with GI50 values of 19 ± 2 μM and 15 ± 
1 M respectively for DU145 and PC3 cell lines as compared to AHGDM attached via 
the lysosomally cleavable GFLG linker (p < 0.001).  HPMA homopolymer and free 
WIFPWIQL peptide controls showed no statistically significant reduction in cell 
viability over equivalent concentration ranges (data not shown). 
 
3.4  Discussion 
The synthesis and in vitro characterization of HPMA copolymer-AHGDM 
conjugates bearing prostate cancer targeting WIFPWIQL peptide is described in this 
chapter.  It is anticipated that the therapeutic index of AHGDM can be improved by 
selectively targeting these conjugates to the cell surface expressed GRP78 of metastatic 












Table 3.2. Cell growth inhibition GI50 values of HPMA copolymer conjugates in 
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Figure 3.5. Growth inhibition of HPMA copolymer–AHGDM-WIFPWIQL 
conjugates.  a) DU145 or b) PC3 cells were treated for 72 hrs with increasing drug 
equivalent concentrations of GDM (black squares), AHGDM (red circles), HPMA 
copolymer-(GFLG-AHGDM) (green triangles), HPMA copolymer-(GFLG-
AHGDM)-WIFPWIQL (blue reverse triangles), or HPMA copolymer-(GG-
AHGDM) (purple diamonds). Following treatment, cell viability was assessed by 
WST-8 assay. c) GI50 values were determined in DU145 (blue bars) and PC3 (orange 
bars) by analysis using GraphPad Prism. 
 
*
 Statistical difference detected (p < 0.05) between untargeted and targeted 




AHGDM and bearing WIFPWIQL peptide were successfully synthesized.  Modification 
of native GDM to AHGDM is necessary to generate a reactive free amine, thus enabling 
conjugation to the HPMA copolymer backbone.  AHGDM was chosen over other amine 
geldanamycin derivatives since, when conjugated to HPMA copolymers, they have 
previously demonstrated favorable stability and cleavage by the lysosomal enzyme 
cathepsin B.
42
  HPMA copolymers achieved an AHGDM drug loading ranging from 5.1 
to 6.3 mol% and were water soluble.  To generate the targetable HPMA copolymer, 
WIFPWIQL peptide was successfully conjugated to the HPMA backbone via the non-
degradable GG linker, and conjugation was verified and quantified by amino acid 
analysis.  The molecular weight and molecular weight distribution of the conjugates 




Competitive binding studies demonstrated binding of WIFPWIQL peptide 
bearing conjugates to cell surface expressed GRP78 in DU145 and PC3 cell lines, and 
untargeted conjugates showed no evidence of competitive binding in either cell line as 
demonstrated in Figure 3.3.  Although a statistical difference in the binding affinity of 
free peptide in comparison with the targeted conjugate at equivalent peptide 
concentrations was detected, the binding affinities were similar and demonstrate that 
attachment of WIFPWIQL peptide to the HPMA copolymer backbone has little effect 
on the ability of WIFPWIQL peptide to actively bind GRP78.  Cell surface expression 






 Growth inhibition studies demonstrated the ability of all conjugates bearing 
AHGDM to limit the proliferation of both DU145 and PC3 cells in vitro.  The 
modification of geldanamycin at position 17 with 1,6-diaminohexane reduced its ability 
to inhibit growth in vitro and is consistent with previous reports.  It is possible that 
alternative geldanamycin analogues having functionality allowing conjugation to 
polymeric backbones may need to be further investigated.  However, previous animal 
studies
14
 have demonstrated that HPMA copolymers bearing AHGDM are tolerated at 
much higher doses than free AHGDM, suggesting that efficacious levels can be 
delivered.  It is interesting to note that conjugation of AHGDM to the HPMA 
copolymer backbone did not result in a significant decrease in its ability to inhibit 
growth of DU145 and PC3 cell lines (Table 3.2, Figure 3.5).  An additional HPMA-
copolymer bearing AHGDM was synthesized to investigate whether release of 
AHGDM from the HPMA copolymer backbone was critical for growth inhibition.  In 
this case, the AHGDM was attached to the copolymer backbone via the nondegradable 
GG linker, as compared to the lysosomally degradable GFLG linker.  The ability of the 
HPMA copolymer containing the nondegradable GG linker to inhibit growth was 
reduced approximately 7-fold and 5-fold for DU145 and PC3 cell lines, suggesting the 
necessity of release of free AHGDM via lysosomal degradation as well as increased 
activity and binding to HSP90 of free AHGDM as compared to HPMA copolymer 
bound AHGDM.  The ability of the nondegradable system to inhibit cell proliferation is 
however maintained, with a GI50 of 19 M and 15 M observed for DU145 and PC3 
cell lines (Table 3.2).  A similar result has been reported for HPMA copolymer 





  However, the exact mechanism of action for the nondegradable system 
requires further investigation. 
The ability to target malignant tumors such as prostate cancer is a long-standing 
goal in oncology.  Unfortunately tumor targeting approaches tend to suffer from lack of 
specificity and incomplete tissue penetration.  By screening combinatorial libraries of 
peptides and antibodies using phage display, unique targeting ligands have been 
identified.  This approach directly selects, in vivo, for circulating probes capable of 
preferential homing into tumors.  As a result, new markers have been uncovered, 
providing a means for selective targeting of therapies and new insights into normal 
prostate and prostate cancer vasculature and tumor cell specificities. 
Application of this technology has led to isolation of GRP78.  This is a 
chaperone heat-shock protein which has been isolated by fingerprinting the circulating 
repertoire of antibodies from cancer patients
45
 and has emerged as an excellent cancer 
target.  GRP78 receptors (i) are abundant and functional on the tumor cell surface, (ii) 
can confer tumor selectivity on specific inhibitors, and (iii) regulate multiple signaling 
pathways related to apoptosis, immune response, and drug resistance.  Given the 
promising therapeutic data in tumor models and the presence of the receptor in patient-
derived samples, this system provides an ideal platform for targeted drug development. 
Studies on several ligand-receptor systems based on the tumor cell membrane 
expression of GRP78 has resulted in identification of a lead peptide motif namely 
WIFPWIQL
31
 which was used in this study.  This peptide has been shown to 
specifically target tumor cells in vitro, in vivo, and in human cancer specimens ex vivo. 
Moreover, synthetic chimeric peptides composed of GRP78-binding motif WIFPWIQL, 
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fused to a programmed cell death inducing sequence promoted tumor suppression in 
xenograft and isogenic mouse models of prostate and breast cancer.
31
  Collectively, 
these preclinical data validate GRP78 on the tumor cell surface as a functional 
molecular target and WIFPWIQL as a useful targeting peptide that show potential for 
translation into clinical applications. 
In this study the attachment of the WIFPWIQL peptide to the side chains of 
biocompatible HPMA copolymers containing AHGDM increased the ability of the 
conjugate to inhibit the growth of both DU145 and PC3 cell lines.  Combined with the 
results from the competitive binding studies which show active binding of the targeted 
conjugate to both cell lines, this increased potency is possibly due to a combination of 
both increased binding and cellular uptake. This result coupled with our previous 
observations that HPMA copolymer-AHGDM conjugates terminated in cyclic RGD  
peptides substantially increase the localization of drug in solid tumors and improve 
safety
14, 23
 (also see Appendix A) bode well for combination delivery of AHGDM to 
both angiogenic and tumor cells for a more effective and less toxic treatment of prostate 
cancer. 
 
3.5  Conclusion 
In this chapter, HPMA copolymer conjugates containing the geldanamycin 
analogue AHGDM and WIFPWIQL peptide for targeting cell surface expressed GRP78 
were synthesized and characterized.  Conjugates were stable under physiological 
conditions.  The HPMA copolymer conjugate containing AHGDM and WIFPWIQL 
peptide showed binding affinity to cell surface expressed GRP78 in both DU145 and 
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PC3 prostate cancer cell lines as compared to the untargeted conjugate.  The targeted 
conjugate also exhibited greater ability to inhibit the growth of prostate cancer cell in 
vitro as compared to the untargeted conjugate.  This conjugate shows promise as a 
therapeutic agent in combination strategies for delivery of aminohexylgeldanamycin to 
solid tumors.  
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As described in Chapter 2, incorporation of anticancer agents within 
nanocarriers represents an effective way of delivering hydrophobic drugs in the blood as 
well as altering their organ distribution in the body.
2
  These nanomedicines have been 
designed to target sites of disease and enhance delivery to solid tumors.  Despite 




The delivery of targeted nanomedicines to solid tumors utilizes a two-pronged 
approach.
2
  First, their nanoscale size (~5-500 nm) is leveraged to reduce the 
accumulation in healthy organs while maximizing extravasation into the tumor mass.  
While the junctions between vascular endothelial cells in healthy tissues are too small 
(~2-6 nm) to allow permeation, larger gaps (up to 1.2 µm), which are present in the 
tumor’s poorly developed and leaky vasculature, allow them to partition out of the 
blood and into the tumor mass.
4
  Described as the enhanced permeability and retention 
(EPR) effect,
5





  Second, once in the tumor interstitial space, contact with 
receptors expressed on the cancer cell surface immobilizes them and triggers their 
internalization via endocytosis followed by drug release.
7
  This binding and uptake can 




Polymer-based nanomedicines have the advantage of solubilizing hydrophobic 
drugs and exhibiting stealth-like characteristics thereby evading immune recognition.
9
  
In such systems drugs can be covalently linked to the polymer backbone and 
specifically released by enzymatic degradation or hydrolysis.
10
  These polymer-drug 
conjugates are typically 5-15 nm in hydrodynamic diameter and can therefore be 
cleared by urinary excretion.
11
  This is advantageous due to rising safety concerns of 
nanomedicines which are not eliminated from the body.
12-15
  The small size, however, 
comes with a cost as rapid renal elimination reduces the availability of the conjugates to 
accumulate in tumors by the EPR effect.
16
  With these advantages and limitations in 
mind, there is therefore a need to develop a strategy which maximizes the delivery of 
polymer therapeutics within the window of opportunity before renal clearance. 
This need is particularly apparent considering conjugates, which aim to 
maximize tumor delivery, have to date demonstrated only moderate clinical benefit.  
For example, early generation polymer-drug conjugates such as N-(2-
hydroxypropyl)methacrylamide (HPMA) copolymer-doxorubicin and poly(ethylene 
glycol) (PEG)-camptothecin have not obtained the same success in the clinic as other 
nanomedicines such as Doxil
®





  While much of this may be related to other variables such as drug release 
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kinetics, the lack of sufficient delivery to the tumor (<<15% of the injected dose) 
represents the primary barrier to success.  Recent efforts to improve this delivery such 
as using high molecular weight biodegradable polymers that exhibit prolonged blood 
circulation as well as using polymers with different architectures (i.e., dendrimers and 
branched polymers) have achieved some success.  However, greater control over both 
passive and active targeting strategies is desirable.
17
 
One method which has been described as a temporary means of enhancing the 
delivery of macromolecules such as albumin, liposomes and other nanomedicines is by 
inducing tumor hyperthermia.
18-23
  Under conditions of elevated temperatures and 
increased blood perfusion, it has been found that the tumor microvascular permeability 
and therefore EPR effect is significantly increased.
24
  This is believed to be a result of 
cytoskeletal disaggregation in endothelial cells leading to further expansion of the 
fenestrae that already surround them.
25-28
  Unfortunately, current techniques for 
inducing tumor hyperthermia such as radiofrequency ablation or hyperthermic 




More recently several laboratories have initiated hyperthermia by taking 
advantage of unique nanoscale events that occur when light is absorbed by plasmonic 
gold nanostructures.  In brief, when light with a wavelength that matches the tunable 
surface plasmon resonance (SPR) of gold nanostructures interacts with these particles, 
coherent oscillations of electrons in the conduction band allow the light to be absorbed 
and photothermal conversion to occur.
30
  When such particles are delivered to 





  Such plasmonic photothermal therapy has been used to achieve tumor 
selective temperatures varying from 50°C to over 70°C, well above the threshold 
required for vascular damage.
32-36
  Previously, it has been shown that this heat delivery 
technique at reduced temperatures (42-45°C) can be applied to selectively increase the 
perfusion and permeability of the tumor vasculature and hence the delivery of 
nanomedicines during laser radiation.
37-41
  In this way, the delivery of nanoworms, 
liposomes and micelles have shown to be recruited to the treatment site and sensitized 
for targeting and drug release.
39-41
 
In this chapter, the aim is to remotely modify the tumor microenvironment with 
laser mediated plasmonic photothermal therapy to increase both passive and active 
polymeric drug targeting.  This technique is used immediately following injection of 
HPMA copolymers to augment EPR at the treatment site and drive their delivery into 
the tumor interstitial space while the copolymer is at its peak concentration in the blood.  
Once at the tumor site, the natural response of tissue to heat shock is taken advantage of 
by conjugation of a targeting ligand which binds to heat shock proteins (HSPs).  This is 
because the expression of HSPs is significantly increased following exposure to heat 
shock.
27
  In this way, the targetability of these cancer cells can be elevated so that the 
copolymer is retained in the tumor and taken up by cells to a higher extent.   
A technique is introduced wherein a laser can be used to direct the localization 
and retention of polymer therapeutics in solid tumors.  With this technique, it is 
believed that polymer-drug conjugates can be administered to patients by clinicians and 




4.2  Materials and methods 
4.2.1  Synthesis and characterization of HPMA copolymer-drug conjugates 
The comonomers were synthesized as described previously.
42, 43
 (See also 
Chapter 3)  Precursor copolymer conjugates containing reactive carboxyl groups 
(thiazolidine-2-thione) were prepared by free radical copolymerization in methanol 
using azobisisobutryonitrile (AIBN) as initiator (Figure 4.1).  The concentrations of 
monomers and AIBN during polymerization were maintained at 17.5% and 0.5% (w/v) 
to control molecular weight.  For the conjugates containing drug, 
aminohexylgeldanamycin (AHGDM) was conjugated to the N-methacryloyl-
glycylphenylalanylleucylglycine (MA-GFLG-OH) lysosomally cleavable linker prior to 
copolymerization.  Finally, copolymerization with the monomer N-methacryloyl-
tyrosinamide (MA-Tyr-CONH2) allows for radiolabeling of the conjugates or 5-[3-
(methacryloyl-aminopropyl)thioureidyl] fluorescein (APMA-FITC) for fluorescent 
tracking of cellular uptake in cells.  Heat shock targeted conjugates were obtained by 
aminolysis of precursor copolymers with the GRP78 targeting peptide (WIFPWIQL), 
synthesized by solid phase.  Untargeted conjugates were obtained by hydrolysis of 
precursor copolymers in the presence of aqueous sodium hydroxide.  Copolymer 
conjugates were purified by dialysis against deionized water, lyophilized, and stored at -
20C.  Weight average molecular weight (Mw), number average molecular weight (Mn), 
and polydispersity (Mw/Mn) were estimated by size exclusion chromatography (SEC) 
using HPMA homopolymer fractions of known molecular weight.  The amount of the 
anticancer agent AHGDM present was quantified by UV spectrometry, and the amount 
of the GRP78 targeting peptide was quantified by amino acid analysis (HPLC method). 
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Figure 4.1.  HPMA copolymer schematic.  Representative HPMA 





Iodine was conjugated to tyrosine residues to obtain radiolabeled copolymers using 
the Iodogen method with slight modification.
44
  Each copolymer (2 mg) and 0.5 mCi 
Na-
125
I were dissolved in 0.5M NaH2PO4 pH 7.0 and incubated at room temperature in 
Iodogen tubes for 10 min.  Free radiolabel was removed by dialysis against saline and 
verified by SEC. 
 
4.2.2  In vitro cell surface GRP78 expression 
For all in vitro experiments, DU145 cells were cultured at 37°C in a humidified 
atmosphere of 5% CO2 in Eagle’s Minimum Essential Medium with Earle’s Balanced 
Salt Solution (ATCC) supplemented with 10 % (v/v) fetal bovine serum (FBS) (Thermo 
Scientific HyClone, Logan, UT).  Cell surface GRP78 expression was evaluated as a 
function of time by flow cytometry.  Human prostate cancer DU145 cells were 
subjected to heat shock (43C / 30 min incubation) or control (37C, continuous 
incubation).  At each time point, cells were removed and incubated with an anti-GRP78 
rabbit polyclonal antibody (Enzo Life Sciences, Farmingdale, NY) followed by 
incubation with a goat anti-rabbit phycoerythrin (PE) conjugated secondary antibody 
(Santa Cruz Biotechnology, Santa Cruz, CA).  Cells were then fixed in 1% 
formaldehyde in phosphate buffered saline (PBS) and analyzed by flow cytometry.  







4.2.3  Cellular uptake of FITC-labeled conjugates 
Cellular uptake as a function of time was quantified by flow cytometry.  DU145 
cells were exposed to heat shock (43C / 30 min incubation) or control (37C, 
continuous incubation).  Eight hrs post heat shock, cells were incubated with 0.1 mg/mL 
of heat shock targeted or untargeted FITC labeled conjugates.  At each time point, cells 
were washed, harvested, fixed in 1% formaldehyde in PBS, and analyzed by flow 
cytometry using FACScan flow cytometer (Becton Dickinson, Franklin Lakes, NJ). 
 
4.2.4  In vitro cytotoxicity 
DU145 cells in 96 well plates (3 x 10
3
 cells per well) were exposed to heat 
shock (43C / 30 min incubation) or control (37C, continuous incubation).  Eight hours 
post heat shock, cells were treated for 4 hrs with increasing concentrations of heat shock 
targeted or untargeted conjugates or AHGDM free drug controls.  Following treatments, 
cells were washed with PBS and growth media replaced.  After 72 hrs total incubation, 
cell viability was assessed using a 2-(2-methoxy-4-nitrophenyl)-3-(4-nitrophenyl)-5-
(2,4-disulfophenyl)-2H-tetrazolium monosodium salt (WST-8) cell viability assay 
(Dojindo Molecular Technologies, Rockville, MD).  IC50 values were calculated by 
nonlinear regression and thermal enhancement defined as IC50 observed for control / 
IC50 observed following heat shock.  
 
4.2.5  In vivo induction of heat shock via photothermal therapy
¥
 
Anesthetized 6- to 12-week old athymic nu/nu mice were subcutaneously 
injected with 10
7
 DU145 cells on each flank and tumors were allowed to grow until 
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approximately 5-7 mm in diameter.  Animals were then administered PEGylated gold 
nanorods, synthesized as previously described,
38
 (9.6 mg/kg) via tail vein injection. 
After 48 hrs, mice were anesthetized, and tumors were swabbed with 50% propylene 
glycol to enhance laser penetration depth.
45
  Tumors on the right flank only were then 
radiated for 10 min using an 808 nm fiber coupled laser diode (Oclaro Inc., San Jose, 
CA) with collimating lens (Thorlabs, Newton, NJ).  Intratumoral temperature was 
monitored using a 33 gauge needle thermocouple (Omega, Stamford, CT) and tumor 
temperature was maintained between 42°C and 43C.  Tumors on the left flank served 
as internal controls. 
 
4.2.6  In vivo GRP78 expression in tumors following photothermal therapy
¥
 
Eight hours following induction of heat shock, mice were euthanized and tumors 
on the right (laser) and left (control) flanks were removed and snap frozen in liquid 
nitrogen.  Immunohistochemical analysis of GRP78 expression was then performed on 
4-micron thick sections of formalin-fixed, paraffin-embedded tissues using a goat 
polyclonal anti-GRP78 antibody (Santa Cruz Biotechnology, Santa Cruz, CA) and a 
polyclonal rabbit anti-goat biotinylated antibody.  Positive signal was visualized using a 
streptavidin-HRP system, utilizing DAB (3-3’ diaminobenzidine) as the chromogen. 
The sections were counterstained with hematoxylin.  The sections were placed in iodine 
to remove any precipitates, and then dipped in sodium thiosulfate to clear the iodine. 
The sections were dehydrated in graded alcohols (70%, 95% x2 and 100% x2), cleared 




4.2.7  Tumor accumulation and biodistribution
¥
 
Prior to induction of heat shock via photothermal therapy, mice were 
intravenously administered via the tail vein a single bolus dose of 50 mg/kg 
125
I 
radiolabeled conjugates (untargeted or heat shock targeted).  At each time point, mice 
were euthanized, blood immediately collected, followed by blood perfusion with saline. 
Tumors and major organs were then collected and analyzed by gamma counting.  
Tumor volumes were estimated as length × width × π/6.  Percent injected dose per gram 
of blood/tissue (% ID / g) was calculated and expressed as a function of time. 
 
4.3  Results and discussion
¥
 
To begin, the HPMA copolymers were synthesized via free radical 
polymerization and characterized (Figure 4.1, Table 4.1).  Molecular weight for the 
conjugates varied from 60 – 80 kDa, and was maintained slightly above renal threshold 
to take advantage of the EPR effect.  For drug containing conjugates, AHGDM content 
was approximately 15% by weight. To generate a targetable HPMA copolymer, the 
WIFPWIQL peptide was conjugated to the HPMA backbone via aminolysis of 
thiazolidine-2-thione side chains, resulting in copolymers with approximately 20% 
peptide content by weight.  This peptide was chosen due to its known affinity to 
glucose-regulated protein-78 (GRP78), a member of the HSP70 family of proteins.
46
  
Previously, we have shown that this receptor-ligand approach can be used to effectively 
deliver HPMA copolymer-drug conjugates to prostate cancer cells.
42
  Full details 






Table 4.1.  Physicochemical characteristics of HPMA copolymers.   
 
Polymer 

































HPMA  93 5 0 2 0 83.9 1.6 - - 
HPMA-
WIFPWIQL  
93 5 0 2 0 72.4 1.6 - 
3.8 
(20.9) 
HPMA-FITC  93 5 0 0 2 62.4 1.4 - - 
HPMA-FITC-
WIFPWIQL  




Weight average molecular weight (Mw) and polydispersity (Mw/Mn) were estimated by 
size exclusion chromatography (SEC).  The amount of the anticancer agent AHGDM 
present was quantified by UV spectrometry, and the amount of the GRP78 targeting 




To determine if heat shock could be used to regulate the targetability of these 
conjugates, the prostate cancer cell surface expression of GRP78 was measured as a 
function of time after heat shock (43°C, 30 min).  This was done by incubation with an 
anti-GRP78 rabbit polyclonal antibody followed by evaluation of expression by flow 
cytometry.  Indeed, it was observed that the receptor’s expression increases after heat 
shock with maximum expression between 8-12 hrs after heat shock (Figure 4.2). 
Next, fluorescently labeled HPMA copolymers with and without the heat shock 
targeting peptide were introduced to cells eight hours postheat shock (43°C, 30 min) or 
control (37°C, continuous incubation).  Quantification by flow cytometry (selected time 
points, Figure 4.3) of uptake in cells indicates significantly increased binding and 
uptake of heat shock targeted conjugates which is in agreement with our previous 
results.
42
  This observation was much more pronounced (3-fold increase), when the cells 
were first treated with heat shock due to increased receptor expression (Figure 4.3). 
New conjugates containing the anticancer drug derivative AHGDM via a 
degradable linker were then prepared to determine if this increased uptake can be 
correlated with increased activity.  Cells were heat shock treated as before, then 
exposed to the HPMA copolymer-AHGDM conjugates for 4 hrs and evaluated for 
growth inhibition.  A short period of incubation (4 hrs) was chosen during the period of 
maximum GRP78 expression (8-12 hrs after hyperthermia, see Figure 4.2) to explicitly 
determine the effect of increased GRP78 expression on cytotoxicity.  In all groups (free 
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Figure 4.2.  Induction of cell surface expressed GRP78 in DU145 cells following 
exposure to heat shock.  After induction of heat shock (43°C, 30 min incubation), 
the cell surface expression of the heat shock protein GRP78 in DU145 prostate 





Figure 4.3.  Cellular uptake kinetics of FITC labeled HPMA copolymers in 
DU145 cells following exposure to heat shock.  Cells were exposed to FITC 
labeled HPMA copolymers between 8 and 12 hrs after heat shock (43°C, 30 min 
incubation).  Quantification of cell association was performed by flow cytometry.  
Prior treatment with heat shock resulted in significantly increased uptake of heat 
shock targeted conjugates.  
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drug, untargeted, and heat shock targeted), treatment with heat shock resulted in greater 
activity (Figure 4.4).  While this effect was only slight for free drug and untargeted 
conjugates, a 4-fold thermal enhancement in conjugate activity was observed for those 
which were heat shock targeted (Figure 4.4). 
Next, the overall hypothesis of enhancing the delivery of these conjugates to 
laser radiated tissue was tested in mice bearing prostate tumors.  Mice bearing two 
tumors, one on each flank, were intravenously (i.v.) administered PEG coated gold 
nanorods and allowed 48 hrs for the particles to accumulate in the tumors via EPR 
(Figure 4.5).
47
  Radiolabeled conjugates (heat shock targeted and untargeted) were then 
administered i.v. followed immediately by laser radiation of the right tumor only for 10 
min.  During laser radiation the temperature in the right tumor was maintained between 
42-43°C by controlling laser power such that only moderate hyperthermia was induced 
to avoid vascular collapse at higher temperatures.
48
  It is important to note here that by 
directing the laser at the right tumor only, it is possible to directly compare the delivery 
of polymeric conjugates to tumors in the presence and absence of laser radiation in the 
same animal. 
While the increased HSP expression profile of prostate cancer cells following 
heat shock was confirmed in vitro, it was necessary to confirm this phenomenon in vivo.  
The left (control) and right (laser treated) tumors were evaluated for GRP78 expression 
by immunohistochemistry.  Heat shock treatment of the right tumors by laser resulted in 
increased HSP expression compared to the untreated tumors (Figure 4.6). 
Quantification of the concentrations in tumors and major organs of 
125
I-
radiolabeled polymeric conjugates was evaluated in vivo in combination with PPTT, to 
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Figure 4.4.  Cytotoxicity of AHGDM bearing copolymers following exposure to 
heat shock.  Polymer-drug conjugates anti-cancer activities (a) and related thermal 
enhancements of toxicity with DU145 human prostate cancer cells (b). Cell were 
exposed to treatments for 4 hrs during the period of maximum heat shock protein 
expression (8-12 hrs after heat shock).  Treatment with heat shock caused increased 
toxicity to cells (lowered IC50, greater thermal enhancement), particularly for those 
which are heat shock targeted.  
 
***Indicates a statistically significant difference (p < 0.001) by one-way analysis of 
variance (ANOVA). Error bars represented as ± standard deviation. 
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Figure 4.5.  Schematic of laser guided delivery of polymeric conjugates in mice.  
Nu/nu mice bearing subcutaneous DU145 tumor xenografts were intravenously 
administered PEGylated GNRs.  After 48 hrs, 
125
I radiolabeled HPMA copolymers 
were intravenously administered, directly followed by laser radiation to the right 
tumor only (left tumor served as internal control).  Tumor accumulation at selected 




Figure 4.6.  In vivo expression of GRP78 following PPTT.  Cell expression of heat 
shock protein GRP78 (red color) in prostate tumors with or without laser treatment. 




determine the localization of the drug carriers as a function of time (Figures 4.7 and 
4.8).  Following administration of the conjugates, a comparison of the laser radiated and 
control tumors 15 min and 4 hrs following laser treatment indicates that a 2-to-3 fold 
increased burst accumulation occurred in the laser radiated tumors (Figure 4.7).  This 
observation indicates that the treatment of tumors with heat causes increased tumor 
blood flow and augments the EPR effect by increasing vascular pore size.
20, 21, 38
  This 
burst accumulation was not maintained after 4 hrs for the untargeted conjugates.  As 
intended in the treatment design, the heat shock targeted conjugates were retained in the 
radiated tumor up to 12 hrs after which elimination began to occur.  This observation is 
supported by GRP78 expression data (Figure 4.2), which shows that HSP expression is 
reduced after 12 hrs.  When this data is expressed as the total area under the tumor 
concentration vs. time curve (AUC), a 4-fold increase in exposure is observed for 
tumors which have been laser radiated (Figure 4.7). 
The biodistribution of the radiolabeled conjugates in major organs was also 
evaluated (Figure 4.8). Similar concentrations in the blood were observed over 72 hrs 
for untargeted and heat shock targeted conjugates.  However, significant accumulation 
was observed for the heat shock targeted conjugate in the liver, spleen, and kidneys.  It 
is speculated that this nonspecific accumulation is most likely due to the increased 
hydrophobic nature of the heat shock targeted conjugate due to the presence of the 
hydrophobic WIFPWIQL peptide (cLogP = 3.9).  This increased hydrophobicity can 
potentiate interactions with biological tissues and increase uptake in reticuloendothelial 
system (RES) organs.
49
  It is anticipated that such nonspecific interactions can be 
minimized by reducing the hydrophobic nature of the conjugates by either reducing the 
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Figure 4.7.  Tumor accumulation of HPMA copolymers following PPTT.  Tumor 
accumulation of radiolabeled polymers (untargeted and heat shock targeted) with or 
without laser treatment (left).  Laser radiation results in a burst accumulation (0—4 
hrs), which is only maintained ( > 24 hrs) for the heat shock targeted polymers due to 
increased GRP78 expression. Total area under the tumor concentration vs. time 
curve (AUC) indicates a 4-fold increase in exposure to polymers (right). 
 
** and *** indicates a statistically significant difference (p < 0.01 and p < 0.001 





Figure 4.8.  Biodistribution of radiolabeled (
125
I) HPMA copolymers.  Data 
expressed as mean ± standard deviation. 
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targeting peptide content or utilizing more hydrophilic targeting moieties.  Based on 
these observations, subsequent studies (see Chapter 5) utilized untargeted conjugates 
bearing scrambled targeting peptide sequences to minimize differences in 
physicochemical properties and reduce these confounding effects. 
In this study, there were some additional controls whose results are not shown 
due to limited space.  For example, some animals did not receive gold nanorods but 
received laser treatment to see if the laser alone would enhance conjugate delivery.  
During laser radiation minimal tumor heating and no delivery enhancement was 
observed.  These results corroborate with our previous findings.
38
  Also, HPMA 
copolymers were administered with and without prior administration of gold nanorods 
to determine if the presence of gold nanorods would impact the delivery of HPMA 
copolymers.  As expected, the presence or absence of gold nanorods did not influence 
the tumor accumulation of the polymer conjugates. 
After sacrifice of the animals at selected time points following laser radiation, 
the entire biodistribution of the radiolabeled HPMA copolymers was evaluated (Figure 
4.8).  The size of the conjugates (~70-80 kDa) was chosen for this study so that the 
polymers would circulate for an extended period of time.
50
  When evaluating the blood 
clearance and biodistribution for the untargeted and heat shock targeted conjugates, a 
few interesting observations are made.  First, while both conjugates have a very similar 
blood clearance rate, the ultimate fate of the polymers was very different.  Though the 
untargeted conjugates were above renal clearance threshold (~45 kDa), the majority of 
the radioactivity was not recovered in the animals.  After gamma counting the cage 
bedding material (data not shown), it was determined that the majority of the conjugates 
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were excreted in the urine.  This is in contrast to the heat shock targeted conjugates 
which showed nonspecific accumulation in the kidneys, spleen and liver in addition to 
urinary excretion.  The difference between these two groups (untargeted vs. heat shock 
targeted) may be explained in two ways.  First, an inherent, baseline expression of 
GRP78 in various cell types may exist which promotes cellular binding and uptake in 
these organs.  Second, presence of the hydrophobic peptide WIFPWIQL in the heat 
shock targeted conjugates increases their hydrophobicity which can lead to a greater 
degree of interaction with biological membranes.  These elevated interactions can 
therefore result in nonspecific accumulation in these organs.  In either case, the 
presence of the peptide resulted in undesirable biodistribution.  In Appendix C, the 
biodistribution of a more hydrophilic GRP78 targeted peptide (WDLAWMFRLPVG) is 
compared with the peptide utilized in this Chapter (WIFPWIQL).  Use of the more 
hydrophilic peptide reduced this undesired distribution to healthy organs while 
maintaining enhanced delivery to tumors (see Appendix C).  This peptide was therefore 





In summary, it is demonstrated that it is possible to direct the delivery of 
targeted polymer therapeutics using plasmonic photothermal therapy by exploiting the 
physiologic response of tumors to heat.  These findings help overcome one of the 
limitations of polymer therapeutics which is poor tumor accumulation.  By using laser 
directed application of heat via gold nanorods, a burst accumulation of the therapeutics 
in the region of interest is possible while they are at their highest concentration in the 
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blood.  By incorporation of a heat shock targeting ligand in the copolymer design, high 
concentration can be maintained as the targeting receptors become increasingly 
available following heat induction.  Ultimately, in a clinical setting, it is anticipated that 
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IN VITRO SYNERGISM AND IN VIVO EFFICACY OF  
COMBINATION TUMOR HYPERTHERMIA AND  




In the continual fight against cancer, chemotherapy remains a powerful tool for 
clinicians, particularly for patients with advanced or metastatic disease.  
Chemotherapeutics are often categorized into different classes such as alkylating agents, 
anti-metabolites, anti-tumor antibiotics, topoisomerase inhibitors, or mitotic inhibitors.
1
  
These may act through various molecular mechanisms; however, they share essentially 
the same goal of preventing the replication and growth of cancer cells.  They are 
pharmacologically designed to act primarily on rapidly dividing cells present within 
cancerous tissue.  However, it is well known that these agents, due to their predesigned 
toxicity towards fast dividing cells of the body, are associated with an array of adverse 
effects including immunosuppression, anemia, gastrointestinal distress, and hair loss.
2
  
Much attention has therefore focused on targeted drug delivery,
3
 whereby specific 
delivery of chemotherapeutics to the tumor site is achieved.  By physically localizing 
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drugs to only the region of interest, exposure to healthy tissue is minimized, resulting in 
decreased side effects.  It is anticipated that this additional physical targeting, coupled 
with the already existing pharmacological targeting can result in improvements in the 
safety profile of chemotherapeutics.  As the goal of the clinician in administering 
chemotherapy is to eradicate or reduce the size of cancerous tumors, these 
improvements in safety offer opportunities for more aggressive treatment, thereby 
increasing the odds of positive, clinical response. 
As described in Chapter 2, much of the work in the field of nanomedicine is 
focused on achieving targeted drug delivery.  One such approach involves the 
conjugation of chemotherapeutics to water soluble polymers.
4, 5
  The primary way in 
which these polymer-drug conjugates achieve site-specific delivery is via the “enhanced 
permeability and retention (EPR) effect” where increased uptake of macromolecules by 
solid tumors can occur due to a combination of increased vascular permeability and 
poor lymphatic drainage present within the tumor microenvironment.
6, 7
  Even with this 
advantage, clinical translation of polymer-drug conjugates has remained elusive due in 
part to marginal efficacy as a result of insufficient tumor accumulation.
8
 
As previously described in Chapter 2, one additional option to achieve enhanced 
delivery is via active targeting.  This approach relies on the inclusion of cancer-specific 
targeting moieties, which are designed to enhance cancer cell binding and 
internalization.
9
  For example, it was previously demonstrated that the attachment of 
cyclic Arg-Gly-Asp (RGD) peptides to the side chains of N-(2-
hydroxypropyl)methacrylamide (HPMA) copolymers can facilitate binding to αvβ3 cell 
adhesion integrins of angiogenic blood vessels in the neovasculature of solid tumors.  In 
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this way, tumor accumulation and retention can be increased several fold as compared 
to their non-targeted counterparts.
10, 11
  
The utilization of such active targeting strategies, while effective, does not 
address the issue of tumor heterogeneity.
12
  Although it is well understood that a tumor 
is not a collective mass of cells with a single phenotype, tumors are often characterized 
as “positive” or “negative” for a particular cancer cell marker or target.  In reality, 
however, tumors are composed of multiple cell populations whose dynamic nature is 
supported by both genetic instability and epigenetic diversity.
13, 14
  Therefore, only a 
subset of cells within a tumor may be susceptible to a particular targeted therapy.  While 
initial treatment often yields progress in terms of tumor reduction, selection occurs 
resulting in tumor adaptation, resistance and recurrence.
15
 
In Chapter 4, a strategy was described which sought to in part overcome these 
limitations by increasing tumor accumulation and the efficiency of active targeting.
16-18
  
This is achieved using a combination of gold nanorod-induced tumor hyperthermia and 
heat shock targeted HPMA copolymer-drug conjugates.  Following exposure to 
hyperthermia, increases in cellular stress induce the expression of heat shock proteins 
(HSPs), which act as molecular chaperones to help stabilize cellular protein structures 
and inhibit protein aggregation.
19
  In particular, it was demonstrated that glucose 
regulated protein 78 kDa (GRP78), a member of the HSP70 family of proteins, is 
induced following heat shock.  While much of this expression occurs within the cell, 
significant expression also occurs on the cell surface, where GRP78 plays a role in the 
transduction of cell proliferation signals.
16, 20
  This induced cell surface expression is 
therefore utilized as a specific cancer target.  Such a strategy is advantageous in that it 
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does not rely on the inherent baseline expression of any particular cell receptor, but is 
directed instead towards this induced target. 
In this strategy, delivery of tumor hyperthermia is performed via gold nanorod 
(GNR) mediated plasmonic photothermal therapy (PPTT).  Gold nanorods, having a 
well-defined size and shape exhibit a localized surface plasmon resonance (SPR) peak 
in the near infrared range.
21
  When excited via a laser light source of a similar 
wavelength, hyperthermia can be induced in an efficient and extremely localized 
fashion.  This tool can therefore be used to induce the expression of cell surface HSPs, 
which serve as targets for delivery.  It was demonstrated that hyperthermia induced via 
this method can increase the tumor accumulation and penetration of macromolecules 
via localized increases in blood flow and vascular permeability.
17, 18
 
This chapter is focused on the evaluation of heat shock protein (GRP78) targeted 
HPMA copolymer-drug conjugates in combination with hyperthermia in a prostate 
cancer model.  Polymer-drug conjugates containing the following chemotherapeutics 
were evaluated: aminohexylgeldanamycin (AHGDM), an HSP90 inhibitor; docetaxel, a 
microtubule stabilizer; and cisplatin, a DNA crosslinker.  These agents were selected for 
evaluation in this strategy due to our previous experience with targeted HPMA 
copolymer-conjugates (see Chapter 4 and Appendix A), as well as reports of enhanced 
activity in combination with hyperthermia.
22-24
  The targeting peptide 
WDLAWMFRLPVG, previously selected by phage display,
25
 was conjugated to the 
side chains of the copolymers to facilitate binding to cell surface expressed GRP78.  
The relative binding affinity towards GRP78 for each conjugate was evaluated in a 
competitive binding assay.  In vitro cytotoxicity was then assessed in combination with 
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hyperthermia to determine if this strategy resulted in antagonistic, additive, or 
synergistic effects.  Finally, utilizing GNR-mediated PPTT to deliver localized 
hyperthermia, this combination strategy was evaluated for efficacy and general 
tolerability in vivo in human prostate cancer bearing mice. 
 
5.2  Materials and methods 
5.2.1  Materials   
Geldanamycin (NSC 122750) was supplied by the National Cancer Institute 
Developmental Therapeutics Program (NCI DTP).  Docetaxel was provided by AK 
Scientific (Mountain View, CA).  Potassium tetrachloroplatinate (Cl4K2Pt) was 
obtained from Alfa Aesar (Ward Hill, MA).  The GRP78 targeting peptide 
WDLAWMFRLPVG and the corresponding scrambled peptide RWLWVADPFLMG 
were synthesized via Fmoc chemistry using a Protein Technologies (Tucson, AZ) PS3 
solid phase peptide synthesizer and identities verified by amino acid analysis and 
ESI/MS.  For competitive binding studies, a rabbit anti-GRP78/BiP antibody (Enzo Life 
Sciences #ADI-SPA-826F) was radiolabeled with 
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I was obtained from American Radiolabeled 
Chemicals, Inc. (St. Louis, MO) and Iodogen reagent (1,3,4,6-tetrachloro-3,6-
diphenylglycoluril) was obtained from Thermo Fisher Scientific (Rockford, IL). 
 
5.2.2  Comonomer synthesis and characterization 










; and N-methacryloyl-tyrosinamide 
(MA-Tyr-CONH2)
30
 were synthesized and characterized according to previously 
described methods.  Conjugation of the anticancer agents docetaxel and AHGDM to 
produce the drug comonomers MA-GFLG-DOC and MA-GFLG-AHGDM were carried 
out as previously described.
31, 32
  The precursor comonomer N-methacryloyl-
glycylphenylalanylleucylglycl-N-Boc-1,2-diaminoethane (MA-GFLG-NH-Et-NH-Boc) 
was synthesized by coupling MA-GFLG-OH to N-Boc-1,2-diaminoethane.  Briefly, 1 
mol eq. of MA-GFLG-OH and 3 mol eq. of N-Boc-1,2,-diaminoethane were dissolved 
in anhydrous DMF.  The solution was cooled to 4°C and 3 mol eq. of DIPC and DIPEA 
were then added dropwise.  The solution was stirred overnight followed by additional 
stirring at room temperature for 1 hr.  DMF was then removed and the resulting residue 
re-dissolved in diethyl ether and washed repeatedly with sodium phosphate buffer at pH 
6.0.  The final product was obtained after removal of diethyl ether and identity verified 
by ESI/MS. 
 
5.2.3  Synthesis and characterization of HPMA copolymer-drug conjugates 
HPMA copolymers were synthesized via free radical copolymerization of 
comonomers in methanol acidified with glacial acetic acid using 2,2’-Azobis[2-(2-
imidazolin-2-yl)propane]dihydrochloride (VA-044) as the initiator.  Polymerization was 
performed in a sealed ampule under N2 gas and the temperature was maintained at 50°C 
for 24 hrs.  The concentrations of monomers and VA-044 during polymerization were 
maintained at 17.5% and 0.5% (w/v) to control molecular weight.  Post polymerization, 
the polymers were precipitated and washed repeatedly in diethyl ether.  Heat shock 
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targeted conjugates were obtained by aminolysis of 2-thiazolidine-2-thione containing 
precursor copolymers with WDLAWMFRLPVG peptide, and non-targeted conjugates 
were obtained by aminolysis with RWLWVADPFLMG (scrambled) peptide in 
anhydrous DMSO/DIPEA (Figure 5.1).  For DOC conjugates, following aminolysis, 
reaction mixtures were diluted in 50 mM pH 6.0 sodium citrate buffer to prevent 
premature release of DOC via hydrolysis.  For AHGDM conjugates, following 
aminolysis, reaction mixtures were diluted in DI water.  Conjugates were then dialyzed 
against distilled water using 3.5 kDa molecular weight cut-off (MWCO) regenerated 
cellulose dialysis membranes (Spectrum Laboratories, Inc., Rancho Dominguez, CA), 
lyophilized, and stored at -20°C. 
Cisplatin conjugates were obtained from MA-GFLG-NH-Et-NH-Boc containing 
copolymers, which were prepared following peptide aminolysis (Figure 5.1).  Following 
aminolysis, boc deprotection was performed in a cleavage cocktail which consisted of 
trifluoroacetic acid:ethanedithiol:triisopropylsilane:water [92.5:2.5:2.5:2.5 v/v].  
Following deprotection, copolymers were again dialyzed and lyophilized.  
Complexation of cisplatin to the resulting diamine side chains was then performed in 
distilled water using 5 mol equivalents of Cl4K2Pt.  The resulting conjugates were again 
dialyzed against distilled water and lyophilized, followed by storage at -20°C. 
Weight average molecular weight (Mw) and polydispersity (Mw / Mn) were 
determined by size exclusion chromatography (SEC) on a Superose 12 column (10 mm 
x 30 cm) (GE Healthcare, Piscataway, NJ) using a Fast Protein Liquid Chromatography 
(FPLC) system (GE Healthcare).  Samples were monitored for UV, differential 








scattering (DLS) detection using a DAWN HELEO II light scattering instrument (Wyatt  
Technologies, Santa Barbara, CA).  SEC coupled with dRI detection was used to 
confirm the absence of small molecular weight impurities.  MALLS was used to 
determine molecular weight and polydispersity.  For AHGDM conjugates, drug content 
was determined by UV spectrophotometry at 332 nm.  For DOC conjugates, drug 
content was measured following enzymatic release of DOC by papain followed by 
quantification of free DOC by HPLC as previously described.
31
  For cisplatin 
conjugates, Pt content was quantified by inductively coupled plasma mass spectrometry 
(ICP-MS) analysis (University of Utah Core Research Facilities, Salt Lake City, UT). 
Targeting peptide content for heat shock targeted and non-targeted (scrambled peptide) 
conjugates was quantified by amino acid analysis (University of Utah Core Research 
Facilities). 
 
5.2.4  Cell culture 
The DU145 human prostate cancer cell line was obtained from ATCC 
(Manassas, VA) and cultured at 37C in a humidified atmosphere of 5% CO2 in Eagle’s 
Minimum Essential Medium (ATCC #30-2003) supplemented with 10% fetal bovine 
serum (FBS) (Thermo Scientific HyClone, Logan, UT).  Cells were maintained in a 
logarithmic growth phase during all studies.   
 
5.2.5  Competitive binding affinity to cell surface expressed GRP78 
The comparative binding affinities of the GRP78 targeting peptide 
WDLAWMFRLPVG and copolymer-drug conjugates bearing the same to cell surface 
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expressed GRP78 on the surface of DU145 cells were assessed using a competitive 
binding assay.  Cells were harvested, washed with PBS, and re-suspended in binding 
PBS (pH 7.4 + 1.0 % bovine serum albumin).  Suspended cells were added to 1.2 m 
pore size 96-well Multiscreen HV filter plates (Millipore, Billerica, MA) at 100,000 
cells per well.  They were co-incubated at 4C with 125I-anti-GRP78 antibody and 
increasing peptide equivalent concentrations of copolymer conjugates or free 
WDLAWMFRLPVG peptide between 0 and 500 M.  After 2 hrs, incubation was 
discontinued and media removed by vacuum filtration using a multiscreen vacuum 
manifold (Millipore).  Retained cells were washed five times with PBS pH 7.4 + 1.0 % 
BSA.  Filters were collected and radioactivity determined using a Cobra Auto-Gamma-
counter (Canberra Industries, Inc., Meriden, CT).  Each experiment was performed in 
triplicate, with three samples per experiment.  Binding percentages relative to cells 
incubated with 
125
I-anti-GRP78 antibody alone were calculated and non-linear 
regression analysis and determination of IC50 values carried out using GraphPad Prism 
(GraphPad Software, Inc., La Jolla, CA).  Incubation with nontargeted copolymer 
conjugates (scrambled peptide) was also performed at equivalent peptide concentrations 
to serve as negative controls. 
 
5.2.6  Single agent in vitro cytotoxicity 
The ability of the HPMA copolymer-drug conjugates to inhibit the growth of 
DU145 human prostate cancer cells was evaluated in vitro using a 2-(2-methoxy-4-
nitrophenyl)-3-(4-nitrophenyl)-5-(2,4-disulfophenyl)-2H-tetrazoliummonosodium salt 
(WST-8) cell viability assay (Dojindo Molecular Technologies, Inc., Rockville, MD).  
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Media containing 0.5% DMSO was used throughout to prevent precipitation of free 
drugs.  This concentration was previously determined to not affect cell viability over the 
time course of the experiments.  DU145 cells (3000 per well) were plated in 96-well 
plates for 24 hrs. Media was then removed and replaced with media containing 
treatments.  Cells were exposed to treatments for 12 hrs.  For each treatment case, drug 
concentrations were varied to include data points ranging from non-toxic to highly 
toxic.  Following drug treatment, media was removed, cells washed with PBS, growth 
media replaced, and cells were allowed to grow for an additional 60 hrs (72 hrs total 
experiment duration).  Media was then removed and cell viability quantified by WST-8 
assay (modified MTT assay) using a SpectraMax M2 microplate UV spectrophotometer 
(Molecular Devices, Sunnyvale, CA).  Each experiment was performed in triplicate, 
with each experiment comprising assessment of viability at eight different drug 
concentrations with three samples analyzed per concentration.  Relative viability was 
calculated by normalization of UV absorbance against untreated cells.  Relative 
viability as a function of log drug concentration was plotted and nonlinear least-squares 
regression analysis and calculation of IC50 values were performed using GraphPad 
Prism. 
 
5.2.7  In vitro cytotoxicity of hyperthermia 
 The cytotoxic effect of hyperthermia treatment alone was evaluated in vitro 
against DU145 using a method analogous to that used to determine single agent 
cytotoxicity.  DU145 cells (3000 per well) were plated in 96-well plates for 24 hrs.  
Cells were then exposed to either 40, 43, or 46°C for various durations spanning 15 min 
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to 48 hrs.  Cells incubated continuously at 37°C served as controls.  Temperatures other 
than 43°C were investigated for informational purposes only and were not used in 
subsequent combination index value calculations.  Following hyperthermia treatment, 
cells were further incubated such that the total experiment duration was 72 hrs, followed 
by cell viability assessment as previously described.  Each experiment was performed in 
triplicate, with six samples analyzed per treatment case. 
 
5.2.8  In vitro combination treatment and combination index analyses 
The cytotoxic effects of the combination treatment of moderate hyperthermia 
and heat shock targeted conjugates were evaluated in vitro (Figure 5.2).  DU145 cells 
(3000 per well) were plated in 96-well plates for 24 hrs.  Media was then removed and 
replaced with media containing treatments.  Subsequently cells were immediately 
exposed to moderate hyperthermia (43°C, 30 min incubation) or control (37°C, 30 min 
incubation).  Following hyperthermia treatment, cells were incubated for an additional 
11.5 hrs (12 hrs total drug exposure).  Following combination treatment, cells were 
washed and allowed to grow for an additional 60 hrs.  Cell viability was then assessed 
as previously described.   
 Thermal enhancement was defined as IC50 of control (37°C) / IC50 when 
combined with hyperthermia (43°C).  Drug effect was defined as (1- [% relative 
viability / 100]).  Combination index analysis was performed using CalcuSyn 
combination index software version 2.1 (Biosoft, Inc., Cambridge, UK) based on the 
Choe-Tolalay method.
33
  Each experiment was performed in triplicate, comprising 
assessment of viability for each combination treatment at eight different drug  
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Figure 5.2.  Method utilized for determination of in vitro combination index 
values of drug treatments in combination with hyperthermia. 
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concentrations with three samples analyzed per concentration.  Combination index was 
then plotted as a function of drug effect for each treatment case.  This form of graphical 
representation was chosen over others commonly used for combination index analysis 
(i.e., isobolograms),
34
 due to the use of a fixed hyperthermia dose and a variable drug 
dose (to obtain a range of effects), as compared to variations in drug ratios commonly 
investigated in these type of studies.  
 
5.2.9  In vivo efficacy 
 Efficacy of the combination treatment of tumor hyperthermia and heat shock 
targeted HPMA copolymer-docetaxel conjugates was evaluated in 8-week-old athymic 
(nu/nu) mice.  Mice were obtained from Charles River Laboratories (Davis, CA) and 
used in accordance with the Institutional Animal Care and Use Committee (IACUC) of 
the University of Utah.  Under anesthesia, mice were subcutaneously injected with 10
7
 
DU145 cells on both the right and left flank of each animal.  When the tumors had 
reached approximately 7 mm in diameter (2-3 weeks), the animals were administered 
PEGylated gold nanorods, synthesized and characterized as previously described,
16
 (9.6 
mg/kg) via tail vein injection.  After 48 hrs, animals were then treated with a single 
intravenous dose of either saline, free docetaxel (formulated in polysorbate 
80:EtOH:saline [20:13:67, v/v/v]), nontargeted (scrambled peptide) conjugate, or heat 
shock targeted HPMA copolymer-docetaxel conjugate at 10 mg/kg (DOC equivalent).  
Immediately following injection, tumors on the right flank received tumor hyperthermia 
via PPTT as previously described.
16
  Briefly, animals were anesthetized and tumors 
were swabbed with 50% propylene glycol to enhance laser penetration.
17
  Tumors on 
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the right flank only were then radiated for 10 min using an 808 nm laser and intra-
tumoral temperature monitored via a 33 gauge needle thermocouple.  Tumor 
temperature was maintained between 42 and 43°C via minor adjustments in laser output 
power.  Tumors on the left of each animal served as internal controls.  Animals were 
then monitored twice a week for changes in tumor volume and animal weight.  Eight 
animals were evaluated per treatment group.  Tumor dimensions (length and width) 
were measured and tumor volume estimated as length × width × π/6.  Normalized tumor 
volume (mean ± SEM) and changes in animal weight (mean ± SEM) were then plotted 
as a function of time.   
 
5.2.10  Statistical analysis 
Differences in relative binding affinity, IC50 values, combination index values, 
normalized tumor volumes, and changes in animal weight were determined by one-way 
ANOVA.  Where differences were detected, Tukey’s test was used to test for 
significance between groups.  The default significance level was set at =0.05 for all 
statistical tests. 
 
5.3  Results and discussion 
5.3.1  Synthesis and characterization 
A representative chemical structure of the HPMA copolymer-drug conjugates 
utilized in this study is given in Figure 5.3, and physicochemical characteristics are 
given in Table 5.1.  All conjugates were synthesized to have a size above the renal 
threshold for HPMA copolymers (approximately 45 kDa),
35




Figure 5.3.  Representative chemical structure of HPMA copolymer-drug 
conjugates.  The chemotherapeutic agent aminohexylgeldanamycin (AHGDM), 
docetaxel (DOC), or cisplatin was conjugated to the copolymer side chain via the 
enzymatically degradable GFLG linker (a), and the glucose regulated protein 78 kDa 






Table 5.1.  Characteristics of HPMA copolymer-drug conjugates 
 
Polymer Description 






























































































where X is AHGDM, DOC, or HN-Et-HN-Boc (precursor for Pt conjugates) 
a 
as measured by SEC/MALLS 
b
 Determined by UV spectroscopy for AHGDM, enzymatic release/HPLC for DOC, and ICP/MS for Pt. 
c




filtration, and resulting in longer blood circulation times.  This was of particular 
importance in our in vivo studies, as our combination strategy relies on two phenomena 
to increase tumor accumulation.  First, tumor hyperthermia, induced immediately 
following intravenous administration of the conjugates, can increase both tumor blood 
flow and vascular permeability, thereby resulting in increased accumulation.  Second, 
tumor hyperthermia can induce the expression of the cell surface heat shock protein 
GRP78.  However, this expression does not occur immediately following exposure to 
hyperthermia, but requires between 8 and 12 hrs before maximum expression is 
observed.
16
  Therefore, the utility of this heat shock targeting strategy requires that the 
conjugates still be available in circulation during this period of maximum expression.  
The conjugates were hence synthesized with molecular weights such that they exhibited 
these required long circulation times. 
 In this chapter, HPMA copolymer-drug conjugates (AHGDM, DOC, or Pt) 
modified with the GRP78 targeting peptide WDLAWMFRLPVG in combination with 
tumor hyperthermia were studied.  For each drug that was evaluated (AHGDM, DOC, 
or Pt), precursor polymers bearing activated carboxyl groups (2-thiazoline-2-thione), 
were first synthesized.  Heat shock protein (GRP78) targeting conjugates were obtained 
following aminolysis with the GRP78 targeting peptide WDLAWMFRLPVG.  While 
some possibility of reaction between the guanidine groups present in the targeting 
peptides and 2-thiazoline-2-thione activated carboxyl groups exists, no evidence of this 
was observed.  Such a reaction would tend to produce higher molecular weight 
copolymers, and no such shift in molecular weight was observed during SEC analysis 
(see Appendix D).  In Chapter 4, the GRP78 targeting peptide WIFPWIQL was used.  
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However, the hydrophobic nature of this peptide limits the amount of drug loading that 
can be achieved while maintaining aqueous solubility.  Conjugates bearing the 
WIFPWIQL peptide also demonstrated significant nonspecific uptake in the liver, 
spleen, and kidneys.
16
  The more hydrophilic alternative peptide (WDLAWMFRLPVG) 
was therefore used in this study.  A brief comparison of the biodistribution of HPMA 
copolymers utilizing these different peptides is also given in Appendix C.  Nontargeted 
conjugates were prepared using a scrambled peptide (RWLWVADPFLMG).  In this 
way, differences in behavior could be attributed to differences in binding affinity for 
GRP78, and not differences in copolymer physicochemical properties.  The total 
amount of targeting peptide in each conjugate ranged from 2.6 – 3.4 mol% (Table 5.1), 
which is consistent with levels previously shown to facilitate sufficient active 
targeting
11, 36
 (see also Appendix A). 
 The amount of each drug that was incorporated into the copolymers was based 
on previous observations of what level could be achieved while maintaining sufficient 
aqueous solubility.  While the percent conversion (mol% of drug incorporation based on 
feed amount) was high and ranged from 90 – 98% for AHGDM and Pt conjugates, 
lower conversions for DOC conjugates of 76 – 80% were observed (Table 5.1).  Since 
DOC is conjugated to the copolymer via ester linkages as compared to amide linkages 
for AHGDM and Pt conjugates, some hydrolysis of the ester bonds likely occurred post 
polymerization, most notably during attachment of the targeting peptides. 
 
5.3.2  Competitive binding affinity to cell surface expressed GRP78 
 
 The relative binding affinities of each of the heat shock targeted conjugates 
towards cell surface expressed GRP78 was evaluated in vitro by a competitive binding 
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assay.  DU145 cells were co-incubated with a fixed concentration of 
125
I-radiolabeled 
anti-GRP78 antibody and increasing concentrations of WDLAWMFRLPVG peptide, 
heat shock targeted conjugates, or controls (nontargeted conjugates).  All heat shock 
targeted conjugates demonstrated some degree of binding towards GRP78, and all non-
targeted conjugates demonstrated no evidence of competitive binding (Figure 5.4).  For 
AHGDM and DOC conjugates, the binding affinities (on a molar peptide basis) for 
targeted conjugates were 1600 ± 200 µM and 1080 ± 70 µM respectively.  These values 
were significantly different from that of free WDLAWMFRLPVG peptide (96 ± 14 
µM), signifying a decrease in the ability of the peptide to bind following conjugation.  
This anticipated result, however, is consistent with previous reports of HPMA 
copolymers-peptide conjugates, demonstrating effectiveness in increasing tumor 
accumulation
11
 (see also Appendix A).  Pt conjugates, however, demonstrated a 
significant shift in binding affinity to 230 ± 40 mM.  While this can possibly be 
explained due to conformational changes in the copolymer due to the presence of the 
cisplatin analogue, it most likely results directly from the synthetic strategy.  Due to the 
highly reactive nature of the cisplain analogue to nucleophilic substitution, it is required 
that the complexation of Cl4K2Pt with -HN-Et-HN2 side groups occur as the last 
synthetic step.  However, during this step, it is possible that some complexation to Arg 
side chains of the heat shock targeting peptide WDLAWMFRLPVG occurs, thereby 
interfering with its ability to effectively bind cell surface GRP78.  This lack of effective 
binding could also be responsible to the lack of synergism observed for heat shock 





Figure 5.4.  Binding affinity of HPMA copolymer-drug conjugates to GRP78 
expressed on the surface of DU145 human prostate cancer cells.  Strong binding 
affinity was observed for HSP targeted conjugates bearing AHGDM and docetaxel, 
and weak affinity was observed for the HSP targeted conjugate bearing cisplatin.  
For all conjugates, binding affinity was reduced as compared to native 
WDLAWMFRLPVG peptide.  No evidence of binding was observed for nontargeted 




5.3.3  Single agent in vitro cytotoxicity 
 The ability of each HPMA copolymer-drug conjugate to inhibit the growth of 
DU145 human prostate cancer cells was evaluated in vitro.  In an effort to mimic a 
realistic in vivo exposure time, the cells were exposed to each treatment case 
(conjugates, free drugs, or controls) for 12 hrs.  This relatively short exposure time also 
provides an opportunity to allow differences in the kinetics or binding and uptake for 
different conjugates (i.e., nontargeted vs. targeted) to affect cytotoxicity.   
 These experiments yielded two primary observations.  First, DOC treatments 
(free drugs and conjugates) were highly potent in inhibiting cell growth, with IC50 
values ranging from 2.47 to 15.7 nM (Table 5.2, Figure 5.5).  In comparison, AHGDM 
and Pt treatments were less potent with IC50 values ranging from 1.81 to 2.76 µM and 
4.4 to 44 µM respectively.  The increased potency of DOC treatments, including that 
observed for the HSP targeted conjugate (1.8 nM), was a primary factor in choosing 
DOC therapy for in vivo evaluation.  These observed values were consistent with 
previous reports for similar conjugates
32, 37
 (see also Appendix A).  Second, statistically 
significant increased cytotoxicity was observed for HSP targeted AHGDM and DOC 
conjugates in comparison with their nontargeted counterparts.  For AHGDM 
conjugates, HSP targeting resulted in a reduced IC50 of 1.85 as compared to 2.76 for the 
non-targeted conjugate (p<0.001) (Table 5.2 and Figure 5.5).  For DOC conjugates, 
HSP targeting resulted in a reduced IC50 of 1.86 as compared to 13.1 for the nontargeted 
conjugate (p<0.001).  These observations can be explained by the inherent cell surface 
expression of GRP78 on the surface of DU145 cells, which facilitates binding and 















Table 5.2.  In vitro cytotoxicity IC50 values of HPMA copolymer-drug 


















Free drugs 1.81 ± 0.05 1.39 ± 0.06 2.47 ± 0.08 1.86 ± 0.06 4.4 ± 0.2 3.2 ± 0.1 
Nontargeted 
conjugates 








Figure 5.5.  Cytotoxicity of single-agents towards DU145 human prostate cancer 
cells.  Growth inhibition IC50 values of free drugs (grey), nontargeted conjugates 
(blue), and HSP targeted conjugates (red).  DOC conjugates were significantly more 
potent than AHGDM or Pt conjugates, with IC50 values in the nanomolar range.  
HSP targeted AHGDM and DOC conjugates were also statistically significantly 
more potent than their nontargeted counterparts.  Data expressed as mean ± SD or 3 
experiments.    
 




HSP targeted Pt conjugate, no difference in potency was observed as compared to the 
nontargeted conjugate.  Again, this is possibly due to the loss of binding affinity of the 
HSP targeting peptide following cisplatin conjugation, as previously discussed. 
 
5.3.4  In vitro cytotoxicity of hyperthermia 
 To ascertain the combined in vitro effects of the conjugates under investigation 
in combination with hyperthermia, it was first necessary to understand the effect 
hyperthermia alone has on cell viability.  DU145 cells were exposed to hyperthermia 
(simple incubation) at varying temperatures (40°C, 43°C, and 46°C).  Exposure time 
ranged from 15 min to 48 hrs.  Following exposure to hyperthermia, cells were 
incubated at 37°C for a total of 72 hrs after initiation of hyperthermia, followed by 
assessment of cell viability.  As anticipated, higher temperatures and increased exposure 
times were associated with decreased cell viability (Figure 5.6).  In terms of potency, 
the exposure times required to decrease cell viability to 50% (relative to unexposed 
cells) were 41 min, 2.7 hrs, and 18.2 hrs for 46°C, 43°C, and 40°C respectively (Figure 
5.6).  It is important to note that for subsequent combination studies, this data indicates 
that exposure to hyperthermia (43°C, 30 min incubation) contributes only a 7.5% 
decrease in relative viability.  The data obtained during the experiment for 43°C 








Figure 5.6.  Cytotoxicity of hyperthermia towards DU145 human prostate 
cancer cells.  Increases in temperature and exposure time were associated with 
increased cytotoxicity.  Exposure times of 18.2 hrs, 2.7 hrs, and 42 min were needed 




5.3.5  In vitro combination treatment and combination index analyses 
 In Chapter 4, it was demonstrated that hyperthermia (43°C, 30 min incubation) 
induces an approximate 4-fold increase in the cell surface expression of GRP78 in 
DU145 cells, and that this increased expression results in increased cellular uptake 
kinetics of HSP targeted HPMA copolymers.
16
  It is therefore anticipated that this 
increased cellular uptake rate will translate into increased cytotoxicity of HSP targeted 
HPMA copolymer-drug conjugates.  In this experiment, DU145 cells were exposed to a 
combination of hyperthermia (43°C, 30 min incubation) and 12 hrs incubation with 
HSP targeted conjugates, nontargeted conjugates, or free drug controls.  This timing 
was selected to be analogous to the exposure that occurs in vivo utilizing a combination 
strategy, where tumor cells are exposed to a brief period of simultaneous drug treatment 
and hyperthermia followed by a longer period of exposure to drug treatment alone.  Cell 
viability was then assessed 72 hrs following initiation of combination treatment.  When 
two therapies are used in combination, their overall effect can be antagonistic, additive, 
or synergistic.  Antagonism, which is normally the least desired, is when the overall 
effect of the combination treatment is less than the sum of the effects of the therapies 
when used individually.  Antagonism can often occur when two therapies are competing 
for a particular target, or when overlap occurs in the biochemical effects of the agents.  
When a combination treatment is additive, the overall effect is equal to the sum of the 
effects of the individual therapies.  Synergism, which is usually most desired, occurs 
when the overall effect of the combination treatment is greater than the sum of the 
effects of the individual therapies.  This can occur when the effects of one therapy 
potentiates the effects of another.  In cancer chemotherapy, this most often occurs when 
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drugs of different mechanisms of action are combined, and where the effects of one 
drug upregulate or otherwise sensitize cells to treatment with the second drug.  Various 
methods exist for determining whether a combination treatment is antagonistic, 
additive, or synergistic.
38
  The most commonly employed, however, is that described by 
Chou and Talalay
33
 and is based on the following equation: 
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where D1 and D2 are the doses of treatment 1 and 2 that give X effect, and Dx1 and Dx2 
are the doses of treatment 1 and 2 that would give the same effect as the combination.  
For a combination treatment of two therapies, this method requires evaluation of the 
effects of each therapy when used individually, as well as in combination.  The result is 
calculation of a combination index (CI) parameter.  When CI is between 1 and ∞ (CI > 
1), the combination treatment is antagonistic.  When CI = 1, the combination treatment 
is additive, and when CI is between 0 and 1 (CI < 1), the treatment is synergistic.  (Note 
that the absolute scales of antagonism and synergism are not equivalent.)  In this study, 
combination index (CI) analysis was performed to determine if the combined effects of 
drug treatment and hyperthermia were antagonistic, additive, or synergistic.  The 
combination index was evaluated as a function of effect, defined as (1- [% relative 
viability / 100]).   
 All free drug controls (AHGDM, DOC, and cisplatin) were nearly additive (CI = 
1) in combination with hyperthermia over the range of effects observed (Figure 5.7).  At 
first glance, these observations appear to contrast other reports suggesting synergism of 
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Figure 5.7.  In vitro combination of hyperthermia and drug therapy.  a)  
Combination index values as a function of drug effect against DU145 cells.  
Treatments consisted of free drug (black), nontargeted (scrambled peptide) 
conjugates (blue), and HSP targeted conjugates (red).  HSP targeted AHGDM and 
DOC conjugates demonstrated significant synergism in combination with 
hyperthermia.  b)  Thermal enhancement ratios (IC50 northermia / IC50 hyperthermia) 
for each treatment case.  c)  Direct comparison of combination index values between 





these compounds with hyperthermia.
22, 23
  However, the combined effects and resulting 
combination index values are highly dependent on the sequence and timing of the 
combination therapy, and these experiments were performed to be analogous to 
potential in vivo exposure.  These results are therefore not directly comparable with 
other studies and are best interpreted in a relative manner between the treatment groups 
in this study.  All nontargeted conjugates were also additive in their combined effects 
with hyperthermia, with the slight exception of the nontargeted Pt conjugate (p-Pt), 
which was antagonistic at low effect levels.  However, this sole observation was highly 
variable, and was not statistically significant.  In combination with hyperthermia, both 
HSP targeted AHGDM and DOC conjugates demonstrated marked synergism with 
combination index values of approximately 0.65 and 0.45 respectively over a range of 
effect levels.  The HSP targeted Pt conjugate demonstrated additive combined effects 
with hyperthermia, possibly due to its lack of binding affinity for GRP78 as previously 
discussed.  For HSP targeted AHGDM and DOC conjugates, however, these results 
clearly demonstrate the potential for increased cellular delivery utilizing this heat shock 
targeted approach.  These levels of synergism were not observed for the non-targeted 
AHGDM and DOC conjugates, which were prepared by addition of the scrambled 
peptide to same precursor polymer, suggesting this effect is primarily due to the HSP 
targeted conjugates’ interaction with cell surface expressed GRP78. 
 To quantify the increase in cytotoxicity observed for treatments in combination 
with hyperthermia as compared to treatment alone, the thermal enhancement ratio of 
each treatment case was evaluated (Figure 5.7).  The thermal enhancement ratio was 
defined as the IC50 observed for the treatment alone (no hyperthermia) divided by the 
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IC50 observed for the treatment in combination with hyperthermia.  These results 
support those from combination index analysis, with HSP targeted AHGDM and DOC 
conjugates exhibiting increased potency with thermal enhancement ratios of 2.2 and 3.9 
respectively.  These combined results demonstrate the ability of cell surface expressed 
GRP78 to facilitate increased delivery of HSP targeted HPMA copolymer-drug 
conjugates, resulting in an increase in overall cytotoxicity.  The HSP targeted DOC 
conjugate was selected for further in vivo evaluation due to its combined high potency, 
significant thermal enhancement, and observed synergism in combination with 
hyperthermia. 
 
5.3.6  In vivo efficacy 
 In Chapter 4, it was demonstrated that tumor hyperthermia, delivered via GNR 
mediated PPTT, and heat shock targeting can increase the tumor accumulation and 
retention of HPMA copolymer-peptide conjugates.  Building upon these results and the 
in vitro results demonstrating synergism of HSP targeted DOC conjugates in 
combination with hyperthermia, in vivo efficacy was evaluated.  Docetaxel therapy in 
combination with tumor hyperthermia, induced via GNR mediated PPTT, was evaluated 
in DU145 human prostate cancer bearing nu/nu mice.  Each animal bore two 
subcutaneous tumors (left and right flank).  Tumors were approximately 7 mm in 
diameter at the time of treatment.  Mice were injected intravenously with a single bolus 
dose of either free DOC, nontargeted (scrambled peptide) DOC conjugates, or HSP 
targeted DOC conjugates at 10 mg/kg DOC.  Injection of saline solutions served as 
negative controls.  Immediately following administration, tumor hyperthermia was 
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performed via GNR mediated PPTT to the right tumor only as previously described,
16
 
and tumor temperature was maintained between 42°C and 43°C for 10 min.  Tumors on 
the left served as northermia controls.  Mice were then monitored twice a week for 
changes in tumor volume and total body weight.  No statistically significant differences 
in animal weights between treatment groups were observed throughout the course of the 
study (Figure 5.8).  This was anticipated, as therapy was given well below the 
maximum tolerated dose of docetaxel.
31
  All treatments demonstrated some level of 
tumor reduction as compared to saline (Figure 5.8), and are discussed in rank order of 
efficacy beginning with the least efficacious.  Tumors treated with saline and 
hyperthermia showed minor tumor regression, with an average normalized tumor 
volume over 30 days of 393% as compared to 624% for saline alone (without 
hyperthermia).  While in vitro experiments evaluating the effect of hyperthermia on 
cytotoxicity suggested minimal damage at this exposure level, the tumor regression 
observed indicates that some amount of tissue damage to the tumor occurred during 
hyperthermia treatment, most likely due to variations in the temperature distribution 
during heating.  The cellular damage by histology is in agreement with previous work 
using similar treatments.
18
  Treatments with free DOC and the non-targeted DOC 
conjugate were equally efficacious, with an observed overall growth of 321%.  
Combined treatment of free DOC or nontargeted DOC conjugates with hyperthermia 
were comparable to treatment with the HSP targeted DOC conjugate alone (no 
hyperthermia), with overall growths of 229%, 165%, and 198% observed respectively.  
The only treatment group which maintained tumor reduction over the entire study 
period was hyperthermia in combination with HSP targeted DOC therapy, wherein 
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Figure  5.8.  In vivo efficacy of tumor hyperthermia and heat shock targeted 
HPMA copolymer-docetaxel therapy.  A combination of tumor hyperthermia, 
delivered via PPTT, and HSP targeted docetaxel therapy (p-DOC-HSP) results in 
maintained tumor regression over a period of 30 days following a single intravenous 
dose at 10 mg/kg DOC eq.  No differences in animal weights were observed between 
treatment groups over the same time period. Data represented as mean ± SEM, with 




tumor volume was maintained at 49% of initial volume after 30 days.  These results 
demonstrate the efficacy of combination therapy and strongly support the proposed heat 
shock targeting rationale. 
 
5.4  Conclusion 
In this chapter, it was demonstrated that tumor hyperthermia can be utilized as a 
tool to increase the active targeting of heat shock targeted HPMA copolymer-drug 
conjugates.  The combined effects of hyperthermia and HSP targeted AHGDM and 
DOC conjugates were found to be synergistic in inducing cytotoxicity to DU145 human 
prostate cancer cells in vitro.  It was further demonstrated that a combination of tumor 
hyperthermia, delivered via GNR mediated PPTT, can increase the efficacy of HSP 
targeted HPMA copolymer-DOC conjugates in human prostate cancer bearing mice.  
These results demonstrate the potential for tumor hyperthermia to increase the delivery 
of targeted macromolecular chemotherapeutics. 
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CONCLUSIONS AND FUTURE DIRECTIONS 
 
6.1 Conclusions 
 Anticancer chemotherapy is often restricted by the inherent adverse effects of 
the agents being administrated, resulting in dose limiting toxicities.  For the drug 
delivery scientist, the overall goal is to deliver a maximal dose to the tumor tissue, 
while minimizing delivery to normal, healthy tissues.  This can be achieved using 
nanoscale sized drug carriers, such as polymer-drug conjugates, which have been shown 
to accumulate preferentially in tumor tissues via the enhanced permeability and 
retention (EPR) effect.  In addition, active targeting strategies, by modification of drug 
carriers with targeting moieties can be used to potentially enhance delivery.  For 
example, previous work
1
 has investigated HPMA copolymer-drug conjugates bearing 
cyclic RGD peptide as drug carriers targeting αvβ3 integrins expressed on the surface of 
angiogenic blood vessels (see also Appendix A).  The work performed in this thesis also 
employed active targeting strategies using small peptides as targeting moieties attached 
to HPMA copolymers.  The goal, however, in addition to evaluating the fundamentals 
of active targeting, was to demonstrate induction of the cell receptor itself.  This was 
achieved by exposure to hyperthermia, which triggers the heat shock protein response.  
Induced expression was then utilized to enhance cellular delivery. 
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 The research presented herein relied heavily on recent studies demonstrating the 
utility of gold nanorod (GNR) mediated plasmonic photothermal therapy (PPTT) in 
generating localized tumor hyperthermia.
2, 3
  In these studies, GNR mediated PPTT 
further demonstrated the ability to increase the passive delivery of macromolecules via 
changes in blood flow and vascular permeability.
3
  It was therefore natural to utilize this 
tool in a heat shock targeting approach to yield an overall therapy which increased both 
the passive and active targeting of macromolecules. 
 It was first necessary to demonstrate that HPMA copolymer-drug conjugates 
could be synthesized that target cell surface expressed GRP78, the inducible target of 
concern.  In Chapter 3, HPMA copolymer-AHGDM drug conjugates bearing the 
GRP78 targeting peptide WIFPWIQL were synthesized and characterized.  Stability of 
the conjugates was assessed in various biological media.  Very minor release was 
observed in all conditions.  Next, the ability of WIFPWIQL peptide to maintain its 
affinity to bind cell surface expressed GRP78 after being conjugated to the HPMA 
copolymer backbone was evaluated in a competitive binding assay.  A reduction in 
binding affinity was observed, which was consistent with previous work utilizing 
targeting peptides.
1, 4
  The ability of the conjugates to inhibit the growth of human 
prostate cancer cell lines was then evaluated.  Conjugates targeting GRP78 
demonstrated increased cytotoxicity as compared to untargeted conjugates.  These 
studies demonstrated that HPMA copolymer-drug conjugates bearing the WIFPWIQL 
peptide could target cell surface expressed GRP78 and enhance cytotoxicity in human 
prostate cancer cells. 
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We hypothesized that tumor hyperthermia, delivered via GNR mediated PPTT, 
could increase the cell surface expression of GRP78, thereby enhancing active binding 
and uptake of GRP78 targeted conjugates and increase cellular delivery.  The focus of 
Chapter 4 was to perform proof of concept studies to test this hypothesis.  First, it was 
demonstrated that additional GRP78 expression occurred on the cell surface of DU145 
cells following in vitro hyperthermia (43°C, 30 min incubation).  Next, the cellular 
uptake kinetics of FITC labeled conjugates targeting GRP78, during the period of 
hyperthermia induced GRP78 expression, was evaluated.  It was observed that GRP78 
targeted conjugates were taken up at a significantly increased rate, as compared to 
untargeted conjugates, suggesting GRP78 mediated binding and uptake.  Next, the 
effect of this induced expression on the cytotoxicity of AHGDM bearing conjugates 
was evaluated.  GRP78 targeted conjugates demonstrated increased toxicity following 
hyperthermia as compared to both untargeted conjugates and free drug controls, 
suggesting GRP78 mediated delivery.  Based on these positive in vitro results, 
analogous experiments were performed in vivo to further evaluate this targeting 
strategy.  Following tumor hyperthermia, delivered via GNR mediated PPTT (42°C-
43°C tumor temperature, 10 min duration), increased expression of GRP78 in tumor 
tissue was observed by immunohistochemistry as compared to untreated tumors.  
Finally, the tumor accumulation and biodistribution of 
125
I radiolabeled GRP78 targeted 
HPMA copolymers were evaluated as a function of time following hyperthermia.  
Modest increases in exposure were observed for tumors receiving either GRP78 
targeted conjugates alone or tumor hyperthermia alone and significant tumor exposure 
was observed when the combination of the two was used.  These results clearly 
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demonstrate the ability of this combination therapy to increase the tumor delivery of 
GRP78 targeted HPMA copolymers.  However, significant non-specific uptake of the 
targeted conjugates was observed in the kidneys, liver, and spleen.  It was hypothesized 
that this may be the result of the hydrophobic nature of the conjugates, due to presence 
of the hydrophobic targeting peptide WIFPWIQL.  Further studies, therefore, utilized a 
less hydrophobic GRP78 targeting peptide, namely WDLAWMFRLPVG in an attempt 
to reduce this non-specific uptake. 
 In Chapter 5, the goal was to demonstrate efficacy of this combination strategy 
in vivo.  Conjugates bearing the anticancer agents aminohexylgeldanamycin (AHGDM), 
docetaxel (DOC), or cisplatin were synthesized using the less hydrophobic GRP78 
targeting peptide WDLAWMFRLPVG and their binding to GRP78 was evaluated.  
They were then assessed in vitro for their ability to synergistically induce cytotoxicity 
in combination with hyperthermia.  Targeted docetaxel and AHGDM conjugates 
demonstrated specific binding to cell surface expressed GRP78, high potency, and 
synergistic effects in combination with hyperthermia.  In DU145 tumor bearing mice, a 
single treatment of tumor hyperthermia, induced via GNR mediated PPTT, and 
intravenous administration of GRP78 targeted HPMA copolymer-docetaxel at 10 mg/kg 
resulted in maintained tumor regression for a period of 30 days.  These results were the 
first demonstration of in vivo efficacy using tumor hyperthermia to increase the delivery 
of HPMA copolymer-drug conjugates.  
 In conclusion, this thesis investigated the use of tumor hyperthermia to increase 
the active delivery of targeted HPMA copolymer-drug conjugates.  Data was collected 
to support initial idea conception, followed by more in depth proof of concept studies, 
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which demonstrated the validity of this therapy.  Finally, in vivo efficacy of the therapy 
was demonstrated in a human prostate cancer animal model.  Overall, these results 
demonstrate the potential for tumor hyperthermia to be used as a tool to increase the 
delivery of heat shock targeted macromolecular chemotherapeutics. 
  
6.2  Future directions 
From a wider perspective, this thesis focused on establishing, as a concept, the 
use of a combination of tumor hyperthermia and heat shock protein targeting to increase 
the delivery of chemotherapeutic drugs.  While the data presented herein focused on the 
goal of achieving increases in tumor delivery, a complete mechanistic understanding of 
the primary phenomena at play remains to be explored.   
For example, it was demonstrated that GRP78 is expressed on the cell surface of 
DU145 cells following hyperthermia.  These experiments, however, only provided a 
snapshot of a very dynamic process.  The kinetics of receptor uptake, trafficking, and 
recycling were not investigated.  It is essential that such investigations be made, as these 
dynamic processes are critical for the cellular delivery of macromolecules.
5, 6
  Detail of 
these processes may yield additional information that can be used to further optimize 
delivery. 
In this thesis, all of the conjugates investigated in combination with 
hyperthermia were synthesized to have molecular weights above renal threshold.  This 
was done to take full advantage of the EPR effect, and ensure that the conjugates were 
maintained in systemic circulation during the period of elevated heat shock protein 
expression.  These drug carriers are not biodegradable, and thus will most likely suffer 
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from poor elimination following administration.  The applicability of targeting cell 
surface expressed HSPs following hyperthermia, however, is not entirely dependent on 
these drug carriers. Other biodegradable polymeric systems such as poly(glutamic acid) 
or backbone degradable HPMA copolymers (see Section 2.24) could potentially be used  
and achieve similar effects.  This issue could also be addressed in an alternate manner.  
Previously, it was demonstrated that actively targeted low molecular weight HPMA 
copolymer-drug conjugates also accumulate in tumors
1
 (see also Appendix A).  It would 
therefore be interesting to see if lower molecular weight conjugates could show similar 
increases in delivery in combination with hyperthermia, as these conjugates have the 
benefit of eventual renal clearance post administration. 
In addition, it is unclear whether the advances in delivery observed in this thesis 
can be achieved using other hyperthermia modalities.  As previously discussed (see 
Section 2.5.3), techniques such as high intensity focused ultrasound (HIFU) are being 
increasing utilized in the clinic for the localized delivery of hyperthermia.  Differences 
in spatial temperature distribution and resulting effects on blood flow and vascular 
permeability between these different hyperthermia modalities should be investigated.   
This thesis also dealt specifically with induction of the heat shock protein 
GRP78 as a target.  However, it is entirely unclear if this is the best target for such a 
strategy, since other inducible heat shock proteins
7
 were not investigated.  For the 
therapy to be fully optimized, some form of screening experiments should be performed 
to, in effect, look at the cell surface receptor expression following hyperthermia to see if 
other proteins are more strongly induced or could offer additional advantages in 
achieving cellular delivery.   
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The overall goal of this research is the development of clinically beneficial 
anticancer therapies.  For this to occur, a number of challenges should be addressed.  
First, the nonspecific uptake of nanomedicines in healthy organs must be minimized.  
This can potentially be achieved through careful optimization of size and other 
physicochemical characteristics, such as hydrophilicity and surface charge.  However, 
this can prove challenging for multifunctional drug carriers, such as actively targeted 
polymer-drug conjugates.  Second, clinical application of this research necessitates the 
ability to apply hyperthermia in a localized, specific, and relatively non-invasive 
manner.  Hyperthermia was applied in this thesis using GNR mediated PPTT.  
However, this technology is still in its infancy, and questions and concerns remain 
regarding its clinical applicability and the potential chronic toxicity of GNRs.  The 
application of hyperthermia via HIFU should therefore be investigated.  If HIFU results 
in similar increases in delivery, this method would be more preferred for clinical 
translation, due to its non-invasive nature and clinical acceptance.
8
 
The use of high temperature localized hyperthermia to induce thermoablative 
cytotoxicity in tumors using various approaches is also an area of current research.
9
  In 
this thesis, the focus was to demonstrate that moderate hyperthermia can increase the 
delivery of targeted chemotherapeutics.  However, chances of a better clinical response 
could possibly be achieved by using a combination of these approaches.  For example, 
the delivery of chemotherapeutics could be enhanced by moderate hyperthermia, 
followed by subsequent high temperature hyperthermia.  This strategy would fully 




These investigations would allow for a more complete mechanistic 
understanding of this combination therapy and build upon the conclusions of this work.  
It is anticipated that this therapy, when fully optimized, can have a significant impact in 
the field of polymer therapeutics, and assist in the clinical translation of nanomedicines, 
with the ultimate goal of finding more effective and less toxic cancer therapies. 
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COMPARISON OF ACTIVE AND PASSIVE TARGETING OF  






Prostate cancer is the leading cause of cancer among men in the United States 
and the second leading cause of death with 217,730 new cases and an estimated 32,050 
deaths in 2010.
2
  In the last decade, much progress in the treatment of prostate cancer 
has been reported.  However, routine treatment regimens have frequently changed due 
to poor prognosis of advanced disease.  Despite standard treatment, the current survival 
from the time of diagnosis in patients with metastatic disease of 3.5 years is 
unacceptable.
3
  These results demand the exploration of new alternatives which 
overcome drawbacks of current treatment modalities. 
Docetaxel (Taxotere®) is a semisynthetic natural product which was approved 
by the FDA in 2004 for metastatic and androgen dependent prostate cancer.  Clinical 
trial results strongly suggest the use of docetaxel as a first line of treatment for prostate 
cancer.
4, 5
  Docetaxel binds to β-tubulin, thereby stabilizing microtubules and inducing 
cell-cycle arrest resulting in apoptosis.
6
  It is up to five times more potent than 
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paclitaxel in vitro with regard to tubulin promotion and inhibition of depolymerization.
7
  
There is incomplete cross resistance between paclitaxel and docetaxel and they act 
synergistically with several drugs including cisplatin and carboplatin in cancer.
8
  
Docetaxel is reported to have both anti-angiogenic and antitumor efficacy.
9
  However, 
treatment with this drug is associated with gastrointestinal toxicity
10
 and can result in 
aggravated risk of acute and subacute pulmonary damage.
11
  Another major problem 
associated with administration of docetaxel is its poor aqueous solubility, requiring 
formulation with the nonionic surfactant polysorbate 80 (Tween 80).  Administration 
of docetaxel is associated with the occurrence of unpredictable acute hypersensitivity 
reactions and cumulative fluid retention.
12
  These adverse effects have been attributed, 
in part, to the presence of polysorbate 80 and have consequently initiated research 
focused on the development of a less-toxic, better-tolerated polysorbate 80-free 
formulation. 
Considerable progress has been made over the past 2-3 decades in the 
development of polymeric carriers for targeted drug delivery to solid tumors.
13, 14
  Due 
to their macromolecular nature, polymeric systems accumulate passively in target 
tissues such as the reticuloendothelial system (RES) (through nonspecific uptake by 
macrophages) or tumors by a process called the Enhanced Permeability and Retention 
(EPR) effect.
15, 16
  The mechanism of the EPR effect has been summarized according to 
the following cascade of events: i) tumor angiogenesis results in hypervasculature, 
providing increased blood flow to the tumor, ii) tumor vasculature becomes highly 
permeable for macromolecules and plasma proteins due to factors such as tumor 
vascular permeability factor, bradykinin, and tumor necrosis factor, iii) a less effective 
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functioning of lymphatic drainage observed in tumors results in long-term retention of 
macromolecular drugs.  These factors result in larger carriers having decreased renal 
clearance, thereby taking longer to be eliminated from the body.
17
   
HPMA copolymers are well characterized, water-soluble, biocompatible, non-
immunogenic and non-toxic synthetic polymeric drug carriers.
13, 18, 19
  The in vivo 
disposition of macromolecules depends to a significant extent on their physicochemical 
properties.  It has been shown that liver and kidney based clearance are the major 
factors affecting the biodistribution of macromolecules
20
 and such clearance is a 
function of molecular weight.  Studies have shown that HPMA copolymers and other 
polymeric macromolecules of molecular weights less than approximately 45kDa 
(hydrodynamic diameter < 5~6 nm) are rapidly filtered by the kidney.
17, 21-23
  Most 
macromolecules that passively target tumors via the EPR effect have sizes larger than 7 
nm, in order to overcome the glomerular renal threshold, thereby resulting in prolonged 
plasma half-life.  Despite significant progress made in the field of macromolecular drug 
delivery, one challenge encountered in the development of such therapy is the fate of 
large macromolecules post treatment.  
Another challenge often overlooked while using the EPR effect as a rationale for 
drug delivery of macromolecules is the elevated interstitial fluid pressure (IVF) which 
reduces convective transport in the core of the tumor.
24, 25
  It is reported that the 
imbalance of the pro and anti-angiogenic factors lead to formation of chaotic new blood 
vessels in tumors.
26-28
  This leads to uneven blood distribution, leaving unevenly 
perfused or unperfused regions inside the tumor.
29-32
  These factors lead to interstitial 
hypertension in the core of the tumor.
33-35
  Interstitial pressure and impaired blood 
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supply reduces the effective transport of anticancer agents in solid tumors.
26
  Active 
targeting can possibly overcome these limitations for drug penetration.
36
 
The tripeptide sequence, Arg-Gly-Asp (RGD) has been identified as a high 
affinity αvβ3 selective ligand by phage display.
37
  The conformationally restrained cyclic 
RGDfK binds to αvβ3 up to 200-fold more avidly than linear peptides.
38
  RGD peptides 




, and poly(ethylene 
glycol)
43
 to improve the biodistribution and increase tumor accumulation.  The RGD 
(Arg-Gly-Asp) peptides have been used to target tumor angiogenesis.
44, 45
  They have 





  They have also been reported to be tumor penetrating and its 
co-administration enhances the efficacy of anticancer drugs.
48
  Compared to non-
targeted systems, previous investigations have identified actively targeted HPMA 
copolymer–cyclo-RGD conjugates that increase tumor accumulation49-53. This 
accumulation takes place through specific interaction of RGD motifs present in the 
copolymer side chains with αvβ3 integrins overexpressed on both angiogenic blood 
vessels
38
 and a variety of tumor cells including prostate cancer.
54
  Enhanced 
accumulation was also demonstrated by active targeting in various human prostate 
cancer xenografts.
49, 52
  Further, these targeted conjugates have also shown to inhibit 
HUVEC cell migration thereby delaying neoangiogenesis.
55
  To enhance efficacy and 
reduce toxicity of docetaxel and to compare and contrast the effects of active vs passive 
targeting, studies presented in this Appendix aim at producing HPMA copolymer-




A.2  Methods 
A.2.1  Chemicals   
All chemicals obtained commercially were of analytical grade and used without 
further purification.  Docetaxel was obtained from AK Scientific (Mountain View, CA).  
RGDfK (MW 604.5) was obtained from New England Peptide Inc. (Boston, MA) at > 
95% purity and used as supplied.  Methacryloyl chloride, glycyl-glycine, and p-
nitrophenol, were obtained from Sigma-Aldrich (St. Louis, MO).  Glycyl-phenylalanine 









, N-methacryloylglycylphenylalanyl-leucylglycine- p nitrophenyl ester (MA-
GFLG-ONp)
58
, and N-methacryloyl-tyrosinamide (MA-Tyr)
59
 were synthesized and 
characterized according to previously described methods.  
 
A.2.2  Synthesis and characterization of comonomers 
A.2.2.1  N-Methacryloylglycylphenylalanylleucylglycyl-docetaxel (MA-GFLG-
Docetaxel).  Docetaxel, (0.335g, 4.1 mmol), 4-(dimethylamino-) pyridine (DMAP, 
0.049g, 4.0 mmol) and MA-GFLG-OH (0.188 g, 4.0 mmol) were dried under vacuum. 
The reaction mixture was dissolved under nitrogen in anhydrous N, N-
dimethylformamide (DMF, 5 ml), cooled with an ice bath (salt/ice) at < 0°C and 
diisopropylcarbodiimide (DIPC, 76 µl, 4.89 mmol) was added drop wise.  The reaction 
mixture was subsequently stirred for an hour before the ice bath was removed and the 
mixture was allowed to warm up to room temperature, stirred overnight and progress 
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monitored by thin layer chromatography (TLC, eluent dichloromethane (DCM): 
methanol (MeOH) (95:5)) for the disappearance of the starting material and the 
formation of MA-GFLG-Docetaxel, and further characterized by mass spectroscopy 
(m/z M
+
+Na = 1272.62).  DMF was removed under vacuum using rotavapor.  The 
product was purified by silica gel chromatography and eluted using ethylacetate 
(EtOAc): MeOH (95:5)).  The product identity was confirmed by Thermo Finnegan 





1250.57605 (100%), 1251.57941 (71.4%), found m/z 1250.57487 (100%), 1251.57827 
(71.4%)). 
 A.2.2.2  N-methacryloylglycylglycyl-RGDfK.  MA-GG-ONp (0.20g, 0.623 
mmol) and RGDfK (0.376 g, 0.623 mmol) were mixed in a round bottom flask, kept in 
a vacuum desiccator for 1 hr followed by addition of anhydrous dimethylsulfoxide 
(DMSO, 5 mL) and stirred for 18 hrs at room temperature. DIPEA (200 µL) was then 
added to the reaction mixture and further stirred for 4 hrs.  The progress of the reaction 
was monitored by mass spectrometry for the disappearance of RGDfK (m/z M
-1
 603.2).  
The reaction mixture was concentrated under high vacuum, followed by addition of 
H2O (25 mL).  This mixture was partitioned in diethyl ether (3 x 25 mL).  The organic 
layer was removed and the aqueous layer lyophilized to obtain a white solid.  Product 
formation was confirmed by Thermo Finnegan LTQ FT high resolution mass 
spectrometry (for C35H50N10O11, calculated m/z 786.36605 (100%), 787.36941 (37.9%), 





A.2.3.   Synthesis and characterization of HPMA copolymer conjugates 
HPMA copolymers were synthesized via free radical copolymerization of comonomers 
in 10% v/v anhydrous DMSO in acetone using N, N′- azobisisobutyronitrile (AIBN) as the 
initiator (Figure A.1).
56
  The feed composition of comonomers for all copolymers is given in 
Table A.1.  The weight composition of the comonomers to solvent was kept at 12.5: 87.5 (w/w). 
The comonomer mixtures were sealed in an ampoule under nitrogen and stirred at 50°C for 24 
hrs.  Solvent was removed by rotary evaporation, copolymer precursor was dissolved in 
methanol and precipitated and washed in diethyl ether.  Copolymer precipitates were dissolved 
in deionized water and purified using dialysis tube molecular weight cut off (MWCO, 3500, 
SpectraPor
®
) to remove small molecular weight impurities.  Samples were characterized for 
weight average molecular weight (Mw), number average molecular weight (Mn) and 
polydispersity (Mw/Mn) by size exclusion chromatography (SEC) on a Superose 6 column (10 
mm x 30 cm) (GE Healthcare, Piscataway, NJ) using a Fast Protein Liquid Chromatography 
(FPLC) system (GE Healthcare).  The peaks that eluted off the column were monitored via both 
ultra-violet absorbance (UV), differential refractive index (RI), and quasi-elastic light scattering 
(QELS) using a DAWN HELEOS II light scattering instrument (Wyatt Technologies, Santa 
Barbara, CA) with imbedded QELS and an OptiLab rEX differential refractometer (Wyatt 
Technologies).  The Superose 6 column was previously calibrated with fractions of known 
molecular weight HPMA homopolymers.  The hydrodynamic radii were determined by QELS 
and calculated from the Stokes-Einstein relation.  All data were collected and analyzed using 
Wyatt Technology Corporation Astra 5.3.4.13 light scattering software (Wyatt Technologies).  
 
A.2.4  Docetaxel and RGDfK content determination in conjugates 
Drug contents of the synthesized copolymers were determined by enzymatic 
release
60
 of free docetaxel and quantification by HPLC.  Briefly, 5.0 mg of the 
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Figure A.1. Schematic synthesis and resulting structure of HPMA copolymer-
RGDfK-docetaxel (P2) conjugates.   
 
a
 Select copolymers contained the monocyclized RGDfK peptide targeteing moiety 

























































Estimated by size exclusion chromatography (SEC), 
b 
Determined by HPLC 
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conjugate was dissolved in 200 µl DMSO.  Ten µl of this solution were incubated in 20 
µl buffer A consisting of 0.1 M citrate phosphate buffer containing 2 mM EDTA at pH 
6.0, 0.6 mM papain and 100 µl of buffer B consisting of 0.1 M citrate phosphate buffer 
containing 2 mM EDTA at pH 6.0 and 10 mM of glutathione.  The mixture was 
incubated at 37°C for 24 hrs.  The condition for complete release of the drug was 
optimized by varying the concentration of papain (0.1 mM to 1.0 mM) over time (data 
not shown).  An aliquot (50µl) of the reaction mixture was removed and diluted in 450 
µl water: acetonitrile (65:35) and evaluated for docetaxel content by HPLC and 
compared to calibration standards prepared using serial dilutions of docetaxel in the 
mobile phase.  Mobile phase consisted of deionized water (Milli-Q system, Millipore, 
Billerica, MA, USA) and HPLC grade acetonitrile (ACN) using the following gradient: 
0 min, 35% ACN; 15 min, 65% ACN; 25 min, 75% ACN; 30 min 95% ACN; 39 min, 
100% ACN; 40 min 65% ACN.  HPLC analyses were performed with an Agilent Series 
1100 HPLC (Agilent Technologies, Wilmington, DE, USA) equipped with an Alltima 
C18 5 m 150 x 4.6 mm column and a photo diode array detector scanning at 200 – 500 
nm.  A flow rate of 1.0 mL/min was maintained and the sample injection volume was 
20 µl.  A post time of 5 min was used to allow column equilibration between samples.  
UV absorbance at 230 nm was used for quantification of docetaxel.  RGDfK content 
was determined by amino acid analysis (University of Utah Core Research Facilities, 






A.2.5  In vitro stability of the conjugates 
The rate of release of docetaxel from the polymer-drug conjugates was 
evaluated in phosphate buffer saline (PBS) at pH 7.4 and in cell culture media.  Two mg 
of each of the three copolymers P1, P2 and P3 (Table A.1) were incubated in 1 ml PBS 
(0.1 M phosphate buffer in 0.05 M of NaCl at pH 7.4) and 1 ml cell culture media 
(recommended media for DU145 from ATCC supplemented with 10% (v/v) fetal 
bovine serum (FBS) (HyClone, Logan, UT)), 100 U/ml penicillin, and 100 mg/ml 
streptomycin (Sigma).  The samples were incubated at 37°C and a 100 µl aliquot was 
removed at times 0 min, 1 hr, 2 hrs, 6 hrs, 12 hrs, and 24 hrs.  The aliquots were 
immediately cooled to 4°C in ice and then free docetaxel was extracted with 
dichloromethane (DCM, 3 x 100 µl).  The organic extract was concentrated under 
nitrogen (N2) and then reconstituted in HPLC grade ACN: deionized water ((Milli-Q 
system) (1:1).  The release of the free drug was analyzed by HPLC and compared to 
calibration standards prepared using serial dilutions of docetaxel in the mobile phase.  
The mobile phase consisted of deionized water ((Milli-Q system) and HPLC grade 
ACN using the following gradient: 0 min, 50% ACN; 10 min, 50% ACN; 10.01 min, 
95% ACN; 13 min 95% ACN; 13.01 min, 50% ACN; 15 min 65% ACN. HPLC 
analyses were performed with an Agilent Series 1100 HPLC (Agilent Technologies, 
Wilimington, DE, USA) equipped with an Alltima C18 5 m 150 x 4.6 mm column and 
a photo diode array detector scanning at 200 – 500 nm.  A flow rate of 1.0 mL/min was 
maintained and the sample injection volume was 20 l.  A post time of 2 min was used 
to allow column equilibration between samples. UV absorbance at 230 nm was used for 
quantification of docetaxel. 
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A.2.6  Cell lines 
Human umbilical vein endothelial cells (HUVEC) and human prostate cancer 
DU145 and PC3 cell lines were obtained from American Type Culture Collection 
(ATCC) (Manassas, VA).  DU145 and PC3 cells were maintained in the recommended 
media from ATCC supplemented with 10% (v/v) FBS, 100 U/ml penicillin, and 100 
mg/ml streptomycin (Sigma).  HUVECs were cultured in endothelial cell growth media-
2 (EGM-2) (Lonza Inc., Allendale, NJ).  Cells were incubated at 37°C in a humidified 
atmosphere of 5% CO2 (v/v) and kept in logarithmic phase of growth throughout all 
experiments. 
 
A.2.7  In vitro cell growth inhibition 
Cell number and growth kinetics were assessed by utilizing a water-soluble 
tetrazolium salt, WST-8 [2-(2-methoxy-4-nitrophenyl)-3-(4-nitrophenyl)-5-(2,4-
disulfophenyl)-2H-tetrazolium, monosodium salt], as a component of Cell Counting 
Kit-8 from Dojindo Molecular Technologies, Inc. (Sunnyvale, CA).  Cells were seeded 
in 100 μl of cultured media at a density of 1 × 104 (DU145) or 1.5 × 104 (PC-3 and 
HUVEC) cells per cm
2
 into a 96-well microtiter plate.  They were subsequently allowed 
to adhere for 24 hrs before medium was replaced with fresh medium containing various 
concentrations of conjugates, free drug, or controls.  Due to the poor water solubility of 
free docetaxel, stock solutions of conjugates, free drug, and controls were prepared in 
DMSO and subsequently diluted, resulting in a final concentration of 0.5 % (v/v) 
DMSO in complete growth medium.  No significant toxicities were observed for any 
cell line when exposed to 0.5% DMSO concentrations for the duration of the 
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experiment.  The cytotoxicity of free drug and HPMA copolymer-docetaxel conjugates 
was evaluated in two different experimental setups: i) continuous incubation with drugs 
for 72 h (DU145, PC-3); ii) short-term incubation or “pulse-chase” experiments where 
cells were incubated with drugs for 2 hrs only, washed with PBS and then incubated for 
an additional 70h (DU145).  In pulse-chase experiments all compounds were added to 
cells either immediately after dilution in cell growth medium or after 16 h of pre-
incubation in the same medium at 37
o
C.  Following treatment with drugs, cells were 
washed once with PBS and WST-8 was added.  The absorbance of colored product at 
450 nm, reference at 630 nm, was measured using a SpectraMax M2 microplate reader 
(Molecular Devices, Sunnyvale, CA).  The number of viable cells exposed to the drugs 
was expressed as a percentage of untreated (control) cells, concentration–response 
curves were graphed, and IC50 values were determined by nonlinear regression analysis 
using GraphPad Prism v. 5.03 (GraphPad Software Inc., La Jolla, CA). 
 
A.2.8  Comparative cell receptor binding assay 
The comparative affinities of free RGDfK and HPMA copolymer conjugates 
were assessed using a competitive binding assay to vβ3 receptors present on HUVEC 
and DU145 cells.  HUVEC and DU145 cells were harvested, washed with PBS, and re-
suspended in binding buffer (20 mmol/L tromethamine, pH 7.4, 150 mmol/L NaCl, 2 
mmol/L CaCl2, 1 mmol/L MgCl2, 0.1% bovine serum albumin).  Cell suspensions were 
added to 1.2 m pore size 96-well Multiscreen HV filter plates (Millipore, Billerica, 
MA) at 100,000 cells per well.  They were then co-incubated at 4C with 0.5 ng 125I-
echistatin (Perkin Elmer, Waltham, MA) and increasing RGDfK peptide equivalent 
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concentrations of copolymer conjugates or free RGDfK peptide between 0 and 500 M.  
Following 20 min incubation, media was removed from cells using a Multiscreen 
vacuum manifold (Millipore) and cells were washed three times with binding buffer.  
Filters were collected and radioactivity determined using a Cobra Auto-Gamma-counter 
(Canberra Industries, Inc., Meriden, CT).  Each experiment was performed in triplicate, 
with n=4 per replicate.  Binding percentage relative to control wells containing only 
125
I-echistatin was calculated and non-linear regression analysis and determination of 
IC50 values was carried out using GraphPad Prism. 
 
A.2.9  In vivo efficacy of HPMA copolymer-drug conjugates 
Six-week-old athymic (nu/nu) mice were obtained from Charles River 
Laboratories (Davis, CA, USA) and used in accordance with the Institutional Animal 
Care and Use Committee (IACUC) of the University of Utah.  Mice were anesthetized 
using 4% isoflurane mixed with oxygen followed by subcutaneous injection of 1 x 10
7
 
DU145 cells per flank (n=5 mice per treatment group).  When the mean tumor size had 
reached approximately 50 mm
3
, the mice were treated with a single dose of conjugates, 
free docetaxel, or control (saline injection) via tail vein injection.  Conjugates were 
prepared in saline and free docetaxel required formulation in polysorbate 80: EtOH: 
saline (20:13: 67, v/v/v) to ensure solubility.  The animals were routinely monitored and 
tumor growth was measured twice weekly and tumor volume was calculated as length  
width
2
  /6.  Tumor volumes at each time point were normalized by the initial volume 
and are reported as mean normalized tumor volume (%) ± standard error of the mean.  
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Animal weights were also measured at each time point and normalized to initial animal 
weight reported as mean ± standard deviation. 
 
A.2.10  Statistical analysis 
Differences in growth inhibition IC50 values were determined by one-way 
ANOVA.  Where differences were detected, Scheffe’s post-hoc analysis was used to 
test for significance between groups.  In vivo data were analyzed by repeated measure 
ANOVA.  Where differences were detected, Scheffe’s post-hoc analysis was used to 
test for significance between groups.  GraphPad Prism v. 5.03 and SPSS v 17 (Chicago, 
IL) was used for statistical analysis.  The significance level was set at =0.05 for all 
statistical tests. 
 
A.3  Results and discussion 
A.3.1  Physicochemical characteristics of polymeric conjugates 
The characteristics of the HPMA copolymer conjugates are listed in Table A.1. 
The sizes of the copolymer conjugates, i.e., P1 (HPMA copolymer-GFLG-Docetaxel 
(low molecular weight)), P2 (HPMA copolymer-GFLG-Docetaxel-GG-RGDfK) and P3 
(HPMA copolymer-GFLG-Docetaxel (high molecular weight)) were controlled by 
changing the ratio of the total comonomers to 3-mercaptoprotionic acid (3-MPA), 
which acts as a chain transfer reagent in the presence of a free radical initiator.
61
  
Docetaxel was attached to the HPMA copolymer backbone via a lysosomally 
degradable oligopeptide linker glycylphenylalanylleucylglycine and targeting peptide 
RGDfK was attached by the non-degradable dipeptide glycylglycine.  The P1 and P2 
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conjugates (with and without αvβ3 integrin targeting peptide RGDfK) had a 4% molar 
equivalent of 3-MPA, while the high molecular weight conjugate had a 1% molar 
equivalent of 3-MPA.  SEC and HPLC profiles of the conjugates indicate the absence of 
small molecular weight impurities or free docetaxel.  Drug content of each polymer was 
measured by releasing docetaxel enzymatically using papain followed by HPLC 
analysis and was found to be 6.8 wt%, 6.84 wt% and 7.15 wt% for P1, P2 and P3 
respectively.  The molecular weights of the copolymers as estimated by SEC on a 
Superose 6 column were 32.6 kDa, 26.9 kDa and 87.1 kDa.  The hydrodynamic 
diameter of the conjugates as measured by quasi elastic light scattering (QELS) were 
3.0 nm, 3.0 nm and 7.6 nm for P1, P2, and P3 respectively.  RGDfK content of P2 was 
estimated by amino acid analysis and was found to be 5.061 wt% of the polymer. 
 
A.3.2  In vitro stability of polymer-drug conjugates 
The in vitro stability of conjugates was investigated at physiological pH as well 
as in cell culture media at pH 7.4.  The three conjugates P1, P2 and P3 released 14.8 ± 
2.6%, 18.6 ± 4.8% and 10.8 ± 2.3% in PBS pH 7.4 and 23.4 ± 3.3, 23.2 ± 2.4 and 24.1 ± 
2.7 in cell culture media in the first 24 hrs (Figure A.2).  The higher release of the 
conjugates in the media is likely due to the presence of serum esterases which cleave 
the ester bond between the conjugate and the drug.  All copolymer systems under study 
had less than 20% release of docetaxel in PBS at pH 7.4 and less than 25% release in 
cell culture media in 24 hrs, indicating adequate stability for in vivo accumulation of a 







Figure A.2.  Stability of polymer-drug conjugates.  Stability of polymer-drug 
conjugates in PBS, pH 7.4 (A) and cell culture medium (B) at 37°C.  Diamond 
represents P1, the untargeted low molecular weight conjugates; the square represents 
P2, the RGDfK targeted low molecular weight conjugates; and the triangle 
represents P3, the high molecular weight conjugate.  The values of three independent 
measurements are presented as mean ± SD. 
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A.3.3  In vitro cell growth inhibition 
All conjugates inhibited proliferation of prostate cancer cell lines and HUVECs 
at nanomolar concentrations (Figure A.3A-C).  Analysis of growth inhibition curves 
revealed that the conjugates were 1.4- to 2.7-fold less toxic than free docetaxel when 
cells were incubated for continuous 72 hrs (Table A.2).  HUVECs were more sensitive 
to docetaxel compared to prostate cancer cell lines as almost half of the drug 
concentrations were required to achieve the same magnitude of cell growth inhibition.  
Besides distinct difference between cytotoxic potential of free and conjugated form of 
docetaxel the difference between IC50 values for polymeric conjugates was found 
statistically insignificant (p > 0.05) for all cell lines tested. 
Considering different routes of cellular entry and the necessity of lysosomal 
degradation of a linker between the polymer backbone and a drug, macromolecular 
therapeutics usually show 50-200 fold difference in toxicity compared to a free drug.
18
 
The difference observed between IC50 values of free and conjugated forms of docetaxel 
was expected but was significantly smaller compared to the difference for other 
macromolecular therapeutics.  It is possible that the hydrolysis of the ester bond and fast 
drug release from the conjugates are responsible for high toxicity of the conjugates.  
The same issue could play an important role in the efficacy of the conjugates in vivo as 
ester bonds could be cleaved by abundant esterases in the bloodstream.
61
  In an attempt 
to mimic in vivo physiological conditions, DU145 cells in this study were exposed to  
the polymer-drug conjugates for 2 hrs, a time period relevant to the plasma half-life of typical 
HPMA copolymer-drug conjugates.
49
  In these sets of experiments DU145 cells were exposed 
to the drugs for 2 hrs only and subsequently were washed with phosphate  




Figure A.3. Toxicity of docetaxel conjugates toward cultured cells. DU145 (A), 
PC-3 (B) prostate cancer cells and HUVECs (C) were exposed to the compounds for 
a continuous 72 hrs. In pulse-chase experiments (D) DU145 cells were incubated 
with the compounds for 2 hrs only, washed with PBS and incubated in fresh growth 
medium for an additional 70 hrs. The legend for this plot indicates how long 
compounds were in contact with cell growth medium. All compounds were added to 
cells either immediately after dilution in cell growth medium (2 hrs) or after 16 hrs 
of preincubation in the same medium at 37°C (16 ± 2 hrs). The values of three to 














Table A.2.  Calculated IC50 values (nM) after continuous 72 hrs incubation of cells 
with drugs. 
 DU145 PC-3 HUVEC 
DOC 2.1+/-0.5 1.8+/-0.4 0.8+/-0.1 
P1 4.4+/-1.1* 4.4+/-0.7* 2.7+/-0.9* 
P2 3.0+/-0.4* 4.3+/-0.4* 2.3+/-0.4* 
P3 3.3+/-0.8* 3.9+/-0.7* 1.9+/-0.5* 
 




number of cells was estimated.  Therefore, this experimental set up allowed testing the influence 
of two important variables in these drug delivery systems: drug release rate and the presence of 
RGDfK targeting moiety.  These experiments revealed a 15- to 20-fold difference between IC50 
values of free and conjugated docetaxel when they were added to DU145 cells immediately 
after dilution in growth medium (Figure A.3D).  This difference is most likely due to the 
difference in the mechanisms of cellular internalization between two forms of the drug, because 
the stability studies performed with polymer-drug conjugates revealed that less than 3% 
docetaxel was released from polymer-drug conjugates in the presence of cell culture media 
within 2 hrs (Figure A.2).  This suggested that the conjugates were not completely hydrolyzed 
within the first two hours.  Prolonged 16 hrs pre-incubation of the conjugates in growth medium 
before the initiation of pulse-chase experiments significantly changed the observed difference 
between the two forms of doxorubicin (Figure A.3D).  After preincubation only 4- to 5-fold 
difference between IC50 values of free and conjugated docetaxel was observed most likely due 
to the release of the drugs from the conjugates.  As in the experiments with 72 hrs continuous 
incubation, no statistically significant difference between IC50 values for the polymeric 
conjugates was found.  Thus, given the two variables evaluated in this experiment, the release 
rate of free docetaxel proved to be the determinant variable that influenced the cytotoxicity of 
the tested constructs in vitro.  High toxicity of the drug masked the binding advantage of the 
RGDfK moiety in vitro.  
 
A.3.4  Competitive binding studies 
Competitive binding studies demonstrated binding of the targeted HPMA 
copolymer-Docetaxel-RGDfK conjugate (P2) to HUVEC and DU145 cell lines with 
IC50 values of 0.5 ± 0.2 M and 2.6 ± 0.3 M respectively (Figure A.4).  RGDfK 
peptide alone showed similar comparative binding affinities of 0.3 ± 0.1 M and 1.5 ± 
219 
 
0.3 M at equivalent peptide concentrations in HUVEC and DU145 cell lines.  
Untargeted conjugate (P1) was also evaluated in both cell lines and showed no evidence 
of active binding (Figure A.4).  These results demonstrate the ability of the targeted 
conjugate P2 (Table A.1) to bind to vβ3 integrins of HUVECs and DU145 cells.  In 
both cases, conjugation of RGDfK to the HPMA copolymer backbone resulted in a 
small decrease in its binding affinity as compared to free RGDfK probably due to steric 
hindrance of the macromolecular system (Figure A.4). 
 
A.3.5  In vivo antitumor efficacy of the conjugates 
One focus of this study was to evaluate whether the efficacy of macromolecules 
with sizes below renal threshold can be enhanced by active targeting.  To this end, we 
have chosen the cyclic integrin targeting peptide RGDfK as it has shown the ability to 
substantially increase tumor accumulation of HPMA copolymers in prostate tumors.
52
  
Docetaxel was chosen as it is the preferred drug of choice for patients with metastatic 
hormone refractive prostate cancer.
10
  Efficacy of the conjugates was evaluated in nu/nu 
mice bearing DU145 prostate tumor xenografts.  A single dose of each conjugate, free 
docetaxel, or control was administered.  Physiological saline was used as a negative 
control and free docetaxel as positive control.  The dose selection for both free drug and 
polymeric conjugates was 20 mg/kg and 40 mg/kg docetaxel equivalent, which 
corresponds to 60 mg/m
2
 and 120 mg/m
2
 in humans weighing 65 kg, as per calculation 
factors shown in the literature.
62, 63
  This dose was based on several phase II/III clinical 
trials
5, 64-72
 using docetaxel as a single agent as well as in combination chemotherapy, 
where doses varied between 30 mg/m
2
 to 75 mg/m
2




Figure A.4. Competitive binding of copolymer conjugates.  Competitive binding 
of HPMA copolymer conjugates and free RGDfK peptide binding of HPMA 
copolymer conjugates with and without RGDfK was compared to free peptide on (A) 
HUVEC and (B) human prostate cancer DU145 cells. Results are expressed as 
means of triplicate ± SD. For sample characteristics see Table A.1. 
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Animals injected with free docetaxel at both 20 mg/kg and 40 mg/kg showed 
signs of hyper- acute toxicity as they were rendered immobile for the first 30 min post 
injection.  The lethargy shown by animals injected with free docetaxel was most likely a 
result of toxicity associated with the drug as well as the polysorbate 80 required to 
dissolve the drug for i.v. injection.  None of the animals in the control group or those 
treated with conjugates showed any signs of acute toxicity.  Mice weights were 
followed up through the duration of the study as an overall measurement of the safety of 
administered compounds.  The normalized weights of animals showed no statistical 
difference between all groups for the duration of study (Figure A.5A).  Animals injected 
with free docetaxel showed statistically significant 2.6 and 2.9 fold reduction in mean 
tumor size as compared to saline at concentrations of 20 mg/kg (P < 0.01) and 40 mg/kg 
(P < 0.001).  Although, conjugate P1 (untargeted, low molecular weight HPMA-
docetaxel) at 20 mg/kg demonstrated a 0.9-fold difference in mean tumor size as 
compared to saline, this difference was not statistically significant (P > 0.1).  However, 
treatment animals with P1 at 40 mg/kg resulted in a 2.3-fold reduction in mean tumor 
size as compared to saline (P < 0.05).  
Conjugate P2 (RGDfK targeted, low molecular weight HPMA copolymer-
docetaxel) and conjugate P3 (untargeted, high molecular weight HPMA copolymer-
docetaxel) at injected doses of 20 mg/kg (Figure A.5B) and 40 mg/kg (Figure A.5C) 
showed reduction in mean tumor size as compared to saline (P < 0.001) of 3.3, 3.2, 3.5 
and 3.4-fold respectively.  While animals injected with both conjugates P2 and P3 
demonstrated reduction in tumor size greater than the group injected with free 
docetaxel, only results with P2 at both 20 mg/kg and 40 mg/kg were statistically 
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Figure A.5. In vivo efficacy.  (A) Normalized animal weights as a function of time. 
Data are expressed as mean ± SEM (n = 5 per treatment group). (B) Efficacy of free 
drug and targeted/nontargeted polymer-drug conjugates P1, P2 and P3 at drug 
equivalent concentration of 20 mg/kg in nu/nu mice bearing DU145 tumor 
xenografts. (C) Efficacy of free drug and targeted/nontargeted polymer-drug 
conjugates P1, P2 and P3 at drug equivalent concentration of 40 mg/kg in nu/nu mice 
bearing DU145 tumor xenografts. Tumor volumes were normalized by their 
respective volume on day 0 (approx 50 mm
3
). Data are expressed as mean ± SEM (n 
= 10 tumors per treatment group). For sample characteristics see Table A.1. 
 



































































































significant.  The efficacy of P1 at 20 mg/kg was statistically inferior to P2 at 20 mg/kg 
and 40 mg/kg (P < 0.01) and P3 at doses of 20 mg/kg and 40 mg/kg (P < 0.05) with a 
mean difference in tumor size of 2.5, 2.4, 2.3 and 2.2 fold.  P1 at 40 mg/kg had no 
statistical difference in mean tumor size with P2 and P3 at 20 mg/kg and 40 mg/kg.  P2 
and P3 had no statistical difference at doses of 20 mg/kg or 40 mg/kg.  
The lack of efficacy for P1 at 20 mg/kg in spite of efficacy observed in free 
docetaxel can be explained below: i) low molecular weight P1 with a hydrodynamic 
diameter of 3.0 nm was small enough to be rapidly eliminated by glomerular filtration, 
thereby minimizing the persistence time of the conjugate in blood circulation which is 
necessary to achieve tumor accumulation due to the EPR effect, and /or ii) the release of 
docetaxel from the conjugate was not fast enough for it to be effective prior to its 
elimination.  Therefore, free docetaxel at this concentration was more effective than the 
untargeted low molecular weight conjugate.  The efficacy of P1 was evident at 40 
mg/kg because sufficient docetaxel could be released from the conjugate prior to 
elimination.  The only advantage shown by animals injected with P1 was the lack of 
adverse hyperacute reaction in response to injection that was observed for free 
docetaxel administration, possibly due to the aqueous solubility acquired by polymer 
conjugation.  
At 20 mg/kg, P2 showed the largest difference in tumor size with saline. 
Conjugate P2, like P1 had a hydrodynamic diameter of 3.0 nm which was well below 
the glomerular renal threshold.  The activity observed in these conjugates most probably 
is a consequence of active targeting as they had vβ3 integrin targeting peptide RGDfK 
linked to the polymer side chains, thereby allowing them to anchor on to the 
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neovasculature of angiogenic blood vessels.  The RGD peptides have also been reported 
to be tumor penetrating and its coadministration enhances the efficacy of anticancer 
drugs.
48
  RGDfK in conjugate P2 may have also contributed to a greater efficacy. 
Conjugate P3, on the other hand, had a hydrodynamic diameter of 7.6 nm which was 
above the glomerular renal threshold.  This increases the plasma half-life and improves 
efficacy by passive targeting via the EPR effect.  Administration of P3 at concentrations 
of 20 mg/kg had a reduction in mean tumor size difference as compared to saline (P < 
0.001) and P1 (P < 0.05).  Again, the difference in activity at 20 mg/kg of P3 when 
compared to free docetaxel was not statistically significant for the study period of 42 
days. 
Further, when comparisons were made between active targeting (P2) and 
passive targeting via the EPR effect (P3) at drug equivalent concentrations of 20 mg/kg, 
though the mean difference in tumor size between the groups was not significant, the 
mean tumor size reduction was greater in case of actively targeted P2 conjugates.  
However at 40 mg/kg, which corresponds to 120 mg/m
2
 in humans and is more than 1.5 
times the highest concentration administered in clinical trials of docetaxel for treatment 
of prostate cancer, free drug and all three conjugates P1, P2 and P3 induced statistically 
significant tumor size reduction as compared to saline.  The efficacy of P1 was evident 
at 40 mg/kg because sufficient docetaxel was released from the conjugate prior to 
elimination.  Administrations of all three conjugates, unlike free docetaxel, 
demonstrated no visible signs of toxicity, and were freely soluble in saline.  
The post hoc analysis of the variance of the mean size of the tumor over entire 
study period of 42 days classified the conjugates and controls into three categories, i.e. 
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those with high activity, those with moderate activity and those with no activity. Each 
compound falls under one or two categories.  According to this analysis saline falls in 
the low activity category, P1 at 20 mg/kg falls under the low and moderate activity 
categories, P1 at 40 mg/kg, free docetaxel at both 20 mg/kg and 40 mg/kg doses fall 
under moderate and high activity categories while P2 and P3 at both 20 mg/kg and 40 
mg/kg fall under the high activity category. 
 To summarize, administrations of all three conjugates, unlike free docetaxel, 
demonstrated no visible signs of toxicity, and were freely soluble in saline.  Actively 
targeted conjugate P2 demonstrated the highest tumor size reduction for the duration of 
the study as compared to free docetaxel, small nontargeted conjugate P1 and passively 
targeted (via EPR) high molecular weight conjugate P3.  All three conjugates were 
soluble in aqueous media and did not show any visible signs of hyper-acute toxicity in 
animals.  Further, while P3 does not have a biodegradable polymer backbone which 
would result in accumulation of the macromolecule post treatment, P2 has the 
advantage of a small size (3.0 nm) which can allow the dose fraction that does not reach 
the tumor to be eliminated. 
 
A.4  Conclusion 
HPMA copolymer-docetaxel conjugates with sizes of 3.0 nm and 7.6 nm, which 
correspond to dimensions below and above the glomerular renal threshold, as well as 
vβ3 integrin targeting conjugate HPMA copolymer-docetaxel-RGDfK of 
hydrodynamic diameter 3.0 nm, were successfully synthesized to evaluate the effect of 
active targeting with passive targeting.  All the conjugates inhibited proliferation of 
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human prostate cancer DU145 and PC3 cells as well as HUVEC at nanomolar 
concentrations.  Cytotoxicity experiments by pulse-chase method where the incubation 
time with free drug and conjugates was limited to 2 hrs resulted in a 15- to 20-fold 
difference in activity of conjugates as compared to free docetaxel.  This suggests that 
the conjugates were not completely hydrolyzed within the first two hours.  Animals 
showed no visible signs of toxicity when injected with conjugates.  HPMA copolymer-
docetaxel conjugates of hydrodynamic diameter 7.6 nm and HPMA copolymer-
docetaxel-RGDfK of hydrodynamic diameter 3.0 nm demonstrated the greatest tumor 
reduction capability with statistically significant tumor regression compared to saline.  
Overall, the results demonstrate that vβ3 integrin targeted, low molecular weight 
conjugates with improved water solubility, reduced toxicity and ease of elimination post 
treatment in vivo are promising candidates for prostate cancer therapy. 
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SYNTHESIS AND EVALUATION OF POLY(STYRENE-CO-MALEIC 
ACID) MICELLAR NANOCARRIERS FOR 
THE DELIVERY OF TANESPIMYCIN 
 
B.1 Introduction 
Heat shock protein 90 (Hsp90) is a 90 kDa chaperone protein that facilitates the 
cellular response to stress by regulating the folding and activity of many client proteins, 
which include critical growth-stimulating proteins involved in the malignant 
transformation of various cancers.
1
  Hsp90 expression is elevated during cellular stress 
conditions such as heat, pH, and glucose deprivation
2
 and in a variety of cancers 
including melanoma, leukemia, colon, lung, breast, and prostate.
3
 
Geldanamycin (GDM), a benzoquinone ansamycin derived from Streptomyces 
hygrocopicus, is a naturally occurring inhibitor of Hsp90 and has been studied 
extensively as an anticancer agent.
4
  GDM binds to the N-terminal ATP-binding site of 
Hsp90 and induces degradation of its client proteins.
5
  This ability of GDM to alter 
multiple oncogenic pathways makes GDM an attractive therapeutic compound.  
However, the clinical use of GDM has been limited by multiple factors.  It exhibits high 
hepatotoxicity at therapeutic doses in animal models,
6
 is poorly soluble in water, and is 
metabolically unstable.
3
  A GDM derivative 17-N-allylamino-17-demethoxy-
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geldanamycin (tanespimycin, 17-AAG) has been widely investigated as an alternative 
to GDM, and has shown less toxicity and comparable activity compared to GDM in 
mouse models.
7, 8
  This drug was the first-in-class Hsp90 inhibitor to enter clinical 
trials.
9
  Although the therapeutic index for tanespimycin is increased as compared to 
GDM, dose limiting toxicity is still due to hepatic and gastrointestinal symptoms.
10
  
Delivery of tanespimycin is difficult due a poor aqueous solubility of 0.02 – 0.05 
mg/mL,
11
 requiring the use of surfactants such as Cremophor EL, which are known to 
induce histamine release, resulting hypersensitivity reactions and anaphylaxis,
12
 and are 
further associated with hyperlipidaemia, abnormal lipoprotein patters, aggregation of 
erythrocytes, and peripheral neuropathy.
13
 
Polymeric carriers can increase the solubility of poorly water soluble drugs and 
can accumulate in tumor tissues via the “enhanced permeability and retention” (EPR) 
effect,
14, 15
 thereby increasing the therapeutic index for a given chemotherapeutic agent.  
Polymeric micelles are characterized by a hydrophilic shell which interacts with an 
external aqueous environment and a hydrophobic core which acts as a depot for 
hydrophobic drugs.  Polymeric micelles were first reported as potential carriers for use 
in cancer treatment in the early 1980s
16
 and the field has matured to include a number of 
candidates currently under clinical investigation.
17
   
The use of poly(styrene-co-maleic acid) (SMA) micelles as drug carriers is 
currently under investigation.
18, 19
  SMA has been proven to be biologically safe and is 
used clinically in SMANCS, a conjugate of half-butyl SMA bound to the antitumor 
protein neocarzinostatin.
20
  Previous studies have demonstrated immunopotentiating 
activity associated with SMA moieties, in contrast to immunosupression that is typically 
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induced by conventional chemotherapeutics.
21, 22
  The styrenic core of SMA micelles 
has been characterized by a high glass transition temperature
23
 and a large 
microviscosity,
24
 which may help facilitate higher stability and more controlled release 
rates of drugs from the micelle core.  In addition, the hydrophilic surface of SMA 
micelles is comprised of carboxyl terminated maleic acid groups, allowing easy surface 
modification or conjugation with targeting moieties. 
Previous work has described the use of HPMA copolymers as drug carriers for 
geldanamycin derivatives
25, 26, 27
.  In these systems, geldanamycin derivatives were 
covalently bound to the polymer backbone via the lysosomally degradable Gly-Phe-
Leu-Gly linker,
28
 resulting in highly stable conjugates with drug release occurring via 
lysosomal degradation following endocytosis.  The use of such systems however 
requires chemical modification of geldanamycin to facilitate conjugation, and such 
modifications result in a decrease in the activity of geldanamycin.  Self-assembled drug 
delivery systems do not suffer from this limitation as the drug is most often bound to the 
carrier through non-covalent hydrophobic interactions. 
In the study presented in this Appendix, SMA was used to prepare polymeric 
micelles containing the Hsp90 inhibitor tanespimycin.  The micelles were characterized 
for drug loading efficiency, drug content, size, and zeta potential.  The release rate of 
tanespimycin from the micelles and the ability of the micelles to inhibit the growth of 
DU145 human prostate cancer cells in vitro were evaluated.  An in vivo preliminary 
single dose study evaluating the efficacy of the micelles was performed in nu/nu mice 




B.2  Materials and Methods 
B.2.1  Materials   
Geldanamycin (NSC 122750) was kindly supplied by the National Cancer 
Institute Developmental Therapeutics Program (NCI DTP).  Allylamine was supplied 
by Alfa Aesar (Ward Hill, MA, USA).  Cumene terminated poly(styrene-co-maleic 
anhydride) was obtained from Sigma-Aldrich Corp. (St. Louis, MO, USA) and supplied 
with a 1.3:1 mole ratio of styrene:maleic anhydride, an average Mn of approximately 
1600 as determined by GPC, and an acid number of 465-495 mg KOH/g.  N-(3-
Dimethylaminopropyl)-N’ethylcarbodiimide hydrochloride (EDAC) was obtained from 
Sigma-Aldrich Corp.  Bovine serum albumin fraction V (BSA) was obtained from MP 
Biomedicals (Solon, OH, USA).  Polyoxyl castor oil (Cremophor EL) was obtained 
from BASF Corp. (Florham Park, NJ, USA).  Poly (ethylene glycol) 400 was obtained 
from Dow Chemical Corp. (Petaluma, CA, USA). 
 
B.2.2  Cell lines and culture 
The human prostate cancer cell line DU145 (ATCC, Rockville, MD, USA) was 
maintained in Eagle’s minimum essential medium (ATCC) supplemented with 10% 
heat inactivated fetal bovine serum.  Cell lines were cultured at 37C in a humidified 
atmosphere of 5% CO2.  For all procedures, cells were harvested using TrypLE
TM
 
Express (Invitrogen, Carlsbad, CA) and cell lines were maintained in a logarithmic 





B.2.3  Synthesis of tanespimycin 
Two-hundred mg (0.357 mmol) of GDM were dissolved in 10 mL anhydrous 
dimethylformamide (DMF) at ambient temperature.  Eighty μL (1.07 mmol) of 
allylamine were added and the solution was kept under nitrogen, protected from 
exposure to light, and allowed to stir overnight at ambient temperature.  The color of the 
solution changed from bright yellow-orange to dark purple and completion of the 
reaction was monitored by TLC on silica gel with chloroform:MeOH [9:1] as mobile 
phase by the disappearance of  GDM.  DMF was removed by rotary evaporator, and the 
resulting crude product was recrystallized from H2O:EtOH [4:1].  The precipitate was 
analyzed by electrospray ionization mass spectrometry (ESI-MS). 
 
B.2.4  Preparation of SMA-tanespimycin 
Preparation of SMA micelles was similar to the method previously reported with 
modifications
29
 (Figure B.1).  First, poly(styrene-co-maleic anhydride) was hydrolyzed 
under aqueous alkaline conditions.  Deionized water was adjusted to pH 14 with 4N 
NaOH and heated to 70C.  Poly(styrene-co-maleic anhydride) was added under stirring 
and the solution was maintained at pH 14 and 70C.  The resulting hydrolyzed SMA 
solution was adjusted to pH 7.0 with 1N HCl, diluted to a final concentration of 50 
mg/mL, and allowed to cool to ambient temperature.  Twelve mL (600 mg SMA) were 
removed and diluted to approximately 60 mL with deionized water.  200 mg of 
tanespimycin was dissolved in minimal DMSO, and added drop wise while stirring, 
resulting in a cloudy solution.  The solution was then adjusted to a pH of 5.0 and 600 
mg EDAC in 5 mL deionized water was added drop wise at pH 5.0 and allowed to stir 
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Figure B.1: Preparation of SMA-tanespimycin micelles. SMA-tanespimycin 
micelles were prepared by first suspending tanespimycin in an aqueous solution of 
hydrolyzed SMA containing EDAC.  The solution was then adjusted to alkaline 
conditions which resulted in encapsulation of tanespimycin by SMA micelles.  The 




for 30 minutes.  Next, the solution was adjusted to pH 10.5 by the addition of 1N 
NaOH, the pH was subsequently adjusted to 7.0 with 1N HCl, and the resulting solution 
was filtered to remove undissolved tanespimycin.  1N HCl was then added dropwise to 
the filtrate to precipitate the micelles.  The precipitated micelles were then centrifuged 
and purified by washing repeatedly with cold 0.01 N HCl in deionized water.  Residual 
water/HCl was removed by lyophilization to obtain the final SMA-tanespimycin 
product. 
 
B.2.5  Loading efficiency of SMA-tanespimycin 
For the purpose of this study, loading efficiency is defined as the total weight of 
the drug in the final SMA-tanespimycin product divided by the initial weight of the 
drug introduced for micellar preparation.  A standard curve was prepared by serial 
dilution of tanespimycin in DMSO and quantification of the drug was by UV 
spectrometry at 335 nm.  Loading efficiency and drug content were then obtained by 
dissolving SMA-tanespimycin in DMSO and measuring absorbance at 335 nm in 
comparison with the standard curve. 
To ensure that the drug was unmodified during micelle preparation, SMA-
tanespimycin was further analyzed by reversed phase high-performance liquid 
chromatography (RP-HPLC).  Analysis was performed with an Agilent 1100 LC system 
equipped with an Alltech Alltima C18 5μm 150 x 4.6 mm column and a photo diode 
array detector scanning at 200 – 500 nm.  The mobile phase consisted of deionized 
water and acetonitrile (ACN), at the following gradient: analysis time 0 min, 35% ACN; 
15 min, 65% ACN; 25 min, 75% ACN; 30 min 95% ACN; 39 min, 100% ACN; 40 
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min, 65% ACN.  A post time of 5 min was used to allow column equilibration between 
samples.  The flow rate was maintained at 1.0 mL/min throughout and the sample 
injection volume was 20 L.  Samples of tanespimycin and SMA-tanespimycin were 
prepared in deionized water:ACN [65:35] and injected for analysis.  The max of 
tanespimycin at 335 nm was used for final quantitative analysis. 
 
B.2.6  Size and zeta potential of SMA-tanespimycin 
SMA-tanespimycin was prepared in 50 mM sodium phosphate buffer pH 7.4 at 
a concentration of 1.0 mg/mL for analysis.  All measurements were performed at 25C.  
A Malvern Zeta Sizer ZEN3600 (Malvern Instruments Inc., Westborough, MA) was 
used to determine mean Z-average size, size distribution and zeta-potential.  All 
measurements were performed on three separately prepared samples. 
. 
B.2.7  Drug release from SMA-tanespimycin 
The release of tanespimycin from the micellar preparations was evaluated using 
a dialysis method and compared to the release in a standard vehicle formulation of 
EtOH:Cremophor EL:PEG 400 [2:1:1] (EtOH:CrEL:PEG).30  SMA-tanespimycin was 
prepared at a concentration of 2.5 mg/mL (0.625 mg/mL tanespimycin) and drug-
EtOH:CrEL:PEG was prepared by dissolving tanespimycin in EtOH:CrEL:PEG 
followed by a 10X dilution to yield a final concentration of 0.625 mg/mL.  Samples 
were prepared in a 50 mM sodium phosphate buffer pH 7.4 or phosphate buffered saline 
(PBS) pH 7.4 with 40 mg/mL BSA.  Four mL of each sample were placed in a dialysis 
tube with a molecular weight cutoff of 3500 Da and dialyzed against 5 L of either 50 
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mM sodium phosphate buffer pH 7.4 or PBS pH 7.4.  Media outside the dialysis 
membrane was changed periodically to ensure a constant sink condition.  At each 
predetermined time point, 200 µL of the sample inside the dialysis membrane was 
removed and analyzed spectrophotometrically at 335 nm.  Quantification of percent 
release was performed by comparison of sample absorbance with calibration curves 
prepared for SMA-tanespimycin and tanespimycin-EtOH-CrEL:PEG for each test 
condition.  All experiments were performed in triplicate.  Percent release is reported as 
mean ± standard deviation. 
 
B.2.8  In vitro growth inhibition against human prostate cancer cells 
The ability of the SMA-tanespimycin to inhibit the growth of DU145 human 
prostate cancer cells was evaluated using a 2-(2-methoxy-4-nitrophenyl)-3-(4-
nitrophenyl)-5-(2,4-disulfophenyl)-2H-tetrazolium,monosodium salt (WST-8) cell 
viability assay.  3,000 DU145 cells per well were plated in 96-well plates for 24 hrs.  
Cell culture medium was then removed and cells were treated with SMA-tanespimycin, 
tanespimycin dissolved in EtOH:CrEL:PEG, or controls for 72 hrs.  Following 
treatment, medium was removed and wells were washed with 200 L PBS.  100 L of 
10% (v/v) WST-8 reagent in complete growth medium was added to each well, cells 
were incubated at 37C / 5% CO2 for 120 min and absorbance at 450 nm minus 630 nm 
was determined by UV spectrophotometry.  Relative viability was calculated by 
normalization of the absorbance of untreated cells.  All experiments were performed in 
triplicate, with n=3 wells per replicate.  Nonlinear least-squares regression analysis and 
calculation of IC50 was performed using GraphPad Prism. 
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B.2.9  Cell growth inhibition studies 
Six-week-old athymic (nu/nu) mice were obtained from Charles River 
Laboratories (Davis, CA, USA) and used in accordance with the Institutional Animal 
Care and Use Committee (IACUC) of the University of Utah.  Mice were anesthetized 
using 4% isoflurane mixed with oxygen followed by subcutaneous injection of 1 x 10
7
 
DU145 cells per flank (n=5 mice per treatment group).  When the mean tumor size had 
reached approximately 50 mm
3
 (about 10 days after tumor inoculation), the mice were 
treated with a single injection of either saline (control), free tanespimycin dissolved in 
DMSO, or SMA-tanespimycin at a dose of 10 mg/kg drug equivalent.  The animals 
were routinely monitored and tumor growth was measured twice weekly and tumor 
volume was calculated as length  width2  /6.  Tumor volumes at each time point were 
normalized by the initial tumor volume and are reported as mean ± standard error of the 
mean.  Animal weights were also measured at each time point and normalized to initial 
weight reported as mean ± standard deviation. 
 
B.2.10  Statistical analysis 
For release studies, tumor regression, and animal weight data, differences 
between data sets were determined by two-way repeated measures ANOVA using 
GraphPad Prism.  Where differences were detected, a Bonferroni posttest was used to 






B.3  Results and discussion 
B.3.1  Synthesis and preparation of SMA-tanespimycin 
The development of polymeric micelles in drug delivery has primarily focused 
on the use of amphiphilic block copolymers with poly(ethylene glycol) (PEG) as the 
hydrophilic segment and a polyester or a poly(amino acid) derivative as the 
hydrophobic segment.
31
  The loading of hydrophobic drugs and the assembly of such 
copolymers into micellar structures is commonly performed using methods such as: 1) 
basic equilibration, 2) dialysis, 3) oil/water emulsion, 4) solution casting, or 5) freeze 
drying.
32
  The present study describes polymeric micelles prepared by varying the pH of 
an aqueous solution containing poly(styrene-co-maleic acid) copolymers and 
tanespimycin, as a hydrophobic drug. 
Tanespimycin was synthesized from GDM, and the resulting purple solid was 
collected and identified as tanespimycin by ESI-MS.  SMA-tanespimycin was prepared 
by varying the pH of an aqueous solution of hydrolyzed SMA (Figure B.1). 
 
B.3.2  Characterization of SMA-tanespimycin 
The preparation of polymeric micelles as drug carriers often employ methods 
that result in either low loading efficiency or low drug loading capacity.
33
  Using the 
aforementioned process, hydrolyzed SMA incorporated tanespimycin with a loading 
efficiency of 93% (Table B.1), a significant improvement over previous studies 
describing polymeric micellar formulations of tanespimycin.
34, 35
  The ability of SMA 
based micelles to achieve high drug loading has previously been demonstrated for the 
















Table B.1: Characteristics of SMA-tanespimycin micelles 
 
 
Property Mean SD 
Amount of tanespimycin introduced for micelle preparation (mg) 150.0 - 
Drug loading efficiency (%)
a 
93.1 - 
Drug loading (% wt/wt) 25.6 - 
Mean micelle diameter (nm)
b,c
 74 7 
Polydispersity index 0.31 0.08 
Zeta potential
c,d
 (mV) -35 3 
 
a
 Drug loading efficiency calculated as mg tanespimycin solubilized by SMA micelles / mg tanespimycin 
introduced for micelle preparation 
b
 Z-average size as measured by dynamic light scattering (DLS) 
c




drug loading of 25.6 % tanespimycin by weight was observed for SMA-tanespimycin as 
determined by UV spectrophotometry (Table B.1).  The micelles were highly soluble, 
with a drug equivalent aqueous solubility of > 5.0 mg/mL as measured in pH 7.4 PBS 
buffer, whereas free tanespimycin was soluble only at 0.021 mg/mL.  To ensure that 
tanespimycin remained unmodified during micelle preparation, SMA-tanespimycin in 
comparison with free tanespimycin was analyzed by RP-HPLC.  Both tanespimycin and 
SMA-tanespimycin showed a prominent peak at 15.2 min, and both peaks exhibited UV 
spectra characteristic of tanespimycin (data not shown).  Drug loading of tanespimycin 
as determined by RP-HPLC was 25.2 % by weight and in agreement with drug loading 
determined by UV spectrophotometry. 
 Size is a critical parameter for macromolecular drug delivery systems designed 
to escape renal filtration.  It has been proposed that carriers with sizes greater than 10 
nm accumulate in the tumor tissues via the EPR effect.  SMA-tanespimycin micelles 
had a mean diameter of 74 ± 7 nm and a poly dispersity index of 0.31 ± 0.08 as 
measured by dynamic light scattering (Figure B.2).  The micelles had a zeta potential of 
-35 ± 3 mV as measured in a 50 mM phosphate buffer at pH 7.4.  SMA micelles were 
characterized by carboxyl terminated maleic acid surface groups which impart a 
negative charge to the micelles. 
The high loading efficiency and possibility to tune the loading ratio of 
tanespimycin into SMA micelles represents significant advantages for industrial scale 









Figure B.2.  Size distribution of SMA-tanespimycin micelles.  The size 
distribution of SMA-tanespimycin micelles was determined using a Malvern Zeta 
Sizer at a concentration of 1.0 mg/mL at pH 7.4.  Data are expressed as mean (solid 




B.3.3  Release of tanespimycin from SMA-tanespimycin micelles 
The incorporation of tanespimycin into SMA micelles can increase tumor uptake 
and alter biodistribution, resulting in an increase in the therapeutic index of the drug.  
For this to occur, it is essential that tanespimycin is retained by the carrier for a period 
of time to allow drug accumulation in tumor tissue via the EPR effect.  However, 
release from the carrier is also essential to allow tanespimycin to elicit its 
pharmacologic effect.  Release rate is therefore a critical parameter in anticancer 
macromolecular drug delivery, and an ideal anticancer carrier should be able to retain 
its cargo for approximately 6 hrs while tumor accumulation occurs,
36
 followed by 
complete drug release.  To address this issue, the in vitro release rate of tanespimycin 
from SMA-tanespimycin micelles was evaluated using a dialysis method and compared 
to the release of tanespimycin formulated in EtOH:CrEL:PEG.  Release was assessed in 
a pH 7.4 buffer where 51% and 95% tanespimycin was released from SMA-
tanespimycin micelles in 2 and 8 hrs respectively.  Release from tanespimycin 
formulated in EtOH:CrEL:PEG was not significantly different, with 60% and 99% 
released in 2 and 8 hrs respectively.  To better ascertain release of tanespimycin from 
the blood plasma compartment in vivo, a second test condition was evaluated wherein 
BSA was included inside the dialysis bag at a physiologically relevant concentration of 
40 mg/mL.  Release of tanespimycin from SMA-tanespimycin micelles in the presence 
of BSA was reduced at all time-points greater than 1 hour (p<0.001) as compared to 
release from pH 7.4 buffer alone (Figure B.3). Release of tanespimycin from SMA-
tanespimycin micelles was also significantly reduced as compared to tanespimycin 
formulated in EtOH:CrEL:PEG at all times greater than 1 hr (p<0.001), with only 62% 
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Figure B.3: Release of tanespimycin from SMA-tanespimycin.  Release of 
tanespimycin from SMA micelles was evaluated using a dialysis method and 
compared to tanespimycin formulated in EtOH:CrEL:PEG as control.  Panel A: 
Release of tanespimycin from SMA-tanespimycin (red) and tanespimycin-
EtOH:CrEL:PEG (blue) in a pH 7.4 buffer and release of tanespimycin from SMA-
tanespimycin (green) and tanespimycin-EtOH:CrEL:PEG (black) in a pH 7.4 buffer 
containing 40 mg/mL BSA.  Panel B: Release of tanespimycin at 8 hrs. Data 
expressed as mean ± SD (N=3).  
 




release observed in 24 hrs (Figure B.3).  This reduction in release rate can be explained 
by the well characterized noncovalent binding of SMA to serum albumin
37
, and it is 
thus anticipated that serum albumin can serve as a secondary carrier for SMA-
tanespimycin micelles in vivo. 
 
 
B.3.4  Cytotoxicity of SMA-tanespimycin micelles in vitro 
 
The ability of SMA-tanespimycin micelles to inhibit the growth of DU145 
human prostate cancer cells was evaluated in vitro using a WST-8 cell viability assay.  
Incorporation of tanespimycin into SMA-tanespimycin micelles resulted in a decrease 
in its ability to inhibit the growth of DU145 cells with an IC50 of 230 ± 10 nM as 
compared to an IC50 of 15.0 ± 0.3 nM for tanespimycin solubilized in EtOH:CrEL:PEG 
(Figure B.4).  For controls, SMA and EtOH:CrEL:PEG solutions were subjected to the 
same dilution protocol and evaluated for growth inhibition ability and showed no 
cytotoxicity over an equivalent concentration range.  During the 72 hrs incubation time 
of these studies, the release of tanespimycin from SMA-tanespimycin micelles was 
most likely minimized because of the lack of a perpetual sink condition.  Although 
SMA-tanespimycin micelles were less toxic as compared to free tanespimycin, they 
remained cytotoxic in the nanomolar concentration range.  This reduction in 
cytotoxicity of SMA-tanespimycin micelles as compared to free tanespimycin can be 
explained by a number of possible factors.  The micelles first need to be taken up by 
cells via endocytosis, whereas tanespimycin can passively diffuse across cellular 
membranes.  Uptake of the micelles could further be reduced due to the interactions of 
the negatively charged carboxylic acid rich surface of the micelles with negatively 
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Figure B.4.  Cell growth inhibition of SMA-tanespimycin micelles.  DU145 
human prostate cancer cells were treated for 72 hrs with increasing drug equivalent 
concentrations of tanespimycin formulated in EtOH:CrEL:PEG (blue), SMA-
tanespimycin micelles (red) [Panel A], EtOH:CreEL:PEG vehicle alone (blue) or 
hydrolyzed SMA (red) [Panel B].  Following treatment, cell viability was assessed 
by WST-8 assay.  Nonlinear regression and IC50 values were determined by analysis 




charged membranes.  Tanespimycin must also be released from the micelle core in 
order for it to elicit its pharmacological effect, which occurs over a prolonged time 
interval, further reducing overall cytotoxic exposure.  The reduced toxicity of SMA-
tanespimycin micelles can potentially be advantageous in an in vivo scenario by 
minimizing systemic exposure of tanespimycin while allowing time for accumulation in 
tumor tissues to occur.   
 
B.3.5  In vivo efficacy of SMA-tanespimycin micelles 
The delivery of tanespimycin via SMA-tanespimycin micelles results in an 
increase in the therapeutic index for tanespimycin.  Toward this aim, a preliminary in 
vivo efficacy study was performed in athymic nu/nu mice bearing subcutaneous DU145 
human prostate cancer xenografts.  As accumulation in tumor tissues via the EPR effect 
was anticipated for SMA-tanespimycin micelles, a subtherapeutic dose of 10 mg/kg 
tanespimycin equivalent was used.  A single dose of SMA-tanespimycin micelles, free 
tanespimycin, or saline were injected via tail-vein injection and animals were monitored 
twice weekly for changes in tumor volume as an indicator of efficacy (Figure B.5).  
Body weight was also recorded as an indicator of general toxicity (Figure B.5).  At a 
single dose of 10 mg/kg tanespimycin equivalent, SMA-tanepsimycin micelles resulted 
in a reduction in normalized mean tumor volume that was maintained throughout the 
duration of the study (23 days), whereas normalized mean tumor volume in saline 
injected animals increased 450%.  Relative to saline injected animals, SMA-
tanespimycin resulted in a statistically significant decrease in normalized mean tumor 
volume at all time points following treatment (p<0.05).  A single dose of free 
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Figure B.5: In vivo efficacy of SMA-tanespimycin micelles. Athymic nu/nu mice 
bearing DU145 tumor xenografts were treated IV with a single dose of 10 mg/kg 
tanespimycin (blue) or 10 mg/kg tanespimycin equivalent SMA-tanespimycin 
micelles (red) and compared with a saline injection control group (black).  Panel A: 
Normalized tumor volume was measured as a function of time for each treatment 
group.  Panel B: Normalized animal weight was assessed as a measure of general 
toxicity.  Data are expressed as mean ± SEM (N=5 per treatment group). 
 




tanespimycin showed no evidence of efficacy at 10 mg/kg, and normalized mean tumor 
volume was not different from saline injected animals at all time points.  Animals in the 
free tanespimycin group were euthanized on day 16 as one animal showed excessive 
tumor burden.  SMA-tanespimycin micelles in comparison with free tanespimycin 
showed a significant reduction in normalized mean tumor volume on day 16 (p<0.05).  
These results coupled with the in vitro cytotoxicity results suggest that SMA-
tanespimycin micelles have the ability to accumulate in tumor tissues and inhibit tumor 
growth in vivo. 
 Animal weights were measured twice a week as an indicator of general toxicity 
during the efficacy study.  Relative to saline injected animals, animals treated with 
SMA-tanespimycin micelles showed no difference in normalized mean animal weight 
during the study.  An 11% reduction in normalized mean animal weight was observed 
for free tanespimycin as compared to saline injected animals at day 5 (p<0.05); 
differences detected at subsequent time points were not statistically significant.  
However, it is unclear whether the solvent used to solubilize tanespimycin has 
contributed to the overt tanespimycin toxicity in this study, or the manifested toxicity 
was totally due to the free drug.  These results demonstrate that SMA-tanespimycin 
micelles were well tolerated. 
 This efficacy study was preliminary in its nature as parameters such as 
maximum tolerated dose and dosing schedule were not optimized.  However, the results 
of the study demonstrate that SMA-tanespimycin micelles were well tolerated and 
effective in reducing DU145 tumor growth, and suggest that the therapeutic index of 
tanespimycin is increased by encapsulation in SMA micelles.  
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 Overall, the data from this study demonstrate that delivery of tanespimycin 
using SMA micelles has several distinct advantages.  First, the aqueous solubility of 
tanespimycin is increased by encapsulation into SMA micelles, and because these 
interactions are noncovalent, the potent activity of tanespimycin is maintained.  Second, 
the preparation of SMA-tanespimycin micelles is simple, straightforward, and efficient 
in loading tanespimycin, thus allowing cost efficient scale up at later stages of 
development.  Third, the macromolecular nature of SMA-tanespimycin micelles allows 
accumulation into tumor tissues, resulting in an increase in the therapeutic index of 
tanespimycin.  These features combine to suggest that SMA-tanespimycin micelles 
have the potential to increase the efficacy and safety profile of tanespimycin. 
 
B.4  Conclusion 
 SMA-tanespimycin micelles were prepared in a simple manner with a high 
loading drug efficiency of 93%.  The micelles incorporated 25.6% tanespimycin by 
weight and exhibited properties that allow for increased blood circulation and tumor 
accumulation in vivo.  Tanespimycin was released from the micelles in a controlled 
manner and showed potent activity against DU145 human prostate cancer cells in vitro.  
The micelles also were well tolerated and exhibited potent anti-cancer in nu/nu mice 
bearing subcutaneous DU145 human prostate cancer tumor xenografts, with a 
significant increase in efficacy as measured by tumor regression as compared to free 
tanespimycin at an equivalent single dose of 10 mg/kg.  These data suggest that the 
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COMPARATIVE BIODISTRIBUTION OF HPMA COPOLYMERS BEARING 
GRP78 TARGETING PEPTIDES: A PRELIMINARY STUDY 
 
C.1 Materials and methods 
125
Iodine labeled HPMA copolymers bearing the GRP78 targeting peptide 
WDLAWMFRLPVG were prepared using materials and methods analogous to those 
used to synthesize and characterize HPMA copolymers bearing the WIFPWIQL peptide 
(See Section 4.2.1).  Biodistribution in major organs was then assessed in athymic nu/nu 
mice bearing DU145 tumor xenografts as previously described (see Section 4.2.7).  
Briefly, mice (n=3 per treatment group) were intravenously administered a single bolus 
dose of 50 mg/kg 
125
I radiolabeled conjugates.  No tumor hyperthermia was induced in 
this study, as the primary objective was to evaluate major organ uptake.  Biodistribution 
was assessed 4 hrs post injection, as this was when the highest levels of nonspecific 
uptake were observed for WIFPWIQL bearing conjugates (see Figure 4.5).  Mice were 
euthanized, blood immediately collected, followed by blood perfusion with saline. 
Tumors and major organs were then collected and analyzed by gamma counting.  





C.2 Results and Discussion 
HPMA copolymers bearing WDLAWMFRLPVG were synthesized and 
characterized to be as similar to WIFPWIQL conjugated copolymers as possible (See 
Figure 4.2b).  The same batch of precursor polymer that was used to prepare 
WIFPWIQL bearing copolymers was used to ensure similarities in molecular weight 
and molecular weight distribution.  Weight average molecular weight and 
polydispersity for the WDLAWMFRLPVG conjugated copolymer were 75.6 kDa and 
1.6 respectively, as determined by SEC.  The amount of targeting peptide conjugated 
was also maintained at a similar level (20% by weight) as WIFPWIQL copolymers. 
Significant reduced concentrations of WDLAWMFRLPVG copolymers in the 
spleen, kidneys, and liver were observed as compared to WIFPWIQL copolymers four 
hours after administration (Figure C.1).  No differences in delivery to the tumor or other 
major organs were observed.  These results suggest that the physicochemical properties 
of the peptides altered the characteristics of the copolymers, resulting in differences in 
biodistribution.  Based on this result, subsequent studies discussed in Chapter 5 utilized 
the WDLAWMFRLPVG peptide to target cell surface expressed GRP78.  It must be 
noted that the influence of the physicochemical properties of the peptides and their 
polymeric conjugates under study, on biodistribution and tumor localization, will need 





Figure C.1.  Biodistribution of WDLAWMFRLPVG and WIFPWIQL 
copolymers.  Four hours after administration, significant reductions in delivery to 
the spleen, kidneys, and liver were observed for WDLAWMFRLPVG containing 











SIZE EXCLUSION CHROMATOGRAMS OF SELECTED 

























Figure D.6.  Size exclusion chromatogram of p-Pt-HSP.  See Table 5.1 for 
physicochemical characteristics. 
